[go: up one dir, main page]

US20100216809A1 - Piperidine/piperazine derivatives - Google Patents

Piperidine/piperazine derivatives Download PDF

Info

Publication number
US20100216809A1
US20100216809A1 US12/663,009 US66300908A US2010216809A1 US 20100216809 A1 US20100216809 A1 US 20100216809A1 US 66300908 A US66300908 A US 66300908A US 2010216809 A1 US2010216809 A1 US 2010216809A1
Authority
US
United States
Prior art keywords
alkyl
alkyloxy
aryl
amino
het
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
US12/663,009
Other versions
US8835437B2 (en
Inventor
Jean-Pierre André Marc Bongartz
Lieven Meerpoel
Gustaaf Maria Boeckx
Guy Rosalia Eugeen Van Lommen
Christophe Francis Robert Buyck
Daniel Obrecht
Philipp Ermert
Anatol Luther
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Spexis AG
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38668783&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20100216809(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Assigned to JANSSEN PHARMACEUTICA N.V. reassignment JANSSEN PHARMACEUTICA N.V. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BUYCK, CHRISTOPHE FRANCIS ROBERT NESTOR
Assigned to POLYPHOR LTD. reassignment POLYPHOR LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: OBRECHT, DANIEL
Assigned to JANSSEN PHARMACEUTICA N.V. reassignment JANSSEN PHARMACEUTICA N.V. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BONGARTZ, JEAN-PIERRE ANDRE MARC
Assigned to JANSSEN PHARMACEUTICA N.V. reassignment JANSSEN PHARMACEUTICA N.V. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: MEERPOEL, LIEVEN
Assigned to JANSSEN PHARMACEUTICA N.V. reassignment JANSSEN PHARMACEUTICA N.V. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BOECKX, GUSTAAF MARIA
Assigned to JANSSEN PHARMACEUTICA N.V. reassignment JANSSEN PHARMACEUTICA N.V. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: VAN LOMMEN, GUY ROSALIA EUGEEN
Assigned to JANSSEN PHARMACEUTICA N.V. reassignment JANSSEN PHARMACEUTICA N.V. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: POLYPHOR LTD
Assigned to POLYPHOR LTD. reassignment POLYPHOR LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: LUTHER, ANATOL
Assigned to POLYPHOR LTD. reassignment POLYPHOR LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ERMERT, PHILIPP
Publication of US20100216809A1 publication Critical patent/US20100216809A1/en
Publication of US8835437B2 publication Critical patent/US8835437B2/en
Application granted granted Critical
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C07D271/107—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with two aryl or substituted aryl radicals attached in positions 2 and 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Definitions

  • the present invention relates to the use of a DGAT inhibitor, in particular a DGAT1 inhibitor, for the manufacture of a medicament for the prevention or the treatment of a disease by elevating the levels of one or more satiety hormones, in particular GLP-1.
  • the present invention also concerns piperidine/piperazine derivatives having DGAT inhibitory activity, in particular DGAT1 inhibitory activity.
  • the invention further relates to methods for their preparation and pharmaceutical compositions comprising them.
  • the invention also relates to the use of said compounds for the manufacture of a medicament for the prevention or the treatment of a disease mediated by DGAT, in particular DGAT 1.
  • Triglycerides represent the major form of energy stored in eukaryotes. Disorders or imbalances in triglyceride metabolism are implicated in the pathogenesis of and increased risk for obesity, insulin resistance syndrome and type II diabetes, nonalcoholic fatty liver disease and coronary heart disease (see, Lewis, et al, Endocrine Reviews (2002) 23:201 and Malloy and Kane, Adv. Intern. Med. (2001) 47:11 1). Additionally, hypertriglyceridemia is often an adverse consequence of cancer therapy (see, Bast, et al. Cancer Medicine, 5th Ed., (2000) B. C. Decker, Hamilton, Ontario, CA).
  • DGAT acyl CoA:diacylglycerol acyltransferase
  • DAG 1,2-diacylglycerol
  • TG triglycerides
  • DGAT uniquely controlled the catalysis of the final step of acylation of diacylglycerol to triglyceride in the two major pathways for triglyceride synthesis, the glycerol phosphate and monoacylglycerol pathways. Because triglycerides are considered essential for survival, and their synthesis was thought to occur through a single mechanism, inhibition of triglyceride synthesis through inhibiting the activity of DGAT has been largely unexplored.
  • mouse DGAT1 Genes encoding mouse DGAT1 and the related human homologs ARGP1 (human DGAT1) and ARGP2 (human ACAT2) now have been cloned and characterized (Cases, et al, Pro.c Nat.l Acad. Sci. (1998) 95:13018; Oelkers, et al, J. Biol. Chem. ( 1998) 273:26765).
  • the gene for mouse DGAT1 has been used to create DGAT knock-out mice to better elucidate the function of the DGAT gene.
  • mice unable to express a functional DGAT1 enzyme are viable and still able to synthesize triglycerides, indicating that multiple catalytic mechanisms contribute to triglyceride synthesis (Smith, et al, Nature Genetics (2000) 25:87).
  • Other enzymes that catalyze triglyceride synthesis for example, DGAT2 and diacylglycerol transacylase, also have been identified (Cases, et al, J. Biol. Chem. (2001) 276:38870).
  • Gene knockout studies in mice have revealed that DGAT2 plays a fundamental role in mammalian triglyceride synthesis and is required for survival.
  • DGAT2 deficient mice are lipopenic and die soon after birth, apparently from profound reductions in substrates for energy metabolism and from impaired permeability barrier function in the skin.(Farese, et al., J. Biol. Chem. (2004) 279: 11767).
  • Dgat1 ⁇ / ⁇ mice are resistant to diet-induced obesity and remain lean. Even when fed a high fat diet (21% fat) Dgat1 ⁇ / ⁇ mice maintain weights comparable to mice fed a regular diet (4% fat) and have lower total body triglyceride levels.
  • the obesity resistance in Dgat1 ⁇ / ⁇ mice is not due to decreased caloric intake, but the result of increased energy expenditure and decreased resistance to insulin and leptin (Smith, et al, Nature Genetics (2000) 25:87; Chen and Farese, Trends Cardiovasc. Med. (2000) 10: 188; and Chen, et al, J. Clin. Invest. (2002) 109:1049).
  • Dgat1 ⁇ / ⁇ mice have reduced rates of triglyceride absorption (Buhman, et al, J. Biol. Chem. (2002) 277:25474). In addition to improved triglyceride metabolism, Dgat1 ⁇ / ⁇ mice also have improved glucose metabolism, with lower glucose and insulin levels following a glucose load, in comparison to wild-type mice (Chen and Farese, Trends Cardiovasc. Med. (2000) 10: 188).
  • the compounds of the present invention exhibit DGAT inhibitory activity, in particular DGAT1 inhibitory activity, and can therefore be used to prevent or treat a disease associated with or mediated by DGAT, such as for example obesity, type II diabetes, heart disease and cancer.
  • DGAT DGAT inhibitory activity
  • the compounds of the invention differ from the prior art compounds in structure, in their pharmacological activity, pharmacological potency, and/or pharmacological profile.
  • DGAT inhibitors can be used to elevate the levels of one or more satiety hormones, in particular glucagon-like-peptide-1 (GLP-1) and therefore DGAT inhibitors, in particular DGAT1 inhibitors, can also be used to prevent or treat a disease which can benefit from elevated levels of a satiety hormone, in particular GLP-1.
  • GLP-1 glucagon-like peptide 1
  • GLP-1 is an intestinal hormone which generally stimulates insulin secretion during hyperglycemia, suppresses glucagon secretion, stimulates (pro) insulin biosynthesis and decelerates gastric emptying and acid secretion.
  • GLP-1 is secreted from L cells in the small and large bowel following the ingestion of fat and proteins.
  • GLP-1 has been suggested, among other indications, as a possible therapeutic agent for the management of type 2 non-insulin-dependent diabetes mellitus as well as related metabolic disorders, such as obesity.
  • GLP-1 a disease which can benefit from elevated levels of GLP-1 can be treated with small molecules (compared to large molecules such as proteins or protein-like compounds, e.g. GLP-1 analogues).
  • WO 2006/034441 discloses heterocyclic derivatives and their use as stearoyl CoA desaturase inhibitors (SCD-1 inhibitors).
  • WO 2006/086445 relates to a combination therapy of a SCD-1 inhibitor and another drug to treat adverse weight gain.
  • WO 2006/004200 and JP2007131584 relate to urea and amino derivatives having DGAT inhibitory activity.
  • WO 2004/047755 relates to fused bicyclic nitrogen-containing heterocycles having DGAT inhibitory activity.
  • WO2005/072740 relates to an anorectic action of a compound having DGAT inhibitory activity.
  • the present invention relates to the use of a DGAT inhibitor for the manufacture of a medicament for the prevention or the treatment, in particular for the treatment, of a disease which can benefit from elevated levels of one or more satiety hormones, in particular GLP-1.
  • the present invention further relates to a compound of formula
  • the invention also relates to a compound of formula (I) as described above, provided that the following compounds
  • the present invention further relates to the use of a compound of formula (I′′′) for the manufacture of a medicament for the prevention or the treatment of a disease mediated by DGAT, in particular the present invention relates to the use of a compound of formula (I′′′) for the manufacture of a medicament for the prevention or the treatment of a disease which can benefit from inhibition of DGAT, in particular for the treatment of a disease which can benefit from inhibition of DGAT, in particular DGAT1, wherein the compound of formula (I′′′) is a compound of formula
  • the present invention also relates to the use of a compound of formula (I) or (I′′′) for the manufacture of a medicament for the prevention or the treatment of a disease which can benefit from elevated levels of one or more satiety hormones, in particular GLP-1, in particular the present invention relates to the use of a compound of formula (I) for the manufacture of a medicament for the treatment of a disease which can benefit from elevated levels of GLP-1.
  • the present invention further relates to the use of a compound of formula (I) for the manufacture of a medicament for the prevention or the treatment of a disease mediated by DGAT, in particular the present invention relates to the use of a compound of formula (I) for the manufacture of a medicament for the prevention or the treatment of a disease which can benefit from inhibition of DGAT, in particular for the treatment of a disease which can benefit from inhibition of DGAT, in particular DGAT1.
  • C 0-3 alkyl as a group or part of a group defines straight or branched chain saturated hydrocarbon radicals having from 0 (then it represents a direct bond) to 3 carbon atoms such as methyl, ethyl, propyl, 1-methyl-ethyl;
  • C 1-2 alkyl as a group or part of a group defines straight or branched chain saturated hydrocarbon radicals having 1 or 2 carbon atoms such as methyl, ethyl;
  • C 1-4 alkyl as a group or part of a group defines straight or branched chain saturated hydrocarbon radicals having from 1 to 4 carbon atoms such as methyl, ethyl, propyl, 1-methylethyl, butyl;
  • C 1-5 alkyl as a group or part of a group defines straight or branched chain saturated hydrocarbon radicals having from 1 to 5 carbon atoms such as the group defined for C 1-4 alkyl and pentyl, 2-methylbutyl and the like;
  • C 1-6 alkyl as a group or part of a group defines straight or branched chain saturated hydrocarbon radicals having from 1 to 6 carbon atoms such as the group defined for C 1-4 alkyl and for C 1-5 alkyl and hexyl, 2-methylpentyl and the like;
  • C 1-6 alkanediyl defines straight or branched chain saturated bivalent hydrocarbon radicals having from 1 to 6 carbon atoms such as methylene, 1,2-ethanediy
  • halo is generic to fluoro, chloro, bromo and iodo.
  • polyhaloC 1-6 alkyl as a group or part of a group is defined as C 1-6 alkyl substituted with one or more, such as for example 2, 3, 4 or 5 halo atoms, for example methyl substituted with one or more fluoro atoms, for example, difluoromethyl or trifluoromethyl, 1,1-difluoro-ethyl, 1,1-difluoro-2,2,2-trifluoro-ethyl and the like.
  • halogen atoms are attached to a C 1-6 alkyl group within the definition of polyhaloC 1-6 alkyl, they may be the same or different.
  • ( ⁇ O) forms a carbonyl moiety when attached to a carbon atom, a sulfoxide moiety when attached to a sulfur atom and a sulfonyl moiety when two of said terms are attached to a sulfur atom.
  • Oxo means ⁇ O.
  • the radical R 1 as defined hereinabove may be an optionally substituted 5-membered monocyclic heterocycle containing at least 2 heteroatoms, an optionally substituted 6-membered aromatic monocyclic heterocycle or an optionally substituted 5-membered heterocycle containing at least 2 heteroatoms fused with a phenyl, cyclohexyl or a 5- or 6-membered heterocycle.
  • a 5-membered monocyclic heterocycle as defined hereinabove or hereinafter may be a 5-membered monocyclic non-aromatic (fully saturated or partially saturated) or aromatic heterocycle containing at least 2 heteroatom, in particular 2 or 3 heteroatoms, each independently selected from O, S, S( ⁇ O) p or N.
  • unsubstituted monocyclic 5-membered heterocycles comprise, but are not limited to, non-aromatic (fully saturated or partially saturated) or aromatic 5-membered monocyclic heterocycles such as for example 1,3-dioxolanyl, imidazolidinyl, thiazolidinyl, dihydrooxazolyl, isothiazolidinyl, isoxazolidinyl, oxadiazolidinyl, triazolidinyl, thiadiazolidinyl, pyrazolidinyl, imidazolinyl, pyrazolinyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, triazolyl, thiadiazolyl, oxadiazolyl, tetrazolyl and the like.
  • non-aromatic (fully saturated or partially saturated) or aromatic 5-membered monocyclic heterocycles such
  • Optional substituents of the above heterocycles are hydroxyl; oxo; carboxyl; halo; C 1-6 alkyl optionally substituted with carboxyl, C 1-4 alkyloxy-carbonyl or aryl-C( ⁇ O)—; hydroxyC 1-6 alkyl optionally substituted with aryl or aryl-C( ⁇ O)—; polyhaloC 1-6 alkyl; C 1-6 alkyloxy optionally substituted with C 1-4 alkyloxy; C 1-6 alkylthio; polyhaloC 1-6 alkyloxy; C 1-6 alkyloxy-carbonyl wherein C 1-6 alkyl may optionally be substituted with aryl; cyano; aminocarbonyl; mono-or di(C 1-4 alkyl)-aminocarbonyl; C 1-6 alkylcarbonyl; amino; mono-or di(C 1-6 alkyl)amino; R 5 R 4 N—C 1-6 alkyl; C 3-6 cycloalkyl
  • a 6-membered aromatic monocyclic heterocycle as defined hereinabove or hereinafter contains at least one heteroatom, in aprticular 1, 2 or 3 heteroatoms, each independently selected from O, S, S( ⁇ O) p or N.
  • heteroatoms in aprticular 1, 2 or 3 heteroatoms, each independently selected from O, S, S( ⁇ O) p or N.
  • unsubstituted monocyclic 6-membered aromatic heterocycles comprise, but are not limited to, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, pyranyl and the like.
  • Optional substituents of the above heterocycles are hydroxyl; oxo; carboxyl; halo; C 1-6 alkyl optionally substituted with carboxyl, C 1-4 alkyloxycarbonyl or aryl-C( ⁇ O)—; hydroxyC 1-6 alkyl optionally substituted with aryl or aryl-C( ⁇ O)—; polyhaloC 1-6 alkyl; C 1-6 alkyloxy optionally substituted with C 1-4 alkyloxy; C 1-6 alkylthio; polyhaloC 1-6 alkyloxy; C 1-6 alkyloxy-carbonyl wherein C 1-6 alkyl may optionally be substituted with aryl; cyano; aminocarbonyl; mono-or di(C 1-4 alkyl)aminocarbonyl; C 1-6 alkylcarbonyl; amino; mono-or di(C 1-6 alkyl)amino; R 5 R 4 N—C 1-6 alkyl; C 3-6 cycloalkyl-NR
  • a 5-membered heterocycle containing at least 2 heteroatoms fused with phenyl, cyclohexyl or a 5- or 6-membered heterocycle as defined hereinabove or hereinafter may be a non-aromatic (fully saturated or partially saturated) or aromatic 5-membered heterocycle containing at least 2 heteroatoms, in particular 2 or 3 heteroatoms, each independently selected from O, S, S( ⁇ O) p or N, in particular O, S or N, more in particular O or N, fused with phenyl, cyclohexyl or a 5- or 6-membered non-aromatic (fully saturated or partially saturated) or aromatic heterocycle containing at least one heteroatom, in particular 1, 2 or3 heteroatoms, each independently selected from O, S, S( ⁇ O) p or N.
  • unsubstituted bicyclic heterocycles comprise, but are not limited to, non-aromatic (fully saturated or partially saturated) or aromatic 8- or 9-membered bicyclic heterocycles such as for example 1,3-benzodioxolyl, benzoxazolyl, benzimidazolyl, indazolyl, benzisoxazolyl, benzisothiazolyl, benzopyrazolyl, benzoxadiazolyl, benzothiadiazolyl, benzotriazolyl, purinyl, pyrrolopyridyl, thienopyridyl, furopyridyl, isothiazolopyridyl, thiazolopyridyl, isoxazolopyridyl, oxazolopyridyl, pyrazolopyridyl, imidazopyridyl, pyrrolopyrazinyl, thienopyrazinyl, furopyrazinyl,
  • Optional substituents of the above heterocycles are hydroxyl; oxo; carboxyl; halo; C 1-6 alkyl optionally substituted with carboxyl, C 1-4 alkyloxycarbonyl or aryl-C( ⁇ O)—; hydroxyC 1-6 alkyl optionally substituted with aryl or aryl-C( ⁇ O)—; polyhaloC 1-6 alkyl; C 1-6 alkyloxy optionally substituted with C 1-4 alkyloxy; C 1-6 alkylthio; polyhaloC 1-6 alkyloxy; C 1-6 alkyloxy-carbonyl wherein C 1-6 alkyl may optionally be substituted with aryl; cyano; aminocarbonyl; mono-or di(C 1-4 alkyl)aminocarbonyl; C 1-6 alkylcarbonyl; amino; mono-or di(C 1-6 alkyl)amino; R 5 R 4 N—C 1-6 alkyl; C 3-6 cycloalkyl-NR
  • the radical Het as defined hereinabove may be an optionally substituted monocyclic non-aromatic or aromatic heterocycle containing at least one heteroatom selected from O, S, S( ⁇ O) p or N; or a optionally substituted bi- or tricyclic non-aromatic or aromatic heterocycle containing at least one heteroatom selected from O, S, S( ⁇ O) p or N.
  • unsubstituted monocyclic heterocycles comprise, but are not limited to, non-aromatic (fully saturated or partially saturated) or aromatic 4-, 5-, 6- or 7-membered monocyclic heterocycles such as for example azetidinyl, tetrahydrofuranyl, pyrrolidinyl, dioxolanyl, imidazolidinyl, thiazolidinyl, tetrahydrothienyl, dihydrooxazolyl, isothiazolidinyl, isoxazolidinyl, oxadiazolidinyl, triazolidinyl, thiadiazolidinyl, pyrazolidinyl, piperidinyl, hexahydropyrimidinyl, hexahydropyrazinyl, dioxanyl, morpholinyl, dithianyl, thiomorpholinyl, piperazinyl, trithianyl, pyrrolinyl, imi
  • unsubstituted bicyclic or tricyclic heterocycles comprise, but are not limited to, non-aromatic (fully saturated or partially saturated) or aromatic 8- to 17-membered bicyclic or tricyclic heterocycles such as for example decahydroquinolinyl, octahydroindolyl, 2,3-dihydrobenzo furanyl, 1,3-benzodioxolyl, 2,3-dihydro-1,4-benzodioxinyl, indolinyl, benzofuryl, isobenzofuryl, benzothienyl, isobenzothienyl, indolizinyl, indolyl, isoindolyl, benzoxazolyl, benzimidazolyl, indazolyl, benzisoxazolyl, benzisothiazolyl, benzopyrazolyl, benzoxadiazolyl, benzothiadiazolyl, benzotriazolyl,
  • Optional substituents of the above heterocycles are hydroxyl; oxo; carboxyl; halo; C 1-6 alkyl optionally substituted with C 1-4 alkyloxy, amino or mono-or di-(C 1-4 alkyl)amino; polyhaloC 1-6 alkyl; C 1-6 alkyloxy optionally substituted with C 1-4 alkyloxy; C 1-6 alkylthio; polyhaloC 1-6 alkyloxy; C 1-6 alkyl-oxycarbonyl; cyano; aminocarbonyl; mono-or di(C 1-4 alkyl)aminocarbonyl; C 1-6 alkylcarbonyl; nitro; amino; mono-or di(C 1-4 alkyl)amino; —S( ⁇ O) p —C 1-4 alkyl.
  • Examples of a 6-membered aromatic heterocycle containing 1 or 2 N atoms in the definition of R 3 are pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl.
  • each definition is independent.
  • Het or R 1 is meant to include all the possible isomeric forms of the heterocycles, for instance, pyrrolyl comprises 1H-pyrrolyl and 2H-pyrrolyl.
  • the carbocycles or heterocycles covered by the terms aryl, Het, R 1 or R 3 may be attached to the remainder of the molecule of formula (I) through any ring carbon or heteroatom as appropriate, if not otherwise specified.
  • the heterocycle when the heterocycle is imidazolyl, it may be 1-imidazolyl, 2-imidazolyl, 4-imidazolyl and the like, or when the carbocycle is naphthalenyl, it may be 1-naphthalenyl, 2-naphthalenyl and the like.
  • X is defined as for instance —NR x —C( ⁇ O)—, this means that the nitrogen of NR x is linked to the R 2 substituent and the carbon atom of C( ⁇ O) is linked to the nitrogen of the ring
  • X is linked to the ring moiety
  • salts of the compounds of formula (I) are those wherein the counterion is pharmaceutically acceptable.
  • salts of acids and bases which are non-pharmaceutically acceptable may also find use, for example, in the preparation or purification of a pharmaceutically acceptable compound. All salts, whether pharmaceutically acceptable or not are included within the ambit of the present invention.
  • the pharmaceutically acceptable salts as mentioned hereinbefore or hereinafter are meant to comprise the therapeutically active non-toxic acid addition salt forms which the compounds of formula (I) are able to form.
  • the latter can conveniently be obtained by treating the base form with such appropriate acids as inorganic acids, for example, hydrohalic acids, e.g.
  • the salt form can be converted by treatment with alkali into the free base form.
  • the compounds of formula (I) containing acidic protons may be converted into their therapeutically active non-toxic metal or amine addition salt forms by treatment with appropriate organic and inorganic bases.
  • the pharmaceutically acceptable salts as mentioned hereinbefore or hereinafter are meant to also comprise the therapeutically active non-toxic metal or amine addition salt forms (base addition salt forms) which the compounds of formula (I) are able to form.
  • Appropriate base addition salt forms comprise, for example, the ammonium salts, the alkali and earth alkaline metal salts, e.g. the lithium, sodium, potassium, magnesium, calcium salts and the like, salts with organic bases, e.g.
  • primary, secondary and tertiary aliphatic and aromatic amines such as methylamine, ethylamine, propylamine, isopropylamine, the four butylamine isomers, dimethylamine, diethylamine, diethanolamine, dipropylamine, diisopropylamine, di-n-butylamine, pyrrolidine, piperidine, morpholine, trimethylamine, triethylamine, tripropylamine, quinuclidine, pyridine, quinoline and isoquino line, the benzathine, N-methyl-D-glucamine, 2-amino-2-(hydroxymethyl)-1,3-propanediol, hydrabamine salts, and salts with amino acids such as, for example, arginine, lysine and the like.
  • salt form can be converted by treatment with acid into the free acid form.
  • salt also comprises the quaternary ammonium salts (quaternary amines) which the compounds of formula (I) are able to form by reaction between a basic nitrogen of a compound of formula (I) and an appropriate quaternizing agent, such as, for example, an optionally substituted C 1-6 alkylhalide, arylhalide, C 1-6 alkyl-carbonylhalide, arylcarbonylhalide, or arylC 1-6 alkylhalide, e.g. methyliodide or benzyliodide.
  • an appropriate quaternizing agent such as, for example, an optionally substituted C 1-6 alkylhalide, arylhalide, C 1-6 alkyl-carbonylhalide, arylcarbonylhalide, or arylC 1-6 alkylhalide, e.g. methyliodide or benzyliodide.
  • C 1-6 alkyl trifluoromethanesulfonates C 1-6 alkyl methanesulfonates, and C 1-6 alkyl p-toluenesulfonates.
  • a quaternary amine has a positively charged nitrogen.
  • Pharmaceutically acceptable counterions include chloro, bromo, iodo, trifluoroacetate, acetate, triflate, sulfate, sulfonate. The counterion of choice can be introduced using ion exchange resins.
  • solvate comprises the hydrates and solvent addition forms which the compounds of formula (I) are able to form, as well as salts thereof. Examples of such forms are e.g. hydrates, alcoholates and the like.
  • N-oxide forms of the present compounds are meant to comprise the compounds of formula (I) wherein one or several tertiary nitrogen atoms are oxidized to the so-called N-oxide.
  • stereochemically isomeric forms as used hereinbefore or hereinafter defines all the possible stereoisomeric forms which the compounds of formula (I), and their N-oxides, salts, or solvates may possess.
  • the chemical designation of compounds denotes the mixture of all possible stereochemically isomeric forms, said mixtures containing all diastereomers and enantiomers of the basic molecular structure as well as each of the individual isomeric forms of formula (I) and their N-oxides, salts or solvates, substantially free, i.e. associated with less than 10%, preferably less than 5%, in particular less than 2% and most preferably less than 1% of the other isomers.
  • a compound of formula (I) is for instance specified as (E)
  • this means that the compound is substantially free of the (Z) isomer.
  • stereogenic centers may have the R- or S-configuration; substituents on bivalent cyclic (partially) saturated radicals may have either the cis- or trans-configuration.
  • Compounds encompassing double bonds can have an E (ent ought) or Z (zusammen) -stereochemistry at said double bond.
  • the terms cis, trans, R, S, E and Z are well known to a person skilled in the art.
  • an R or S descriptor is assigned (based on Cahn-Ingold-Prelog sequence rule) to the lowest-numbered chiral center, the reference center.
  • the configuration of the second stereogenic center is indicated using relative descriptors [R*,R* ] or [R*,S*], where the first R* is always specified as the reference center and [R*,R*] indicates centers with the same chirality and [R *,S*] indicates centers of unlike chirality. For example, if the lowest-numbered chiral center in the molecule has an S configuration and the second center is R, the stereo descriptor would be specified as S—[R*,S*].
  • the position of the highest priority substituent on the asymmetric carbon atom in the ring system having the lowest ring number is arbitrarily always in the “ ⁇ ” position of the mean plane determined by the ring system.
  • the position of the highest priority substituent on the other asymmetric carbon atom in the ring system relative to the position of the highest priority substituent on the reference atom is denominated “ ⁇ ”, if it is on the same side of the mean plane determined by the ring system, or “ ⁇ ”, if it is on the other side of the mean plane determined by the ring system.
  • the compounds of (I) may be synthesized in the form of racemic mixtures of enantiomers which can be separated from one another following art-known resolution procedures.
  • the racemic compounds of formula (I) may be converted into the corresponding diastereomeric salt forms by reaction with a suitable chiral acid. Said diastereomeric salt forms are subsequently separated, for example, by selective or fractional crystallization and the enantiomers are liberated therefrom by alkali.
  • An alternative manner of separating the enantiomeric forms of the compounds of formula (I) involves liquid chromatography using a chiral stationary phase.
  • Said pure stereochemically isomeric forms may also be derived from the corresponding pure stereochemically isomeric forms of the appropriate starting materials, provided that the reaction occurs stereospecifically.
  • Preferably if a specific stereoisomer is desired, said compound will be synthesized by stereospecific methods of preparation. These methods will advantageously employ enantiomerically pure starting materials.
  • a first embodiment of the present invention are those compounds of formula (I) having the following formula
  • R 1 represents a 5-membered monocyclic heterocycle containing at least 2 heteroatoms; a 6-membered aromatic monocyclic heterocycle; or a 5-membered heterocycle containing at least 2 heteroatoms fused with phenyl, cyclohexyl or a 5- or 6-membered heterocycle; wherein each of said heterocycles may optionally be substituted with at least one substituent, in particular one, two, three, four or five substituents, each substituent independently being selected from hydroxyl; oxo; carboxyl; halo; C 1-6 alkyl optionally substituted with aryl-C( ⁇ O)—; hydroxyC 1-6 alkyl optionally substituted with aryl or aryl-C( ⁇ O)—; polyhaloC 1-6 alkyl; C 1-6 alkyloxy optionally substituted with C 1-4 alkyloxy; C 1-6 alkylthio; polyhaloC 1-6 alkyloxy; C 1-6 alkyloxy-carbonyl wherein C
  • the invention also relates to a compound of formula (I) as described in the above embodiment, provided that the following compounds
  • a second embodiment of the present invention are those compounds of formula (I) or, whenever possible, any subgroup thereof as mentioned hereinbefore as embodiment wherein X represents —NR x —C( ⁇ O)—; —Z—C( ⁇ O)—; —Z—NR x —C( ⁇ O)—; —S( ⁇ O)p-; —NR x —C( ⁇ S)— or —O—C( ⁇ O)—; in particular X represents —NR x —C( ⁇ O)—; —Z—C( ⁇ O)—; —Z—NR x —C( ⁇ O)—; more in particular X represents —NR x —C( ⁇ O— or —Z—C( ⁇ O)—.
  • a third embodiment of the present invention are those compounds of formula (I) or, whenever possible, any subgroup thereof as mentioned hereinbefore as embodiment wherein A represents N.
  • a fourth embodiment of the present invention are those compounds of formula (I) or, whenever possible, any subgroup thereof as mentioned hereinbefore as embodiment wherein A represents CH, in particular wherein A represents CH and the dotted line does not represent a bond.
  • a fifth embodiment of the present invention are those compounds of formula (I) or, whenever possible, any subgroup thereof as mentioned hereinbefore as embodiment wherein R 1 represents a 5-membered monocyclic heterocycle containing at least 2 heteroatoms, in particular pyrazolyl, triazolyl or oxadiazolyl; a 6-membered monocyclic aromatic heterocycle, in particular pyrimidinyl; or a 5-membered aromatic heterocycle containing at least 2 heteroatoms fused with a 5-membered heterocycle, in particular imidazopyrazolyl or imidazothiazolyl; wherein each of said heterocycles may optionally be substituted, preferably with one or two substituents.
  • Particular substituents of said heterocycles include oxo, C 1-6 alkyl optionally substituted with aryl-C( ⁇ O)— or C 1-4 alkyloxycarbonyl; hydroxyC 1-6 alkyl optionally substituted with aryl or aryl-C( ⁇ O)—; amino; mono-or di(C 1-6 alkyl)amino; R 5 R 4 N—C 1-6 alkyl; C 3-6 cycloalkyl-NR x —; aryl-NR x —; Het-NR x —; C 3-6 cycloalkylC 1-4 alkyl-NR x —; arylC 1-4 alkyl-NR x —; HetC 1-4 alkyl-NR x —; C 3-6 cycloalkyl; C 3-6 cycloalkylC 1-4 alkyl; aryl; aryloxy; arylC 1-4 alkyl; aryl-C( ⁇ O)—; aryl
  • a sixth embodiment of the present invention are those compounds of formula (I) or, whenever possible, any subgroup thereof as mentioned hereinbefore as embodiment wherein the compound of formula (I) is a compound of formula (I′)
  • a seventh embodiment of the present invention are those compounds of formula (I) or, whenever possible, any subgroup thereof as mentioned hereinbefore as embodiment wherein the compound of formula (I) is a compound of formula (I′′)
  • An eighth embodiment of the present invention are those compounds of formula (I) or, whenever possible, any subgroup thereof as mentioned hereinbefore as embodiment wherein the compound of formula (I) is a compound of formula (I′) or (I′′) and wherein R 3a and R 3b each independently represent halo, polyhaloC 1-6 alkyl, C 1-6 alkyl or C 1-6 alkyloxy, in particular both R 3a and R 3b represent halo, more in particular both R 3a and R 3b represent chloro.
  • a ninth embodiment of the present invention are those compounds of formula (I) or, whenever possible, any subgroup thereof as mentioned hereinbefore as embodiment wherein the compound of formula (I) is a compound of formula (I′) or (I′′) and wherein R 3c represents hydrogen, hydroxyl, carboxyl; halo; amino; mono-or di-(C 1-4 alkyl)amino; C 1-6 alkyl; C 1-6 alkyloxy; C 1-6 alkyloxycarbonyl; C 1-6 alkylthio; C 1-4 alkylcarbonylamino; R 5 R 4 N—C( ⁇ O)—; R 5 R 4 N—C 1-6 alkyl; Het-C( ⁇ O)— or HetC 1-4 alkyl; or R 3c represents hydrogen.
  • a tenth embodiment of the present invention are those compounds of formula (I) or, whenever possible, any subgroup thereof as mentioned hereinbefore as embodiment wherein p represents 2.
  • An eleventh embodiment of the present invention are those compounds of formula (I) or, whenever possible, any subgroup thereof as mentioned hereinbefore as embodiment wherein Z represents C 1-6 alkanediyl, in particular CH 2 or CH 2 -CH 2 .
  • a twelfth embodiment of the present invention are those compounds of formula (I) or, whenever possible, any subgroup thereof as mentioned hereinbefore as embodiment wherein Rx represents hydrogen.
  • a thirteenth embodiment of the present invention are those compounds of formula (I) or, whenever possible, any subgroup thereof as mentioned hereinbefore as embodiment wherein R 8 represents hydrogen.
  • a fourteenth embodiment of the present invention are those compounds of formula (I) or, whenever possible, any subgroup thereof as mentioned hereinbefore as embodiment wherein R 8 represents halo, C 1-4 alkyl or C 1-4 alkyl substituted with hydroxyl; in particular R 8 represents halo or C 1-4 alkyl.
  • a fifteenth embodiment of the present invention are those compounds of formula (I) or, whenever possible, any subgroup thereof as mentioned hereinbefore as embodiment wherein R 3 represents C 3-6 cycloalkyl, phenyl, naphtalenyl, 1,3-benzodioxolyl or a 6-membered aromatic heterocycle containing 1 or 2 N atoms, wherein said C 3-6 cycloalkyl, phenyl, naphtalenyl, 1,3-benzodioxolyl or 6-membered aromatic heterocycle may optionally be substituted with at least one substituent, in particular one or two substituents, preferably each substituent independently selected from hydroxyl; carboxyl; halo; C 1-6 alkyl optionally substituted with hydroxy; polyhaloC 1-6 alkyl; C 1-6 alkyloxy; C 1-6 alkylthio; C 1-6 alkyloxycarbonyl; amino; mono-or di(C 1-4 alkyl)amino; C 1 -4 alky
  • a sixteenth embodiment of the present invention are those compounds of formula (I) or any subgroup thereof as mentioned hereinbefore as embodiment wherein one or more, preferably all, of the following restrictions apply:
  • a seventeenth embodiment of the present invention are those compounds of formula (I) or any subgroup thereof as mentioned hereinbefore as embodiment wherein one or more, preferably all, of the following restrictions apply:
  • Preferred compounds of formula (I) are selected from
  • compounds of formula (I) wherein X represents X i —NH—C( ⁇ O)— with X 1 representing a direct bond or Z, said compounds being represented by formula (I-a), can be prepared by reacting an intermediate of formula (II) with an intermediate of formula (III) in the presence of a suitable solvent, such as for example N,N-dimethylformamide or dichloromethane or acetonitrile, optionally in the presence of a suitable base, such as for example N,N-diethyl-ethanamine.
  • a suitable solvent such as for example N,N-dimethylformamide or dichloromethane or acetonitrile
  • a suitable base such as for example N,N-diethyl-ethanamine.
  • Intermediates of formula (II) are commercially available or can be prepared by reacting R 2 —X 1 —NH 2 with phosgene in the presence of a suitable solvent, such as for example toluene.
  • the above reaction can also be performed as a fast synthesis reaction thereby using appropriate reagents well-known for fast synthesis, such as for example for the purification of the reaction mixture 1-ethenyl-4-(isocyanatomethyl)-benzene polymer with ethenylbenzene and tris-2-aminoethylamine linked to polystyrene can be used.
  • Compounds of formula (I-a) wherein X i represents a direct bond, said compounds being represented by formula (I-a-1), can be prepared by reacting an intermediate of formula (II′) with Cl 3 COC( ⁇ O)—Cl or C( ⁇ O)Cl 2 , optionally in the presence of HCl in diethylether, and in the presence of a suitable solvent, such as for example toluene or acetonitrile, followed by reaction with an intermediate of formula (III) in the presence of a suitable solvent, such as for example acetonitrile, N,N-dimethylformamide or dichloromethane, optionally in the presence of a suitable base, such as for example N,N-diethyl-ethanamine or N,N-diisopropyl-ethanamine.
  • a suitable solvent such as for example toluene or acetonitrile
  • a suitable solvent such as for example acetonitrile, N,N-dimethylformamide
  • Compounds of formula (I) wherein X represents —X 1 —C( ⁇ O)— with X 1 representing a direct bond or Z, said compounds being represented by formula (I-b), can be prepared by reacting an intermediate of formula (IV) with an intermediate of formula (III) in the presence of a suitable dehydrating (coupling) agent, such as for example N′-(ethylcarbonimidoyl)-N,N-dimethyl-1,3-propanediamine monohydrochloride (EDCI), dicyclohexylcarbodiimide (DCC), carbonyl diimidazole (CDI), 1-[bis(di-methylamino)methylene]-1H-benzotriazoliumhexafluorophosphate(1-)3-oxide (HBTU), 1-[bis(dimethyl-amino)methylene]-5-chloro-1H-benzotriazolium-hexafluoro-phosphate(1-) 3-oxide (HCTU), O-benz
  • This reaction of an intermediate of formula (IV) with an intermediate of formula (III) can also be performed in the presence of a suitable activating agent, such as for example Cl—C( ⁇ O)—C( ⁇ O)—Cl, a suitable base, such as for example N,N-diethyl-ethanamine, and a suitable solvent, such as for example N,N-dimethylformamide.
  • a suitable activating agent such as for example Cl—C( ⁇ O)—C( ⁇ O)—Cl
  • a suitable base such as for example N,N-diethyl-ethanamine
  • a suitable solvent such as for example N,N-dimethylformamide.
  • Compounds of formula (I-b) wherein X 1 represents a direct bond can be prepared by reacting an intermediate of formula (IV′) wherein W 1 represents a suitable leaving group, such as for example halo, e.g. chloro and the like, with an intermediate of formula (III) in the presence of a suitable base, such as for example N-methyl morpholine, and a suitable solvent, such as for example N,N-dimethylformamide.
  • a suitable base such as for example N-methyl morpholine
  • a suitable solvent such as for example N,N-dimethylformamide.
  • Compounds of formula (I) wherein X represents X 1 —NH—C( ⁇ S)— with X 1 representing a direct bond or Z, said compounds being represented by formula (I-c), can be prepared by reacting an intermediate of formula (XV) with an intermediate of formula (III) in the presence of a suitable solvent, such as for example tetrahydrofuran or dichloromethane, optionally in the presence of a suitable base, such as for example N,N-diethylethanamine.
  • a suitable solvent such as for example tetrahydrofuran or dichloromethane
  • Compounds of formula (I) wherein X represents —S( ⁇ O) p —, said compounds being represented by formula (I-d), can be prepared by reacting an intermediate of formula (XIV) wherein W 3 represents a suitable leaving group, such as for example halo, e.g. chloro and the like, with an intermediate of formula (III) in the presence of a suitable base, such as for example N,N-diisopropyl-ethanamine or N,N-diethyl-ethanamine, and a suitable solvent, such as for example dichloromethane.
  • a suitable base such as for example N,N-diisopropyl-ethanamine or N,N-diethyl-ethanamine
  • a suitable solvent such as for example dichloromethane.
  • Compounds of formula (I) wherein X represents —C( ⁇ O)—C 2-6 alkenediyl-, said compounds being represented by formula (I-e), can be prepared by reacting an intermediate of formula (XV) with an intermediate of formula (III) in the presence of a suitable solvent, such as for example an alcohol, e.g. ethanol.
  • a suitable solvent such as for example an alcohol, e.g. ethanol.
  • Compounds of formula (I) wherein R 2 represents R 3 , said R 3 being substituted with R 5 R 4 N—C 1-6 alkyl, said R 2 being represented by —R 3′ —C 1-6 alkyl-NR 4 R 5 and said compounds being represented by formula (I-f), can be prepared by reacting an intermediate of formula (XVI) wherein W 4 represents a suitable leaving group, such as for example CH 3 —S( ⁇ O) 2 —O—, with NHR 4 R 5 in the presence of a suitable solvent, such as for example acetonitrile.
  • Intermediates of formula (XVI) can be prepared by reacting the corresponding OH derivatives with CH 3 —S( ⁇ O) 2 —Cl in the presence of a suitable base, such as for example pyridine, and a suitable solvent, such as for example dichloromethane.
  • a suitable base such as for example pyridine
  • a suitable solvent such as for example dichloromethane
  • Compounds of formula (I) wherein the R 1 substituent is substituted with amino can be prepared from the corresponding compound wherein the amino function is protected by a suitable protecting group, such as for example a tertiair butyloxycarbonyl group, in the presence of a suitable acid, such as for example trifluoroacetic acid, and a suitable solvent, such as for example dichloromethane.
  • a suitable protecting group such as for example a tertiair butyloxycarbonyl group
  • a suitable acid such as for example trifluoroacetic acid
  • a suitable solvent such as for example dichloromethane
  • the compounds of formula (I) may further be prepared by converting compounds of formula (I) into each other according to art-known group transformation reactions.
  • the compounds of formula (I) may be converted to the corresponding N-oxide forms following art-known procedures for converting a trivalent nitrogen into its N-oxide form.
  • Said N-oxidation reaction may generally be carried out by reacting the starting material of formula (I) with an appropriate organic or inorganic peroxide.
  • Appropriate inorganic peroxides comprise, for example, hydrogen peroxide, alkali metal or earth alkaline metal peroxides, e.g. sodium peroxide, potassium peroxide;
  • appropriate organic peroxides may comprise peroxy acids such as, for example, benzenecarboperoxoic acid or halo substituted benzenecarboperoxoic acid, e.g.
  • 3-chlorobenzenecarboperoxoic acid peroxoalkanoic acids, e.g. peroxoacetic acid, alkylhydroperoxides, e.g. tert.butyl hydro-peroxide.
  • Suitable solvents are, for example, water, lower alcohols, e.g. ethanol and the like, hydrocarbons, e.g. toluene, ketones, e.g. 2-butanone, halogenated hydrocarbons, e.g. dichloromethane, and mixtures of such solvents.
  • This reaction can also be performed as a fast synthesis reaction thereby using appropriate reagents well-known for fast synthesis, such as for example dicyclohexylcarbodiimide (DCC) or carbonyl diimidazole (CDI), linked to an appropriate carrier, e.g. polystyrene.
  • appropriate fast-synthesis reagents can be used, such as for example 1-ethenyl-4-(isocyanatomethyl)-benzene polymer with ethenylbenzene.
  • the compounds of formula (I) and some of the intermediates in the present invention may contain an asymmetric carbon atom.
  • Pure stereochemically isomeric forms of said compounds and said intermediates can be obtained by the application of art-known procedures.
  • diastereoisomers can be separated by physical methods such as selective crystallization or chromatographic techniques, e.g. counter current distribution, chiral liquid chromatography and the like methods.
  • Enantiomers can be obtained from racemic mixtures by first converting said racemic mixtures with suitable resolving agents such as, for example, chiral acids, to mixtures of diastereomeric salts or compounds; then physically separating said mixtures of diastereomeric salts or compounds by, for example, selective crystallization or chromatographic techniques, e.g. liquid chromatography and the like methods; and finally converting said separated diastereomeric salts or compounds into the corresponding enantiomers.
  • suitable resolving agents such as, for example, chiral acids
  • Intermediates of formula (III) can be prepared by deprotecting an intermediate of formula (V) wherein P represents a suitable protective group, such as for example benzyl or C 1-4 alkyloxycarbonyl, e.g. CH 3 CH 2 —O—C( ⁇ O)— or (CH 3 ) 3 C—O—C( ⁇ O)—.
  • P represents a suitable protective group, such as for example benzyl or C 1-4 alkyloxycarbonyl, e.g. CH 3 CH 2 —O—C( ⁇ O)— or (CH 3 ) 3 C—O—C( ⁇ O)—.
  • deprotection conditions are deprotection in the presence of a suitable acid, such as for example HBr, in the presence of Na 2 SO 3 , or deprotection in the presence of a suitable base, such as for example KOH, in the presence of a suitable solvent, such as for example water, ethylene glycol or an alcohol, e.g. propanol.
  • a suitable acid such as for example HBr
  • Na 2 SO 3 or deprotection in the presence of a suitable base, such as for example KOH
  • a suitable solvent such as for example water, ethylene glycol or an alcohol, e.g. propanol.
  • Intermediates of formula (V) wherein R 1 represents optionally substituted pyrazolyl can be prepared by reacting an intermediate of formula (VI) with an intermediate of formula (VII) in the presence of a suitable solvent, such as for example an alcohol, e.g. ethanol, and optionally in the presence of sodium.
  • a suitable solvent such as for example an alcohol, e.g. ethanol, and optionally in the presence of sodium.
  • Intermediates of formula (V) wherein R 1 represents optionally substituted triazolyl said intermediates being represented by formula (V-b) wherein R 1a represents the optional substituent, can be prepared by reacting an intermediate of formula (VIII) with an intermediate of formula (VII) in the presence of a suitable solvent, such as for example an alcohol, e.g. ethanol, and in the presence of a suitable base, such as for example sodium, or in the Presence of a suitable acid, such as for example acetic acid.
  • a suitable solvent such as for example an alcohol, e.g. ethanol
  • a suitable base such as for example sodium
  • a suitable acid such as for example acetic acid
  • Intermediates of formula (V) wherein R 1 represents optionally substituted pyrimidinyl can be prepared by reacting an intermediate of formula (VI) with an intermediate of formula (IX) in the presence of a suitable solvent, such as for example an alcohol, e.g. ethanol, and optionally in the presence of sodium.
  • a suitable solvent such as for example an alcohol, e.g. ethanol, and optionally in the presence of sodium.
  • Intermediates of formula (V) wherein R 1 represents optionally substituted imidazopyrazolyl, said intermediates being represented by formula (V-d) wherein R 1a represents the optional substituent, can be prepared by reacting an intermediate of formula (X) with an intermediate of formula (XI) in the presence of a suitable solvent, such as for example N,N-dimethylformamide, a suitable base, such as for example DIPEA, and a suitable dehydrating (coupling) agent, such as for example N′-(ethylcarbonimidoyl)-N,N-dimethyl-1,3-propanediamine monohydrochloride (EDCI), dicyclohexylcarbodiimide (DCC), carbonyl diimidazole (CDI), 1-[bis(di-methylamino)methylene]-1H-benzotriazoliumhexafluorophosphate(1-)3-oxide (HBTU), 1-[bis(dimethyl-amino)methylene]-5-chloro
  • This reaction of an intermediate of formula (X) with an intermediate of formula (XI) can also be performed in the presence of a suitable activating agent, such as for example Cl—C( ⁇ O)—C( ⁇ O)—Cl, a suitable base, such as for example N,N-diethyl-ethanamine, and a suitable solvent, such as for example N,N-dimethylformamide.
  • a suitable activating agent such as for example Cl—C( ⁇ O)—C( ⁇ O)—Cl
  • a suitable base such as for example N,N-diethyl-ethanamine
  • a suitable solvent such as for example N,N-dimethylformamide.
  • intermediates of formula (V-d) can also be directly prepared from an intermediate of formula (X) and an intermediate of formula (XI) in the presence of POCl 3 .
  • Intermediates of formula (V) wherein R 1 represents optionally substituted oxadiazole can be prepared by reacting an intermediate of formula (X) with an intermediate of formula (XXI) in the presence of a suitable solvent, such as for example N,N-dimethylformamide, a suitable base, such as for example DIPEA, and a suitable dehydrating (coupling) agent, such as for example N′-(ethylcarbonimidoyl)-N,N-dimethyl-1,3-propanediamine monohydrochloride (EDCI), dicyclohexylcarbodiimide (DCC), carbonyl diimidazole (CDI), 1-[bis(di-methylamino)methylene]-1H-benzotriazoliumhexafluorophosphate(1-)3-oxide (HBTU), 1-[bis(dimethyl-amino)methylene]-5-chloro
  • a suitable solvent such as for example N,N-dimethylformamide
  • Intermediates of formula (V) wherein R 1 represents optionally substituted oxadiazole said intermediates being represented by formula (V-e-2) wherein R 1a represents the optional substituent, can be prepared by reacting an intermediate of formula (XOH) with an intermediate of formula (XXIV) in the presence of a suitable base, such as for example sodium hydride, and a suitable solvent, such as for example tetrahydrofuran.
  • a suitable base such as for example sodium hydride
  • a suitable solvent such as for example tetrahydrofuran.
  • Intermediates of formula (V) wherein R 1 represents optionally substituted imidazothiazole, said intermediates being represented by formula (V-f) wherein R 1a represents the optional substituent can be prepared by reacting an intermediate of formula (XII) (see below) with Br 2 in the presence of HBr/acetic acid, followed by reacting the resulting intermediate of formula (XXV) with 2-amino-thiazole in the presence of a suitable solvent, such as for example an alcohol, e.g. ethanol.
  • a suitable solvent such as for example an alcohol, e.g. ethanol.
  • R 1 in an intermediate of formula (V) represents an unsubstituted heterocycle or triazolone
  • R 1a can be introduced by reaction with W 1 —R 1a , wherein W 1 represents a suitable leaving group, such as for example halo, e.g. chloro or bromo, in the presence of a suitable base, such as for example NaH, KOH, Na 2 CO 3 or Cs 2 CO 3 , and a suitable solvent, such as for example N,N-dimethylformamide or N,N-dimethylacetamide.
  • a suitable base such as for example NaH, KOH, Na 2 CO 3 or Cs 2 CO 3
  • a suitable solvent such as for example N,N-dimethylformamide or N,N-dimethylacetamide.
  • Intermediates of formula (X) wherein P is for instance benzyl can be prepared by hydrolysis of the corresponding ester in the presence of a suitable acid, such as for example HCl, or a suitable base, such as for example sodium hydroxide, in the presence of a suitable solvent, such as for example dioxane.
  • a suitable acid such as for example HCl
  • a suitable base such as for example sodium hydroxide
  • a suitable solvent such as for example tetrahydrofuran, dioxane or an alcohol, e.g. methanol.
  • the corresponding esters can be prepared by reacting the protected piperidine/piperazine with ethyl benzoate substituted in position 4 with a suitable leaving group, such as for example halo, e.g. fluoro and the like, in a suitable solvent, such as for example N,N-dimethylacetamide.
  • a suitable leaving group such as for example halo, e.g. fluoro and the like
  • Intermediates of formula (VI) can be prepared by reacting an intermediate of formula (XII) with CH 3 O—CH(OCH 3 )—N(CH 3 ) 2 .
  • Intermediates of formula (VIII) can be prepared by reacting an intermediate of formula (XIII) with CH 3 O—CH(OCH 3 )—N(CH 3 ) 2 .
  • Intermediates of formula (XII) wherein P represents tertiair butyloxycarbonyl can be prepared by reacting 1-[4-(1-piperazinyl)phenyl]ethanone with C,C′-bis(1,1-dimethylethyl) dicarbonic acid ester in the presence of a suitable solvent, such as for example dichloromethane.
  • a suitable solvent such as for example dichloromethane.
  • Intermediates of formula (XII) wherein P represents benzyl can be prepare by reacting 1-[4-(1-piperazinyl)phenyl]ethanone with benzylbromide in the presence of a suitable base, such as for example Na 2 CO 3 , and a suitable solvent, such as for example tetrahydrofuran.
  • Intermediates of formula (XIII) can be prepared by reacting an intermediate of formula (X) with NH 3 in the presence of a suitable solvent, such as for example N,N-dimethylformamide, and in the presence of a suitable dehydrating (coupling) agent, such as for example N-(ethylcarbonimidoyl)-N,N-dimethyl-1,3-propanediamine monohydrochloride (EDCI), dicyclohexylcarbodiimide (DCC), carbonyl diimidazole (CDI), 1-[bis(di-methylamino)methylene]-1H-benzotriazoliumhexafluorophosphate(1-)3-oxide (HBTU), 1-[bis(dimethyl-amino)methylene]-5-chloro-1H-benzotriazoliumhexafluorophosphate(1-) 3-oxide (HCTU), O-benzotriazolyltetramethylisouronium tetrafluoroborate (TB
  • Intermediates of formula (II) wherein X 1 represents a direct bond and R 2 contains a Het-C 1-4 alkyl substituent, wherein Het represents a monocyclic, saturated N containing heterocycle represented by formula (XXXII), said intermediate of formula (IV) being represented by formula (II-a), can be prepared by reacting an intermediate of formula (XXI) with an intermediate of formula (XXVI) in the represence of a suitable dehydrating (coupling) agent, such as for example N-(ethylcarbonimidoyl)-N,N-dimethyl-1,3-propanediamine monohydrochloride (EDCI), dicyclohexylcarbodiimide (DCC), carbonyl diimidazole (CDI), 1-[bis(di-methylamino)methylene]-1H-benzotriazoliumhexafluorophosphate(1-)3-oxide (HBTU), 1-[bis(dimethylamino)-methylene]
  • the resulting intermediate of formula (XXVII) can then be reduced in a next step in the presence of a suitable reducing agent, such as for example borane, in the presence of a suitable solvent, such as for example tetrahydrofuran, to an intermediate of formula (XXVIII), which can then be converted into an intermediate of formula (II-a) with phosgene in the presence of HCl in diethylether and a suitable solvent, such as for example toluene or acetonitrile.
  • a suitable reducing agent such as for example borane
  • a suitable solvent such as for example tetrahydrofuran
  • Intermediates of formula (XXVII) can also be converted into an intermediate of formula (II-b) with phosgene in the presence of HCl in diethylether and a suitable solvent, such as for example toluene or acetonitrile or dichloromethane.
  • Intermediates of formula (II′) wherein R 2 contains a Het-C 1-4 alkyl substituent, said intermediate being represented by formula (II′-a), can be prepared by reacting an intermediate of formula (XIX) with an intermediate of formula (XX) wherein W 6 represents a suitable leaving group, such as for example halo, e.g. chloro and the like, in the presence of a suitable solvent, such as for example acetonitrile, resulting in an intermediate of formula (II′-a) with can be converted into an intermediate of formula (II-a) as described hereinabove for intermediate (XXVIII).
  • a suitable solvent such as for example acetonitrile
  • Intermediates of formula (IV) can be prepared by hydrolysis of an intermediate of formula (XXIX)) in the presence of LiOH, an acid, such as for example HCl, and a suitable solvent, such as for example an alcohol, e.g. methanol.
  • Intermediates of formula (XXIX)) wherein R 2 contains Het-C 1-4 alkyl as substituent, said intermediates being represented by formula (XXIX-a) can be prepared by reacting an intermediate of formula (XXX) wherein W 7 represents a suitable leaving group, such as for example halo, e.g. bromo and the like, with an intermediate of formula (XXI).
  • Intermediates of formula (XXX-a) as depicted below, can be prepared by reacting an intermediate of formula (XXXI) with N-bromosuccinimide in the presence of 2,2′-(1,2-diazenediyl)-bis[2-methylpropanenitrile] and a suitable solvent, such as for example CCl 4 .
  • Intermediates of formula (XXXI) wherein X 1 represents CH 2 said intermediates being represented by formula (XXXI-a)
  • Intermediates of formula (XXXII) can be prepared by reacting an intermediate of formula (II′-b) with 1,1-dimethylethyl-nitrous acid ester, CuCl 2 , 1,1-dichloroethene in a suitable solvent, such as for example acetonitrile.
  • Intermediates of formula (XXVIII-a) can be prepared by reacting an intermediate of formula (IV) wherein X 1 is substituted with a protected (P, such as for example tertiair butyloxycarbonyl) amino group, said intermediate being represented by formula (IV-a), with an intermediate of formula (III) in the presence of a suitable dehydrating (coupling) agent, such as for example N′-(ethylcarbonimidoyl)-N,N-dimethyl-1,3-propanediamine monohydrochloride (EDCI), dicyclohexylcarbodiimide (DCC), carbonyl diimidazole (CDI), 1-[bis(di-methylamino)methylene]-1H-benzotriazoliumhexafluorophosphate(1-)3-oxide (HBTU), 1-[bis(dimethyl-amino)-methylene]-5-chloro-1H-benzotriazolium-hexafluorophosphate(1-)
  • Intermediates of formula (IV) wherein X 1 represents CHOH said intermediates being represented by formula (IV-b) can be prepared by reducing an intermediate of formula (XVII) in the presence of ZnBr 2 , Si(CH 3 ) 3 —CN and an acid, such as for example HCl, in the presence of a suitable solvent, such as for example dichloromethane.
  • Intermediates of formula (XVII) can be prepared by reacting an intermediate of formula (XOCH) wherein W 8 represents a suitable leaving group, such as for example halo, e.g. bromo and the like, with N,N-dimethylformamide in the presence of BuLi and a suitable solvent such as for example tetrahvdrofuran
  • the present invention relates to the use of a DGAT inhibitor, in particular a DGAT1 inhibitor, to elevate levels of one or more satiety hormones, in particular GLP-1 levels.
  • the present invention also relates to the use of a DGAT inhibitor, in particular a DGAT1 inhibitor, for the manufacture of a medicament for the prevention or the treatment, in particular for the treatment, of a disease which can benefit from an elevated level of one or more satiety hormones, in particular a disease which can benefit from an elevated GLP-1 level.
  • GLP-1 levels are elevated in plasma or in portal blood, more in particular in plasma.
  • GLP-1 plasma level or an elevated GLP-1 level in portal blood it is meant that the GLP-1 level of a subject having taken a DGAT1 inhibitor is elevated or increased compared to the subject under the same conditions but not having taken the DGAT1 inhibitor.
  • GLP-1 levels are elevated in fasting conditions or postprandial, more in particular postprandial.
  • Therapeutic uses for a compound which elevates GLP-1 level include, but are not limited to, improving learning, enhancing neuro-protection, and/or alleviating a symptom of a disease or disorder of the central nervous system, e.g., through modulation of neurogenesis, and e.g., Parkinson's Disease, Alzheimer's Disease, Huntington's Disease, ALS, stroke, hemorrhage, cerebrovascular accident, ADD, and neuropsychiatric syndromes; converting liver stem/progenitor cells into functional pancreatic cells; preventing beta-cell deterioration and stimulation of beta-cell proliferation; treating pancreatitis; treating obesity; suppressing appetite and inducing satiety; treating irritable bowel syndrome or inflammatory bowel disease such as Crohn's disease and ulcerative colitis; reducing the morbidity and/or mortality associated with myocardial infarction and stroke; treating acute coronary syndrome characterized by an absence of Q-wave myocardial infarction; attenuating post-surgical catabolic changes
  • GLP-1 cerebral hypothalamic thalamic thalamic thalamic thalamic thalamic thalamic thalamic thalamic thalamic thalamic thalamic thalamic thalamic thalamic thalamic thalamic thalamic thalamic thalamic thalamic thalamic thalamic thalamic thalamic thalamic thalamic thalasis pulmonary fibroblast fibroblast fibroblast fibroblast fibroblast fibroblast fibroblast fibroblast fibroblast fibroblast fibroblast fibroblast fibroblast fibroblast fibroblast fibroblast fibroblast fibroblast fibroblast fibroblast fibroblast fibroblast fibroblast fibroblast fibroblast fibroblast fibroblast fibroblast fibroblast fibroblast fibroblast fibroblast fibroblast fibroblast fibroblast fibroblast fibroblast fibroblast fibroblast fibroblast fibroblast fibroblast fibroblast fibroblast fibroblast
  • the present compounds of formula (I), their N-oxide forms, their pharmaceutically acceptable salts or their solvates can be used as a medicine.
  • the present invention relates to a compound of formula (I), a N-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof for use as a medicine, in particular for use as a medicine for the prevention or the treatment of a disease which can benefit from an elevated GLP-1 level.
  • the present invention also relates to the use of a compound of formula (I) for the manufacture of a medicament for the prevention or the treatment of a disease which can benefit from an elevated GLP-1 level, such as the diseases and disorders mentioned above.
  • a method of treating a warm-blooded mammal, including a human, suffering from or a method of preventing a warm-blooded mammal, including a human, to suffer from a disease which can benefit from an elevated level of GLP-1 in particular a method of treating a warm-blooded mammal, including a human, suffering from a disease which can benefit from an elevated level of GLP-1.
  • Said methods comprise the administration of an effective amount of a DGAT inhibitor, in particular a DGAT1 inhibitor, to a warm-blooded mammal, including a human.
  • a method of treating a warm-blooded mammal, including a human, suffering from or a method of preventing a warm-blooded mammal, including a human, to suffer from a disease which can benefit from an elevated level of GLP-1 in particular a method of treating a warm-blooded mammal, including a human, suffering from a disease which can benefit from an elevated level of GLP-1.
  • Said methods comprise the administration of an effective amount of a compound of formula (I), a N-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, to a warm-blooded mammal, including a human.
  • the present invention also relates to a compound of formula (I), a N-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof for use as a medicine, in particular for use as a medicine for the prevention or the treatment of a diseases which can benefit from inhibition of DGAT, in particular DGAT1.
  • the invention also relates to the use of a compound of formula (I), a N-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, for the manufacture of a medicament for the prevention or the treatment of a disease or disorder which can benefit from inhibition of DGAT, in particular DGAT1.
  • DGAT1 Diseases or disorders which can benefit from inhibition of DGAT, in particular DGAT1 include, but are not limited to metabolic disorders, such as obesity and obesity related disorders (including peripheral vascular disease, cardiac failure, myocardial ischaemia, cerebral ischaemia, cardiac myopathies), diabetes, in particular type II diabetes mellitus, and complications arising therefrom (such as retinopathy, neuropathy, nephropathy), syndrome X, insulin resistance, impaired glucose tolerance, conditions of impaired fasting glucose, hypoglycemia, hyperglycemia, hyperuricemia, hyperinsulinemia, pancreatitis, hypercholesterolemia, hyperlipidemia, dyslipidemia, mixed dyslipidemia, hypertriglyceridemia and nonalcoholic fatty liver disease, fatty liver, increased mesenteric fat, non-alcoholic steatohepatitis, liverfibrosis, metabolic acidosis, ketosis, dysmetabolic syndrome; dermatological conditions such as acne, psoriasis; cardiovascular diseases, such as atherosclerosis, arterio
  • DGAT diseases or disorders which can benefit from inhibition of DGAT, in particular DGAT1
  • diseases or disorders which can benefit from inhibition of DGAT are selected from obesity, hypercholesterolemia, hyperlipidemia, dyslipidemia, mixed dyslipidemia, hypertriglyceridemia, fatty liver, nonalcoholic fatty liver disease, liverfibrosis, non-alcoholic steatohepatitis and diabetes, in particular type II diabetes.
  • a method of treating a warm-blooded mammal, including a human, suffering from or a method of preventing a warm-blooded mammal, including a human, to suffer from a disease which can benefit from inhibition of DGAT in particular a method of treating a warm-blooded mammal, including a human, suffering from a disease which can benefit from inhibition of DGAT.
  • Said methods comprise the administration of an effective amount of a compound of formula (I), a N-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, to a warm-blooded mammal, including a human.
  • the present invention also provides compositions for preventing or treating a disease which can benefit from an elevated GLP-1 level or which can benefit from inhibition of DGAT, in particular DGAT1, in particular for treating a disease which can benefit from elevated GLP-1 levels or which can benefit from inhibition of DGAT, in particular DGAT1.
  • Said compositions comprise a therapeutically effective amount of a compound of formula (I), a N-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, and a pharmaceutically acceptable carrier.
  • compositions of the present invention may be formulated into various pharmaceutical forms for administration purposes.
  • compositions there may be cited all compositions usually employed for systemically administering drugs.
  • an effective amount of the particular compound, optionally in salt form, as the active ingredient is combined in intimate admixture with a pharmaceutically acceptable carrier, which carrier may take a wide variety of forms depending on the form of preparation desired for administration.
  • a pharmaceutically acceptable carrier which carrier may take a wide variety of forms depending on the form of preparation desired for administration.
  • These pharmaceutical compositions are desirable in unitary dosage form suitable, particularly, for administration orally, rectally, percutaneously, or by parenteral injection.
  • any of the usual pharmaceutical media may be employed such as, for example, water, glycols, oils, alcohols and the like in the case of oral liquid preparations such as suspensions, syrups, elixirs, emulsions and solutions; or solid carriers such as starches, sugars, kaolin, diluents, lubricants, binders, disintegrating agents and the like in the case of powders, pills, capsules, and tablets. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit forms, in which case solid pharmaceutical carriers are obviously employed.
  • the carrier will usually comprise sterile water, at least in large part, though other ingredients, for example, to aid solubility, may be included.
  • injectable solutions for example, may be prepared in which the carrier comprises saline solution, glucose solution or a mixture of saline and glucose solution.
  • injectable suspensions may also be prepared in which case appropriate liquid carriers, suspending agents and the like may be employed.
  • solid form preparations which are intended to be converted, shortly before use, to liquid form preparations.
  • the carrier optionally comprises a penetration enhancing agent and/or a suitable wetting agent, optionally combined with suitable additives of any nature in minor proportions, which additives do not introduce a significant deleterious effect on the skin.
  • Said additives may facilitate the administration to the skin and/or may be helpful for preparing the desired compositions.
  • These compositions may be administered in various ways, e.g., as a transdermal patch, as a spot-on, as an ointment.
  • the compounds of the present invention may also be administered via inhalation or insufflation by means of methods and formulations employed in the art for administration via this way.
  • the compounds of the present invention may be administered to the lungs in the form of a solution, a suspension or a dry powder. Any system developed for the delivery of solutions, suspensions or dry powders via oral or nasal inhalation or insufflation are suitable for the administration of the present compounds.
  • the compounds of the present invention may also be topically administered in the form of drops, in particular eye drops.
  • Said eye drops may be in the form of a solution or a suspension. Any system developed for the delivery of solutions or suspensions as eye drops are suitable for the administration of the present compounds.
  • Unit dosage form refers to physically discrete units suitable as unitary dosages, each unit containing a predetermined quantity of active ingredient calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier.
  • unit dosage forms are tablets (including scored or coated tablets), capsules, pills, powder packets, wafers, suppositories, injectable solutions or suspensions and the like, and segregated multiples thereof.
  • the exact dosage and frequency of administration depends on the particular compound of formula (I) used, the particular condition being treated, the severity of the condition being treated, the age, weight, sex, extent of disorder and general physical condition of the particular patient as well as other medication the individual may be taking, as is well known to those skilled in the art. Furthermore, it is evident that said effective daily amount may be lowered or increased depending on the response of the treated subject and/or depending on the evaluation of the physician prescribing the compounds of the instant invention.
  • the pharmaceutical composition will preferably comprise from 0.05 to 99% by weight, more preferably from 0.1 to 70% by weight, even more preferably from 0.1 to 50% by weight of the compound of formula (I), and, from 1 to 99.95% by weight, more preferably from 30 to 99.9% by weight, even more preferably from 50 to 99.9% by weight of a pharmaceutically acceptable carrier, all percentages being based on the total weight of the composition.
  • the present invention also relates to
  • a DGAT inhibitor in particular a DGAT1 inhibitor, more in particular a compound of formula (I), a N-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, and a dipeptidyl peptidase-4 inhibitor (DPP-4 inhibitor).
  • DPP-4 inhibitor dipeptidyl peptidase-4 inhibitor
  • DPP-4 is a membrane-spanning cell surface aminopeptidase widely expressed in many tissues, such as liver, lung, kidney, intestinal brush-border membranes, lymphocytes, endothelial cells. DPP-4 cleaves peptides with a proline or alanine residue in the second aminoterminal position. Many gastro-intestinal hormones are substrates for DPP-4, among them GLP-1. A DPP-4 inhibitor thus inhibits cleavage of GLP-1 and hence provides for an increase in the level of GLP-1. Therefore, a combination as indicated above can be used to combine the activity of the DGAT inhibitor and the DPP4 inhibitor in order to elevate GLP-1 levels.
  • a DGAT inhibitor in particular a DGAT1 inhibitor, more in particular a compound of formula (I), a N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof
  • a DPP4 inhibitor By administering a DGAT inhibitor, in particular a DGAT1 inhibitor, more in particular a compound of formula (I), a N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, with a DPP4 inhibitor, different mechanisms may be targeted in order to achieve elevated levels of GLP-1.
  • the use of such a combination may reduce the dosage of the DGAT inhibitor and the DPP4 inhibitor required for a desired elevation in GLP-1 level as compared to when the DGAT inhibitor or the DPP4 inhibitor is administered as a monotherapy. Therefore, these combinations may reduce or eliminate side effects of monotherapy while not interfering with the GLP-1 level increasing activity.
  • a DGAT inhibitor in particular a DGAT1 inhibitor, more in particular a compound of formula (I), a N-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof
  • a DPP4 inhibitor can be used as a medicine.
  • the present invention also relates to a product comprising (a) a DGAT inhibitor, in particular a DGAT1 inhibitor, more in particular a compound of formula (I), a N-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, and (b) a DPP4 inhibitor, as a combined preparation for simultaneous, separate or sequential use in the treatment of a disease which can benefit from an elevated level of GLP-1.
  • the different drugs of such a combination or product may be combined in a single preparation together with pharmaceutically acceptable carriers or they may each be present in a separate preparation together with pharmaceutically acceptable carriers.
  • Said DPP4 inhibitor which may be combined with a DGAT inhibitor according to the present invention, in particular a DGAT1 inhibitor, may be a known DPP4 inhibitor such as for example sitagliptin, vildagliptin, and saxagliptin.
  • a DGAT inhibitor in particular a DGAT1 inhibitor, more in particular a compound of formula (I), a N-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, and a GLP-1 analogue.
  • Said GLP-1 analogue can be considered as an agonist at the GLP-1 receptor.
  • a DGAT inhibitor in particular a DGAT1 inhibitor, more in particular a compound of formula (I), a N-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof
  • a GLP-1 analogue can be used as a medicine.
  • the present invention also relates to a product containing (a) a DGAT inhibitor, in particular a DGAT1 inhibitor, more in particular a compound of formula (I), a N-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, and (b) a GLP-1 analogue, as a combined preparation for simultaneous, separate or sequential use in the treatment of a disease which can benefit from an elevated level of GLP-1.
  • the different drugs of such a combination or product may be combined in a single preparation together with pharmaceutically acceptable carriers or they may each be present in a separate preparation together with pharmaceutically acceptable carriers.
  • Said GLP-1 analogue which may be combined with a DGAT inhibitor according to the present invention may be a known GLP-1 analogue such as for example exenatide, exenatide LAR or liraglutide.
  • a DGAT inhibitor in particular a DGAT1 inhibitor, more in particular a compound of formula (I), a N-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, and an anti-diabeticum.
  • a DGAT inhibitor in particular a DGAT1 inhibitor, more in particular a compound of formula (I), a N-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, and an anti-diabeticum can be used as a medicine.
  • the present invention also relates to a product containing (a) a DGAT inhibitor, in particular a DGAT1 inhibitor, more in particular a compound of formula (I), a N-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, and (b) an anti-diabeticum, as a combined preparation for simultaneous, separate or sequential use in the treatment of a disease which can benefit from an elevated level of GLP-1 or DGAT inhibition, such as for example diabetes, in particular type II diabetes.
  • the different drugs of such a combination or product may be combined in a single preparation together with pharmaceutically acceptable carriers or they may each be present in a separate preparation together with pharmaceutically acceptable carriers.
  • Said anti-diabeticum which may be combined with a DGAT inhibitor according to the present invention may be a known anti-diabeticum such as for example metformin, glibenclamide, rosiglitazon, pioglitazon, repaglinide, glimepiride, acarbose, glicazide, glipizide, nateglinide, tolbutamide, a protein tyrosine phosphatase 1 inhibitor, or a 11-beta-hydroxysteroid dehydrogenase inhibitor.
  • a known anti-diabeticum such as for example metformin, glibenclamide, rosiglitazon, pioglitazon, repaglinide, glimepiride, acarbose, glicazide, glipizide, nateglinide, tolbutamide, a protein tyrosine phosphatase 1 inhibitor, or
  • a DGAT inhibitor in particular a DGAT1 inhibitor, more in particular a compound of formula (I), a N-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, and a phosphodiesterase (PDE) inhibitor, in particular a PDE10A or PDE11A inhibitor.
  • PDE phosphodiesterase
  • a DGAT inhibitor in particular a DGAT1 inhibitor, more in particular a compound of formula (I), a N-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, and a phosphodiesterase (PDE) inhibitor, in particular a PDE10A or PDE11A inhibitor, can be used as a medicine.
  • a DGAT inhibitor in particular a DGAT1 inhibitor, more in particular a compound of formula (I), a N-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof
  • PDE phosphodiesterase
  • the present invention also relates to a product containing (a) a DGAT inhibitor, in particular a DGAT1 inhibitor, more in particular a compound of formula (I), a N-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, and (b) a phosphodiesterase (PDE) inhibitor, in particular a PDE10A or PDE11A inhibitor, as a combined preparation for simultaneous, separate or sequential use in the treatment of a disease which can benefit from an elevated level of GLP-1 or DGAT inhibition, such as for example diabetes, in particular type II diabetes, or obesity.
  • the different drugs of such a combination or product may be combined in a single preparation together with pharmaceutically acceptable carriers or they may each be present in a separate preparation together with pharmaceutically acceptable carriers.
  • Said phosphodiesterase (PDE) inhibitor in particular a PDE10A or PDE11A inhibitor, which may be combined with a DGAT inhibitor according to the present invention may be a known PDE inhibitor such as for example papaverine, PQ-10, dipyridamole, ibudilast or tadalafil.
  • a DGAT inhibitor in particular a DGAT1 inhibitor, more in particular a compound of formula (I), a N-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, and an appetite suppressant.
  • a DGAT inhibitor in particular a DGAT1 inhibitor, more in particular a compound of formula (I), a N-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, and an appetite suppressant can be used as a medicine.
  • the present invention also relates to a product containing (a) a DGAT inhibitor, in particular a DGAT1 inhibitor, more in particular a compound of formula (I), a N-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, and (b) an appetite suppressant, as a combined preparation for simultaneous, separate or sequential use in the treatment of a disease which can benefit from an elevated level of GLP-1 or DGAT inhibition, such as for example diabetes, in particular type II diabetes, or obesity.
  • the different drugs of such a combination or product may be combined in a single preparation together with pharmaceutically acceptable carriers or they may each be present in a separate preparation together with pharmaceutically acceptable carriers.
  • Said appetite suppressants, which may be combined with a DGAT inhibitor according to the present invention may be a known appetite suppressant such as for example sibutramine and phentermine.
  • a DGAT inhibitor in particular a DGAT1 inhibitor, more in particular a compound of formula (I), a N-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, and an anti-obesity drug with a CNS (central nervous system) mode of action such as for example a CB1 antagonist or inverse agonists.
  • a CNS central nervous system
  • a DGAT inhibitor in particular a DGAT1 inhibitor, more in particular a compound of formula (I), a N-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, and an anti-obesity drug with a CNS (central nervous system) mode of action can be used as a medicine.
  • a DGAT inhibitor in particular a DGAT1 inhibitor, more in particular a compound of formula (I), a N-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, and an anti-obesity drug with a CNS (central nervous system) mode of action
  • CNS central nervous system
  • the present invention also relates to a product containing (a) a DGAT inhibitor, in particular a DGAT1 inhibitor, more in particular a compound of formula (I), a N-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, and (b) an anti-obesity drug with a CNS (central nervous system) mode of action, as a combined preparation for simultaneous, separate or sequential use in the treatment of a disease which can benefit from an elevated level of GLP-1 or DGAT inhibition, such as for example diabetes, in particular type II diabetes, or obesity.
  • the different drugs of such a combination or product may be combined in a single preparation together with pharmaceutically acceptable carriers or they may each be present in a separate preparation together with pharmaceutically acceptable carriers.
  • Said anti-obesity drugs with a CNS (central nervous system) mode of action which may be combined with a DGAT inhibitor according to the present invention may be a known a anti-obesity drug such as for example Rimonabant, orlistat, SLV-319, or MK-0364.
  • a DGAT inhibitor in particular a DGAT1 inhibitor, more in particular a compound of formula (I), a N-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, and an hypolipidemic drug such as for example 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA) reductase inhibitors, squalene synthase inhibitors, FXR (farnesoid X receptor) and LXR (liver X receptor) ligands, cholestyramine, fibrates, nicotinic acid and aspirin.
  • HMG-CoA 3-hydroxy-3-methyl-glutaryl coenzyme A
  • FXR farnesoid X receptor
  • LXR liver X receptor
  • a DGAT inhibitor in particular a DGAT1 inhibitor, more in particular a compound of formula (I), a N-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, and an hypolipidemic drug can be used as a medicine.
  • the present invention also relates to a product containing (a) a DGAT inhibitor, in particular a DGAT1 inhibitor, more in particular a compound of formula (I), a N-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, and (b) an hypolipidemic drug, as a combined preparation for simultaneous, separate or sequential use in the treatment of a disease which can benefit from an elevated level of GLP-1 or DGAT inhibition, such as for example diabetes, in particular type II diabetes, or obesity.
  • the different drugs of such a combination or product may be combined in a single preparation together with pharmaceutically acceptable carriers or they may each be present in a separate preparation together with pharmaceutically acceptable carriers.
  • Said hypolipidemic drug which may be combined with a DGAT inhibitor according to the present invention may be a known hypolipidemic drug such as for example lovastatin, pravastatin, simvastatin, pravastatin, cerivastatin, mevastatin, velostatin, fluvastatin, dalvastatin, atorvastatin, rosuvastatin and rivastatin.
  • a DGAT inhibitor in particular a DGAT1 inhibitor, more in particular a compound of formula (I), a N-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, and an agonist of peroxisome proliferator-activator receptor such as for example fenofibrate.
  • a DGAT inhibitor in particular a DGAT1 inhibitor, more in particular a compound of formula (I), a N-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, and an agonist of peroxisome proliferator-activator receptor such as for example fenofibrate, can be used as a medicine.
  • the present invention also relates to a product containing (a) a DGAT inhibitor, in particular a DGAT1 inhibitor, more in particular a compound of formula (I), a N-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, and (b) an agonist of peroxisome proliferator-activator receptor such as for example fenofibrate, as a combined preparation for simultaneous, separate or sequential use in the treatment of a disease which can benefit from an elevated level of GLP-1 or DGAT inhibition, such as for example diabetes, in particular type II diabetes, or obesity.
  • the different drugs of such a combination or product may be combined in a single preparation together with pharmaceutically acceptable carriers or they may each be present in a separate preparation together with pharmaceutically acceptable carriers.
  • a DGAT inhibitor in particular a DGAT1 inhibitor, more in particular a compound of formula (I), a N-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, and an antihypertensive agent.
  • a DGAT inhibitor in particular a DGAT1 inhibitor, more in particular a compound of formula (I), a N-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, and an antihypertensive agent, can be used as a medicine.
  • the present invention also relates to a product containing (a) a DGAT inhibitor, in particular a DGAT1 inhibitor, more in particular a compound of formula (I), a N-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, and (b) an antihypertensive agent, as a combined preparation for simultaneous, separate or sequential use in the treatment of a disease which can benefit from an elevated level of GLP-1 or DGAT inhibition, such as for example diabetes, in particular type II diabetes, or obesity.
  • the different drugs of such a combination or product may be combined in a single preparation together with pharmaceutically acceptable carriers or they may each be present in a separate preparation together with pharmaceutically acceptable carriers.
  • Said anti-hypertensive agent which may be combined with a DGAT inhibitor according to the present invention may be a known anti-hypertensive agent, e g loop diuretics such as ethacrynic acid, furosemide and torsemide, angiotensin converting enzyme (ACE) inhibitors such as benazepril, captopril, enalapril, fosinopril, lisinopril, moexipril, perinodopril, quinapril, ramipril and trandolapril; inhibitors of the Na-K-ATPase membrane pump such as digoxin; neutralendopeptidase (NEP) inhibitors; ACE/NEP inhibitors such as omapatrilat, sampatrilat and fasidotril; angiotensin II antagonists such as candesartan, eprosartan, irbesartan, losart
  • THF tetrahydrofuran
  • Et 2 O diethyl ether
  • CH 3 OH methanol
  • Pd(OH) 2 palladium hydroxide
  • POCl 3 phosphoric trichloride
  • EtOAc ethyl acetate
  • Na 2 CO 3 carbonic acid disodium salt
  • NaHCO 3 carbonic acid monosodium salt
  • CH 2 Cl 2 ’ or ‘DCM’ means dichloromethane
  • CH 3 CN means acetonitrile
  • EtOH means ethanol
  • DIPE diisopropyl ether
  • HBTU means 1-[bis(di-methylamino)methylene]-1H-benzotriazoliumhexafluorophosphate(1-)3-oxide
  • DMF means N,N-dimethyl-formamide
  • DMA means N,N-dimethyl-formamide
  • DMA means N,N-dimethyl-formamide
  • Isolute HM-NTM filter is a product of Argonaut, Foster City, Calif. 94404, USA, and is a short column comprising a modified form of diatomaceous earth that can remove water from a sample in combinatorial chemistry appations.
  • ExtrelutTM is a product of Merck KgaA, Darmstadt, Germany, and is a short column comprising diatomaceous earth.
  • the product was purified by reversed-phase high-performance liquid chromatography (Shandon Hyperprep® C18 BDS (Base Deactivated Silica) 8 ⁇ m, 250 g, I.D. 5 cm). Two mobile phases were used (phase A: a 0.25% NH 4 HCO 3 solution in water; phase B: CH 3 CN). First, 85% A and 15% B with a flow rate of 40 ml/min was hold for 0.5 minutes. Then a gradient was applied to 10% A and 90% B in 41 minutes with a flow rate of 80 ml/min. Then a gradient was applied to 100% B in 20 minutes with a flow rate of 80 ml/min and hold for 4 minutes.
  • phase A a 0.25% NH 4 HCO 3 solution in water
  • phase B CH 3 CN
  • the product was purified by reversed-phase high-performance liquid chromatography (Shandon Hyperprep® C18 BDS (Base Deactivated Silica) 8 ⁇ m, 250 g, I.D. 5 cm).
  • Two mobile phases were used (phase A: 90% of a 0.5% NH 4 OAc solution in water+10% CH 3 CN; phase B: CH 3 CN).
  • phase A 90% of a 0.5% NH 4 OAc solution in water+10% CH 3 CN
  • phase B CH 3 CN
  • 85% A and 15% B with a flow rate of 40 ml/min was hold for 0.5 minutes.
  • a gradient was applied to 10% A and 90% B in 41 minutes with a flow rate of 80 ml/min.
  • a gradient was applied to 100% B in 20 minutes with a flow rate of 80 ml/min and hold for 4 minutes.
  • phase A 90% of a 0.5% NH 4 OAc solution in water+10% CH 3 CN; phase B: CH 3 OH; phase C: CH 3 CN).
  • phase B 90% of a 0.5% NH 4 OAc solution in water+10% CH 3 CN; phase B: CH 3 OH; phase C: CH 3 CN).
  • the residue was purified by reversed phase high-performance liquid chromatography (Shandon Hyperprep® C18 BDS (Base Deactivated Silica) 8 ⁇ m, 250 g, I.D. 5 cm). A gradient with 2 mobile phases was applied. Phase A: 90% of a 0.5% NH 4 OAc solution in water+10% CH 3 CN; phase B: CH 3 CN). The desired fractions were collected and the eluent was evaporated. The residue was neutralized with NaHCO 3 , extracted with DCM and dried (MgSO 4 ), filtered and the solvent was evaporated, yielding 254 mg of intermediate 29 (43%).
  • 2,6-Dichloro-4-chloromethyl-phenylamine (11 g, 0.0445 mol) was added portionwise to a stirring solution of pyrrolidine (15.84 g, 0.223 mol) in CH 3 CN (250 ml). The reaction mixture was placed in a water bath (exothermic reaction). The solvent was evaporated and the residue was dissolved in CH 2 Cl 2 (150 ml) and a 50% saturated NaHCO 3 solution (100 ml). The mixture was stirred for 15 minutes. The organic layer was separated, dried (MgSO 4 ), filtered and the solvent was evaporated and co-evaporated with toluene.
  • Phase A a 0.25% NH 4 HCO 3 solution in water
  • phase B (optional): CH 3 OH
  • phase C CH 3 CN
  • the desired fractions were collected and the solvent was evaporated. The residue was dried, yielding 0.802 g of intermediate 43.
  • Norite (0.8 g) was added to a solution of methyl 4-amino-3,5-dichlorobenzoic acid ester (8.00 g; 36.3 mmol) and trichloromethyl carbonochloridic acid ester (8.0 ml; 66.2 mmol) in dry toluene (72 ml).
  • the resulting mixture was heated at stirring in stainless steel bomb of a Parr apparatus at 110° C. for 20 hours. Then the reaction mixture was cooled and filtered through a pad of celite. The filtrate was bubbled with argon for 2 hours to remove phosgene and hydrogen chloride. Then the filtrate was concentrated in vacuum.
  • 1,3-Dichloro-2-isocyanatobenzene (0.000698 mol) was added to a slightly cloudy solution of intermediate 22 (0.000698 mol) in CH 2 Cl 2 (10 ml, p.a.), stirred at room temperature. The reaction mixture was stirred overnight at room temperature. The mixture was purified by flash column chromatography over a Biotage 60 cartridge (eluent: CH 2 Cl 2 /(7N NH 3 /CH 3 OH) from 100/0 to 95/5 v/v). The product fractions were collected and the solvent was evaporated, yielding 0.171 g of compound 7.
  • Phase A 90% of a 0.5% NH 4 OAc solution in water+10% CH 3 CN; phase B (optional): CH 3 OH; phase C: CH 3 CN).
  • the desired fractions were collected, partially evaporated at 30° C. and neutralized to pH 8-9 with a saturated NaHCO 3 solution.
  • the formed precipitate was filtered off and dried, yielding 820 mg of compound 54 (78%).
  • Table 1a lists compounds of formula (I) according to the present invention prepared by analogy to one of the above Example Nr.
  • the HPLC measurement was performed using an Alliance HT 2790 (Waters) system comprising a quaternary pump with degasser, an autosampler, a column oven (set at 40° C., unless otherwise indicated), a diode-array detector (DAD) and a column as specified in the respective methods below.
  • Flow from the column was split to a MS detector.
  • the MS detector was configured with an electrospray ionization source. Mass spectra were acquired by scanning from 100 to 1000 in 1 second using a dwell time of 0.1 second.
  • the capillary needle voltage was 3 kV and the source temperature was maintained at 140° C. Nitrogen was used as the nebulizer gas.
  • Data acquisition was performed with a Waters-Micromass MassLynx-Openlynx data system.
  • the LC measurement was performed using an Acquity UPLC (Waters) system comprising a binary pump, a sample organizer, a column heater (set at 55° C.), a diode-array detector (DAD) and a column as specified in the respective methods below.
  • Flow from the column was split to a MS detector.
  • the MS detector was configured with an electrospray ionization source. Mass spectra were acquired by scanning from 100 to 1000 in 0.18 seconds using a dwell time of 0.02 seconds.
  • the capillary needle voltage was 3.5 kV and the source temperature was maintained at 140° C. Nitrogen was used as the nebulizer gas.
  • Data acquisition was performed with a Waters-Micromass MassLynx-Openlynx data system.
  • the LCMS analyses for the compounds were done at the Surveyor MSQTM (Thermo Finnigan, USA) comprising a photo diode array detector (PDA; 190-800 nm) and a column as specified in the respective methods below. Flow from the column was split to a MS spectrometer.
  • the MS detector was configured with APCI (atmospheric pressure chemical ionization, +or ⁇ ions). Mass spectra were acquired by scanning from 45 to 1000 (of atomic mass unit) in 0.3 seconds. Typical APCI conditions use a corona discharge current of 10 ⁇ A and a cone voltage of 30 V.
  • the APCI probe temperature was 640° C. Nitrogen was used as the nebulizer gas. Data acquisition was performed with an XcaliburTM data system.
  • Reversed phase HPLC was carried out on an Xterra MS C18 column (3.5 ⁇ m, 4.6 ⁇ 100 mm) with a flow rate of 1.6 ml/min.
  • Three mobile phases (mobile phase A: 95% 25 mM ammoniumacetate+5% acetonitrile; mobile phase B: acetonitrile; mobile phase C: methanol) were employed to run a gradient condition from 100% A to 1% A, 49% B and 50 C in 6.5 minutes, to 1% A and 99% B in 1 minute and hold these conditions for 1 minute and reequilibrate with 100% A for 1.5 minutes.
  • An injection volume of 10 ⁇ l was used.
  • Cone voltage was 10 V for positive ionization mode and 20 V for negative ionization mode.
  • Reversed phase HPLC was carried out on a Chromolith (4.6 ⁇ 25 mm) with a flow rate of 3 ml/min.
  • Three mobile phases (mobile phase A: 95% 25 mM ammoniumacetate+5% acetonitrile; mobile phase B: acetonitrile; mobile phase C: methanol) were employed to run a gradient condition from 96% A, 2% B and 2% C, to 49% B and 49% C in 0.9 minutes, to 100% B in 0.3 minutes and hold for 0.2 minutes.
  • An injection volume of 2 ⁇ l was used.
  • Cone voltage was 10 V for positive ionization mode and 20 V for negative ionization mode.
  • Reversed phase HPLC was carried out on a Waters XTerra MS C18 column (3.5 ⁇ m, 2.1 ⁇ 30 mm) with a flow rate of 1.0 ml/min.
  • Two mobile phases (mobile phase A: 0.1% aqueous solution of formic acid; mobile phase B: acetonitrile) were used. First, 100% A was hold for 0.1 minutes. Then a gradient was applied to 5% A and 95% B in 3 minutes and hold for 0.8 minutes. The injection volume was 1 The column was at room temperature.
  • melting points were determined with a DSC823e (Mettler-Toledo). Melting points were measured with a temperature gradient of 30° C/minute. Maximum temperature was 400° C. Values are peak values and are obtained with experimental uncertainties that are commonly associated with this analytical method.
  • melting points were determined by using a Gallenkamp apparatus from Sanyo Gallenkamp. The melting points determined in this way are indicated with ‘*’.
  • the inhibiting activity of the present compounds on DGAT1 activity was screened in a single well procedure assay using DGAT1 comprising membrane preparations and DGAT1 substrate comprising micelles and determining formed radio-active triacylglycerol coming in close proximity of a flashplate surface by radio luminescence.
  • DGAT1 activity is meant the transfer of coenzyme A activated fatty acids to the 3-position of 1,2-diacylglycerols, thus forming a triglyceride molecule, by enzyme DGAT1.
  • Step 1 if the Assay: Expression of DGAT1
  • human DGAT1 (NM012079.2) was cloned into the pFastBac vector, containing translation start, a FLAG-tag at the N-terminus as described in literature and a viral Kozak sequence (AAX) preceding the ATG to improve expression in insect cells. Expression was done as described in literature (Cases, S., Smith, S. J., Zheng, Y., Myers H. M., Lear, S. R., Sande, E., Novak, S., Collins, C., Welch, C. B., Lusis, A. J., Erickson, S. K. and Farese, R. V. (1998) Proc. Natl. Acad. Sci. USA 95, 13018-13023.) using SF9 cells.
  • 72 h transfected SF9 cells were collected by centrifugation (13000 rpm-15 min-4° C.) and lysed in 2 ⁇ 500 ml lysisbuffer (0.1M Sucrose, 50 mM KCl, 40 mM KH 2 PO 4 , 30 mM EDTA pH 7.2. Cells were homogenized by cell disruptor. After centrifugation 1380 rpm-15min-4° C. (SN discarded), pellet was resuspended in 500 ml lysisbuffer and total cell membranes collected by ultracentrifugation at 34000rpm(100 000 g) for 60 min (4° C.). The collected membranes were resuspended in lysis buffer, divided in aliquots and stored with 10% glycerol at -80° C. until use.
  • ml lysisbuffer 0.1M Sucrose, 50 mM KCl, 40 mM KH 2 PO 4 , 30 mM EDTA pH 7.2. Cells were homo
  • Step 3 of the Assay Preparation of DGAT Substrate Comprising Micelles Materials
  • Step 4 of the Assay DGAT FlashPlateTM Assay
  • DGAT activity in membrane preparations was assayed in 50 mM Tris-HCl (pH 7.4), 150 mM MgCl 2 , 1 mM EDTA and 0.2% BSA, containing 50 ⁇ M DAG, 32 ⁇ g/ml PC/PS and 8.4 ⁇ M [ 3 H]-oleoylCoA (at a specific activity of 30 nCi/well) in a final volume of 50 ⁇ l in 384-well format using the red shifted Basic Image FlashPlateTM (Perkin Elmer Cat.No. SMP400).
  • 10 ⁇ l enzyme mix and 10 ⁇ l substrate mix were added to 30 ⁇ l of assay buffer, optionally in the presence of 1 ⁇ l DMSO (blank and controls) or 1 ⁇ l of the compound to be tested.
  • This reaction mixture was incubated for 120 minutes at 37° C. and the enzymatic reaction stopped by adding 20 ⁇ l of the stop mix.
  • the plates were sealed and the vesicles allowed to settle overnight at room temperature. Plates were centrifuged for 5 minutes at 1500 rpm and measured in Leadseeker. Experiments with different concentrations of the test compound were performed and curves were calculated and drawn based on % CTRL min (% of normalized control).
  • % CTRL min (sample ⁇ LC )/( HC ⁇ LC ) Equation 1:
  • HC high control
  • LC low control
  • sample refers to the radio luminescence value measured in the wells with substrate, enzyme and test compound at a particular concentration.
  • % CTRL min values form a sigmoidal dose response descending curve and from this curve pIC 50 values were calculated ( ⁇ logIC 50 where IC 50 represents the concentration at which the test compound gives 50% inhibition of DGAT1 activity).
  • Table 3 shows the pIC 5O values for the compounds of formula (I).
  • the inhibiting activity of the compounds on DGAT2 was also determined in the above assay, slightly modified to obtain optimal assay conditions for DGAT2.
  • the tested compounds did not show inhibiting activity for DGAT2 (Human DGAT2 (NM032564) was cloned and expressed as described in J. Biolog. Chem. 276(42), pp 38870-38876 (2001)).
  • Elevation of GLP-1 plasma levels by a DGAT inhibitor can be studied as follows:
  • Dogs are deprived from food for a period of 22 hours. At time 0, animals are given a liquid meal, containing 18% fat (w/w), by gavage with a stomach tube. The test compound is given orally together with the meal. Afterwards, a postprandial plasma profile is determined for GLP-1. Therefore, blood is collected at predetermined time intervals in ice-cooled Vacutainers EDTA-plasma tubes and GLP-1 levels are measured in the samples taken at 0 hour (just before the meal) and at 0.5, 1, 2, 4, 6, 8 and 24 hours after dosing. Six dogs (3 males and 3 females) are included per dosage group and the plasma GLP-1 profile is compared with their own GLP-1 profile previously determined in the same conditions but without administration of the test compound.
  • GLP-1 determinations in plasma are performed with a Glucagon-like peptide-1 (active) ELISA kit 96-well plate of LINCO Research.
  • Active ingredient (a.i.) as used throughout these examples relates to a compound of formula (I), including any stereochemically isomeric form thereof, a N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof; in particular to any one of the exemplified compounds.
  • An aqueous suspension is prepared for oral administration so that each milliliter contains 1 to 5 mg of active ingredient , 50 mg of sodium carboxymethyl cellulose, 1 mg of sodium benzoate, 500 mg of sorbitol and water ad 1 ml.
  • a parenteral composition is prepared by stirring 1.5% (weight/volume) of active ingredient in 0.9% NaCl solution.

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

The invention further relates to a DGAT inhibitor of formula (I), including any stereochemically isomeric form thereof, wherein A represents CH or N; the dotted line represents an optional bond in case A represents a carbon atom; X represents —NRx—C(═O)—; —Z—C(═O)—; —Z—NRx—C(═O)—; —S(═O)p-; C(═S)—; —NRx—C(═S)—; —Z—C(═S)—; —Z—NRx—C(═S)—; —O—C(═O)—; —C(═O)—C(═O)—; R1 represents a 5-membered monocyclic heterocycle containing at least 2 heteroatoms; a 6-membered aromatic monocyclic heterocycle; or a 5-membered heterocycle containing at least 2 heteroatoms fused with phenyl, cyclohexyl or a 5-or 6-membered heterocycle; wherein each of said heterocycles may optionally be substituted; R2 represents R3; R3 represents C3-6cycloalkyl, phenyl, naphtalenyl, 2,3-dihydro-1,4-benzodioxinyl, 1,3-benzodioxlyl, 2,3-dihydrobenzofuranyl or a 6-membered aromatic heterocycle containing 1 or 2 N atoms, wherein said C3-6cycloalkyl, phenyl, naphtalenyl, 2,3-dihydro-1,4-benzo-dioxinyl, 1,3-benzodioxolyl, 2,3-dihydrobenzofuranyl or 6-membered aromatic heterocycle may optionally be substituted; a N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof. The invention further relates to methods for preparing such compounds, pharmaceutical compositions comprising said compounds as well as the use as a medicine of said compounds.
Figure US20100216809A1-20100826-C00001

Description

    FIELD OF THE INVENTION
  • The present invention relates to the use of a DGAT inhibitor, in particular a DGAT1 inhibitor, for the manufacture of a medicament for the prevention or the treatment of a disease by elevating the levels of one or more satiety hormones, in particular GLP-1. The present invention also concerns piperidine/piperazine derivatives having DGAT inhibitory activity, in particular DGAT1 inhibitory activity. The invention further relates to methods for their preparation and pharmaceutical compositions comprising them. The invention also relates to the use of said compounds for the manufacture of a medicament for the prevention or the treatment of a disease mediated by DGAT, in particular DGAT 1.
    • BACKGROUND TO THE INVENTION
  • Triglycerides represent the major form of energy stored in eukaryotes. Disorders or imbalances in triglyceride metabolism are implicated in the pathogenesis of and increased risk for obesity, insulin resistance syndrome and type II diabetes, nonalcoholic fatty liver disease and coronary heart disease (see, Lewis, et al, Endocrine Reviews (2002) 23:201 and Malloy and Kane, Adv. Intern. Med. (2001) 47:11 1). Additionally, hypertriglyceridemia is often an adverse consequence of cancer therapy (see, Bast, et al. Cancer Medicine, 5th Ed., (2000) B. C. Decker, Hamilton, Ontario, CA).
  • A key enzyme in the synthesis of triglycerides is acyl CoA:diacylglycerol acyltransferase, or DGAT. DGAT is a microsomal enzyme that is widely expressed in mammalian tissues and that catalyzes the joining of 1,2-diacylglycerol (DAG) and fatty acyl CoA to form triglycerides (TG) at the endoplasmic reticulum (reviewed in Chen and Farese, Trends Cardiovasc. Med. (2000) 10: 188 and Farese, et al, Curr. Opin. Lipidol. (2000) 11:229). It was originally thought that DGAT uniquely controlled the catalysis of the final step of acylation of diacylglycerol to triglyceride in the two major pathways for triglyceride synthesis, the glycerol phosphate and monoacylglycerol pathways. Because triglycerides are considered essential for survival, and their synthesis was thought to occur through a single mechanism, inhibition of triglyceride synthesis through inhibiting the activity of DGAT has been largely unexplored.
  • Genes encoding mouse DGAT1 and the related human homologs ARGP1 (human DGAT1) and ARGP2 (human ACAT2) now have been cloned and characterized (Cases, et al, Pro.c Nat.l Acad. Sci. (1998) 95:13018; Oelkers, et al, J. Biol. Chem. (1998) 273:26765). The gene for mouse DGAT1 has been used to create DGAT knock-out mice to better elucidate the function of the DGAT gene.
  • Unexpectedly, mice unable to express a functional DGAT1 enzyme (Dgat1−/− mice) are viable and still able to synthesize triglycerides, indicating that multiple catalytic mechanisms contribute to triglyceride synthesis (Smith, et al, Nature Genetics (2000) 25:87). Other enzymes that catalyze triglyceride synthesis, for example, DGAT2 and diacylglycerol transacylase, also have been identified (Cases, et al, J. Biol. Chem. (2001) 276:38870). Gene knockout studies in mice have revealed that DGAT2 plays a fundamental role in mammalian triglyceride synthesis and is required for survival. DGAT2 deficient mice are lipopenic and die soon after birth, apparently from profound reductions in substrates for energy metabolism and from impaired permeability barrier function in the skin.(Farese, et al., J. Biol. Chem. (2004) 279: 11767).
  • Significantly, Dgat1−/− mice are resistant to diet-induced obesity and remain lean. Even when fed a high fat diet (21% fat) Dgat1−/− mice maintain weights comparable to mice fed a regular diet (4% fat) and have lower total body triglyceride levels. The obesity resistance in Dgat1−/− mice is not due to decreased caloric intake, but the result of increased energy expenditure and decreased resistance to insulin and leptin (Smith, et al, Nature Genetics (2000) 25:87; Chen and Farese, Trends Cardiovasc. Med. (2000) 10: 188; and Chen, et al, J. Clin. Invest. (2002) 109:1049). Additionally, Dgat1−/− mice have reduced rates of triglyceride absorption (Buhman, et al, J. Biol. Chem. (2002) 277:25474). In addition to improved triglyceride metabolism, Dgat1−/− mice also have improved glucose metabolism, with lower glucose and insulin levels following a glucose load, in comparison to wild-type mice (Chen and Farese, Trends Cardiovasc. Med. (2000) 10: 188).
  • The finding that multiple enzymes contribute to catalyzing the synthesis of triglyceride from diacylglycerol is significant, because it presents the opportunity to modulate one catalytic mechanism of this biochemical reaction to achieve therapeutic results in an individual with minimal adverse side effects. Compounds that inhibit the conversion of diacylglycerol to triglyceride, for instance by specifically inhibiting the activity of DGAT1, will find use in lowering corporeal concentrations and absorption of triglycerides to therapeutically counteract the pathogenic effects caused by abnormal metabolism of triglycerides in obesity, insulin resistance syndrome and overt type II diabetes, congestive heart failure and atherosclerosis, and as a consequence of cancer therapy.
  • Because of the ever increasing prevalence of obesity, type II diabetes, heart disease and cancer in societies throughout the world, there is a pressing need in developing new therapies to effectively treat and prevent these diseases. Therefore there is an interest in developing compounds that can potently and specifically inhibit the catalytic activity of DGAT, in particular DGAT1.
  • We have now unexpectedly found that the compounds of the present invention exhibit DGAT inhibitory activity, in particular DGAT1 inhibitory activity, and can therefore be used to prevent or treat a disease associated with or mediated by DGAT, such as for example obesity, type II diabetes, heart disease and cancer. The compounds of the invention differ from the prior art compounds in structure, in their pharmacological activity, pharmacological potency, and/or pharmacological profile.
  • We have also unexpectedly found that DGAT inhibitors can be used to elevate the levels of one or more satiety hormones, in particular glucagon-like-peptide-1 (GLP-1) and therefore DGAT inhibitors, in particular DGAT1 inhibitors, can also be used to prevent or treat a disease which can benefit from elevated levels of a satiety hormone, in particular GLP-1. Glucagon-like peptide 1 (GLP-1) is an intestinal hormone which generally stimulates insulin secretion during hyperglycemia, suppresses glucagon secretion, stimulates (pro) insulin biosynthesis and decelerates gastric emptying and acid secretion. GLP-1 is secreted from L cells in the small and large bowel following the ingestion of fat and proteins. GLP-1 has been suggested, among other indications, as a possible therapeutic agent for the management of type 2 non-insulin-dependent diabetes mellitus as well as related metabolic disorders, such as obesity.
  • Thus, by the present finding, a disease which can benefit from elevated levels of GLP-1 can be treated with small molecules (compared to large molecules such as proteins or protein-like compounds, e.g. GLP-1 analogues).
    • BACKGROUND PRIOR ART
  • WO 2006/034441 discloses heterocyclic derivatives and their use as stearoyl CoA desaturase inhibitors (SCD-1 inhibitors).
  • WO 2006/086445 relates to a combination therapy of a SCD-1 inhibitor and another drug to treat adverse weight gain.
  • WO 2006/004200 and JP2007131584 relate to urea and amino derivatives having DGAT inhibitory activity.
  • WO 2004/047755 relates to fused bicyclic nitrogen-containing heterocycles having DGAT inhibitory activity.
  • WO2005/072740 relates to an anorectic action of a compound having DGAT inhibitory activity.
    • DESCRIPTION OF THE INVENTION
  • The present invention relates to the use of a DGAT inhibitor for the manufacture of a medicament for the prevention or the treatment, in particular for the treatment, of a disease which can benefit from elevated levels of one or more satiety hormones, in particular GLP-1.
  • The present invention further relates to a compound of formula
  • Figure US20100216809A1-20100826-C00002
      • including any stereochemically isomeric form thereof, wherein
      • A represents CH or N;
      • the dotted line represents an optional bond in case A represents a carbon atom;
      • X represents —NRx—C(═O)—; —Z—C(═O)—; —Z—NRx—C(═O)—; —S(═O)p-; —C(═S)—;
      • —NRx—C(═S)—; —Z—C(═S)—; —Z—NRx—C(═S)—; —O—C(═O)—; —C(═O)—C(═O)—;
      • Z represents a bivalent radical selected from C1-6alkanediyl, C2-6alkenediyl or C2-6alkynediyl; wherein each of said C1-6alkanediyl, C2-6alkenediyl or C2-6alkynediyl may optionally be substituted with hydroxyl or amino; and wherein two hydrogen atoms attached to the same carbon atom in C1-6alkanediyl may optionally be replaced by C1-6alkanediyl;
      • Rx represents hydrogen or C1-4alkyl;
      • R1 represents a 5-membered monocyclic heterocycle containing at least 2 heteroatoms; a 6-membered aromatic monocyclic heterocycle; or a 5-membered heterocycle containing at least 2 heteroatoms fused with phenyl, cyclohexyl or a 5- or 6-membered heterocycle; wherein each of said heterocycles may optionally be substituted with at least one substituent, in particular one, two, three, four or five substituents, each substituent independently being selected from hydroxyl; oxo; carboxyl; halo; C1-6alkyl optionally substituted with carboxyl, C1-4alkyloxycarbonyl or aryl-C(═O)—; hydroxyC1-6alkyl optionally substituted with aryl or aryl-C(═O)—; polyhaloC1-6alkyl; C1-6alkyloxy optionally substituted with C1-4alkyloxy; C1-6alkylthio; polyhaloC1-6alkyloxy; C1-6alkyloxy-carbonyl wherein C1-6alkyl may optionally be substituted with aryl; cyano; aminocarbonyl; mono-or di(C1-4alkyl)-aminocarbonyl; C1-6alkylcarbonyl; amino; mono-or di(C1-6alkyl)amino; R5R4N—C1-6alkyl; C3-6cycloalkyl-NRx—; aryl-NRx—; Het-NRx—; C3-6cycloalkyl-C1-4alkyl-NRx—; arylC1-4alkyl-NRx—; HetC1-4alkyl-NRx—; —S(═O)p—C1-4alkyl; C3-6cycloalkyl; C3-6cycloalkylC1-4alkyl; C3-6cycloalkyl-C(═O)—; aryl; aryloxy; arylC1-4alkyl; aryl-C(═O)—; aryl-C(═O)—C1-4alkyl; Het; HetC1-4alkyl; Het-C(═O)—; Het-C(═O)—C1-4alkyl; Het-O—;
      • R2 represents R3;
      • R3 represents C3-6cycloalkyl, phenyl, naphtalenyl, 2,3-dihydro-1,4-benzodioxinyl, 1,3-benzodioxolyl, 2,3-dihydrobenzo furanyl or a 6-membered aromatic heterocycle containing 1 or 2 N atoms, wherein said C3-6cycloalkyl, phenyl, naphtalenyl, 2,3-dihydro-1,4-benzodioxinyl, 1,3-benzodioxolyl, 2,3-dihydrobenzofuranyl or 6-membered aromatic heterocycle may optionally be substituted with at least one substituent, in particular one, two, three, four or five substituents, each substituent independently selected from hydroxyl; carboxyl; halo; C1-6alkyl optionally substituted with hydroxy; polyhaloC1-6alkyl; C1-6alkyloxy optionally substituted with C1-4alkyloxy; C1-6alkylthio; polyhalo-C1-6alkyloxy; C1-6alkyloxycarbonyl wherein C1-6alkyl may optionally be substituted with aryl; cyano; C1-6alkylcarbonyl; nitro; amino; mono-or di(C1-4alkyl)amino; C1-4alkylcarbonylamino; —S(═O)p—C1-4alkyl; R5R4N—C(═O)—; R5R4N—C1-6alkyl; C3-6cycloalkyl; C3-6cycloalkylC1-4alkyl; C3-6cycloalkyl-C(═O)—; aryl; aryloxy; arylC1-4alkyl; aryl-C(═O)—C1-4alkyl; aryl-C(═O)—; Het; HetC1-4alkyl; Het-C(═O)—C1-4alkyl; Het-C(═O)—; Het-O—;
      • R4 represents hydrogen; C1-4alkyl optionally substituted with hydroxyl or C1-4alkyloxy; R7R6N—C1-4alkyl; C1-4alkyloxy; Het; aryl; R7R6N—C(═O)—C1-4alkyl;
      • R5 represents hydrogen or C1-4alkyl;
      • R6 represents hydrogen; C1-4alkyl; C1-4alkylcarbonyl;
      • R7 represents hydrogen or C1-4alkyl; or
      • R6 and R7 may be taken together with the nitrogen to which they are attached to form a saturated monocyclic 5, 6 or 7-membered heterocycle which may further contain one or more heteroatoms selected from O, S, S(═O)p or N; and which heterocycle may optionally be substituted with C1-4alkyl;
      • R8 represents hydrogen, halo, C1-4alkyl, C1-4alkyl substituted with hydroxyl; aryl represents phenyl or phenyl substituted with at least one substituent, in particular one, two, three, four or five substituents, each substituent independently being selected from hydroxyl; carboxyl; halo; C1-6alkyl optionally substituted with C1-4alkyloxy, amino or mono-or di(C1-4alkyl)amino; polyhaloC1-6alkyl; C1-6alkyloxy optionally substituted with C1-4alkyloxy; C1-6alkylthio; polyhaloC1-6alkyloxy; C1-6alkyloxycarbonyl; cyano; amino carbonyl; mono-or di(C1-4alkyl)aminocarbonyl; C1-6alkylcarbonyl; nitro; amino; mono-or di(C1-4alkyl)amino; —S(═O)p—C1-4alkyl;
      • Het represents a monocyclic non-aromatic or aromatic heterocycle containing at least one heteroatom selected from O, S, S(═O)p or N; or a bicyclic or tricyclic non-aromatic or aromatic heterocycle containing at least one heteroatom selected from O, S, S(═O)p or N; said monocyclic heterocycle or said bi-or tricyclic heterocycle optionally being substituted with at least one substituent, in particular one, two, three, four or five substituents, each substituent independently being selected from hydroxyl; oxo; carboxyl; halo; C1-6alkyl optionally substituted with C1-4alkyloxy, amino or mono-or di(C1-4alkyl)amino; polyhaloC1-6alkyl; C1-6alkyloxy optionally substituted with C1-4alkyloxy; C1-6alkylthio; polyhaloC1-6alkyloxy; C1-6alkyl-oxycarbonyl; cyano; aminocarbonyl; mono-or di(C1-4alkyl)aminocarbonyl; C1-6alkylcarbonyl; nitro; amino; mono-or di(C1-4alkyl)amino; —S(═O)p—C1-4alkyl
      • p represents 1 or 2;
      • provided that the following compounds
  • Figure US20100216809A1-20100826-C00003
    X R1 R2
    Figure US20100216809A1-20100826-C00004
    Figure US20100216809A1-20100826-C00005
    Figure US20100216809A1-20100826-C00006
    Figure US20100216809A1-20100826-C00007
    Figure US20100216809A1-20100826-C00008
    Figure US20100216809A1-20100826-C00009
    Figure US20100216809A1-20100826-C00010
    Figure US20100216809A1-20100826-C00011
    Figure US20100216809A1-20100826-C00012
    Figure US20100216809A1-20100826-C00013
    Figure US20100216809A1-20100826-C00014
    Figure US20100216809A1-20100826-C00015
    Figure US20100216809A1-20100826-C00016
    Figure US20100216809A1-20100826-C00017
    Figure US20100216809A1-20100826-C00018
    Figure US20100216809A1-20100826-C00019
    Figure US20100216809A1-20100826-C00020
    Figure US20100216809A1-20100826-C00021
    Figure US20100216809A1-20100826-C00022
    Figure US20100216809A1-20100826-C00023
    Figure US20100216809A1-20100826-C00024
    Figure US20100216809A1-20100826-C00025
    Figure US20100216809A1-20100826-C00026
    Figure US20100216809A1-20100826-C00027
    Figure US20100216809A1-20100826-C00028
    Figure US20100216809A1-20100826-C00029
    Figure US20100216809A1-20100826-C00030
    Figure US20100216809A1-20100826-C00031
    Figure US20100216809A1-20100826-C00032
    Figure US20100216809A1-20100826-C00033
    Figure US20100216809A1-20100826-C00034
    Figure US20100216809A1-20100826-C00035
    Figure US20100216809A1-20100826-C00036
    Figure US20100216809A1-20100826-C00037
    Figure US20100216809A1-20100826-C00038
    Figure US20100216809A1-20100826-C00039
    Figure US20100216809A1-20100826-C00040
    Figure US20100216809A1-20100826-C00041
    Figure US20100216809A1-20100826-C00042
      • are excluded;
      • a N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof.
  • The invention also relates to a compound of formula (I) as described above, provided that the following compounds
  • Figure US20100216809A1-20100826-C00043
    X R1 R2 Salt
    Figure US20100216809A1-20100826-C00044
    Figure US20100216809A1-20100826-C00045
    Figure US20100216809A1-20100826-C00046
    Figure US20100216809A1-20100826-C00047
    Figure US20100216809A1-20100826-C00048
    Figure US20100216809A1-20100826-C00049
    Figure US20100216809A1-20100826-C00050
    Figure US20100216809A1-20100826-C00051
    Figure US20100216809A1-20100826-C00052
    Figure US20100216809A1-20100826-C00053
    Figure US20100216809A1-20100826-C00054
    Figure US20100216809A1-20100826-C00055
    Figure US20100216809A1-20100826-C00056
    Figure US20100216809A1-20100826-C00057
    Figure US20100216809A1-20100826-C00058
    Figure US20100216809A1-20100826-C00059
    Figure US20100216809A1-20100826-C00060
    Figure US20100216809A1-20100826-C00061
    Figure US20100216809A1-20100826-C00062
    Figure US20100216809A1-20100826-C00063
    Figure US20100216809A1-20100826-C00064
    Figure US20100216809A1-20100826-C00065
    Figure US20100216809A1-20100826-C00066
    Figure US20100216809A1-20100826-C00067
    Figure US20100216809A1-20100826-C00068
    Figure US20100216809A1-20100826-C00069
    Figure US20100216809A1-20100826-C00070
    Figure US20100216809A1-20100826-C00071
    Figure US20100216809A1-20100826-C00072
    Figure US20100216809A1-20100826-C00073
    Figure US20100216809A1-20100826-C00074
    Figure US20100216809A1-20100826-C00075
    Figure US20100216809A1-20100826-C00076
    Figure US20100216809A1-20100826-C00077
    Figure US20100216809A1-20100826-C00078
    Figure US20100216809A1-20100826-C00079
    Figure US20100216809A1-20100826-C00080
    Figure US20100216809A1-20100826-C00081
    Figure US20100216809A1-20100826-C00082
    Figure US20100216809A1-20100826-C00083
    Figure US20100216809A1-20100826-C00084
    Figure US20100216809A1-20100826-C00085
    Figure US20100216809A1-20100826-C00086
    Figure US20100216809A1-20100826-C00087
    Figure US20100216809A1-20100826-C00088
    Figure US20100216809A1-20100826-C00089
    Figure US20100216809A1-20100826-C00090
    Figure US20100216809A1-20100826-C00091
    Figure US20100216809A1-20100826-C00092
    Figure US20100216809A1-20100826-C00093
    Figure US20100216809A1-20100826-C00094
    Figure US20100216809A1-20100826-C00095
    Figure US20100216809A1-20100826-C00096
    Figure US20100216809A1-20100826-C00097
    Figure US20100216809A1-20100826-C00098
    Figure US20100216809A1-20100826-C00099
    Figure US20100216809A1-20100826-C00100
    Figure US20100216809A1-20100826-C00101
    Figure US20100216809A1-20100826-C00102
    Figure US20100216809A1-20100826-C00103
    Figure US20100216809A1-20100826-C00104
    Figure US20100216809A1-20100826-C00105
    Figure US20100216809A1-20100826-C00106
    Figure US20100216809A1-20100826-C00107
    Figure US20100216809A1-20100826-C00108
    Figure US20100216809A1-20100826-C00109
    Figure US20100216809A1-20100826-C00110
    Figure US20100216809A1-20100826-C00111
    Figure US20100216809A1-20100826-C00112
    Figure US20100216809A1-20100826-C00113
    Figure US20100216809A1-20100826-C00114
    Figure US20100216809A1-20100826-C00115
    Figure US20100216809A1-20100826-C00116
    Figure US20100216809A1-20100826-C00117
    Figure US20100216809A1-20100826-C00118
    Figure US20100216809A1-20100826-C00119
    Figure US20100216809A1-20100826-C00120
    Figure US20100216809A1-20100826-C00121
    Figure US20100216809A1-20100826-C00122
    Figure US20100216809A1-20100826-C00123
    Figure US20100216809A1-20100826-C00124
    Figure US20100216809A1-20100826-C00125
    Figure US20100216809A1-20100826-C00126
    Figure US20100216809A1-20100826-C00127
    Figure US20100216809A1-20100826-C00128
    Figure US20100216809A1-20100826-C00129
    Figure US20100216809A1-20100826-C00130
    Figure US20100216809A1-20100826-C00131
    Figure US20100216809A1-20100826-C00132
    Figure US20100216809A1-20100826-C00133
    Figure US20100216809A1-20100826-C00134
    Figure US20100216809A1-20100826-C00135
    Figure US20100216809A1-20100826-C00136
    Figure US20100216809A1-20100826-C00137
    Figure US20100216809A1-20100826-C00138
    Figure US20100216809A1-20100826-C00139
    Figure US20100216809A1-20100826-C00140
    Figure US20100216809A1-20100826-C00141
    Figure US20100216809A1-20100826-C00142
    Figure US20100216809A1-20100826-C00143
    Figure US20100216809A1-20100826-C00144
    Figure US20100216809A1-20100826-C00145
    Figure US20100216809A1-20100826-C00146
    Figure US20100216809A1-20100826-C00147
    Figure US20100216809A1-20100826-C00148
    Figure US20100216809A1-20100826-C00149
    Figure US20100216809A1-20100826-C00150
    Figure US20100216809A1-20100826-C00151
    Figure US20100216809A1-20100826-C00152
    Figure US20100216809A1-20100826-C00153
    Figure US20100216809A1-20100826-C00154
    Figure US20100216809A1-20100826-C00155
    Figure US20100216809A1-20100826-C00156
    Figure US20100216809A1-20100826-C00157
    Figure US20100216809A1-20100826-C00158
    Figure US20100216809A1-20100826-C00159
    Figure US20100216809A1-20100826-C00160
    Figure US20100216809A1-20100826-C00161
    Figure US20100216809A1-20100826-C00162
    Figure US20100216809A1-20100826-C00163
    Figure US20100216809A1-20100826-C00164
    Figure US20100216809A1-20100826-C00165
    Figure US20100216809A1-20100826-C00166
    Figure US20100216809A1-20100826-C00167
    Figure US20100216809A1-20100826-C00168
    Figure US20100216809A1-20100826-C00169
    Figure US20100216809A1-20100826-C00170
    Figure US20100216809A1-20100826-C00171
    Figure US20100216809A1-20100826-C00172
    Figure US20100216809A1-20100826-C00173
    Figure US20100216809A1-20100826-C00174
    Figure US20100216809A1-20100826-C00175
    Figure US20100216809A1-20100826-C00176
    Figure US20100216809A1-20100826-C00177
    Figure US20100216809A1-20100826-C00178
    Figure US20100216809A1-20100826-C00179
    Figure US20100216809A1-20100826-C00180
    Figure US20100216809A1-20100826-C00181
    Figure US20100216809A1-20100826-C00182
    Figure US20100216809A1-20100826-C00183
    Figure US20100216809A1-20100826-C00184
    Figure US20100216809A1-20100826-C00185
    Figure US20100216809A1-20100826-C00186
    Figure US20100216809A1-20100826-C00187
    Figure US20100216809A1-20100826-C00188
    Figure US20100216809A1-20100826-C00189
    Figure US20100216809A1-20100826-C00190
    Figure US20100216809A1-20100826-C00191
    Figure US20100216809A1-20100826-C00192
    Figure US20100216809A1-20100826-C00193
         		trifluoroacetate salt
    Figure US20100216809A1-20100826-C00194
    Figure US20100216809A1-20100826-C00195
    Figure US20100216809A1-20100826-C00196
    Figure US20100216809A1-20100826-C00197
    Figure US20100216809A1-20100826-C00198
    Figure US20100216809A1-20100826-C00199
      • are excluded.
  • The present invention further relates to the use of a compound of formula (I′″) for the manufacture of a medicament for the prevention or the treatment of a disease mediated by DGAT, in particular the present invention relates to the use of a compound of formula (I′″) for the manufacture of a medicament for the prevention or the treatment of a disease which can benefit from inhibition of DGAT, in particular for the treatment of a disease which can benefit from inhibition of DGAT, in particular DGAT1, wherein the compound of formula (I′″) is a compound of formula
  • Figure US20100216809A1-20100826-C00200
      • including any stereochemically isomeric form thereof, wherein
      • A represents CH or N;
      • the dotted line represents an optional bond in case A represents a carbon atom;
      • X represents —NRx—C(═O)—; —Z—C(═O)—; —Z—NRx—C(═O)—; —S(═O)p-; —C(═S)—;
      • —NRx—C(═S)—; —Z—C(═S)—; —Z—NRx—C(═S)—; —O—C(═O)—; —C(═O)—C(═O)—;
      • Z represents a bivalent radical selected from C1-6alkanediyl, C2-6alkenediyl or C2-6alkynediyl; wherein each of said C1-6alkanediyl, C2-6alkenediyl or C2-6alkynediyl may optionally be substituted with hydroxyl or amino; and wherein two hydrogen atoms attached to the same carbon atom in C1-6alkanediyl may optionally be replaced by C1-6alkanediyl;
      • Rx represents hydrogen or C1-4alkyl;
      • R1 represents a 5-membered monocyclic heterocycle containing at least 2 heteroatoms; a 6-membered aromatic monocyclic heterocycle; or a 5-membered heterocycle containing at least 2 heteroatoms fused with phenyl, cyclohexyl or a 5- or 6-membered heterocycle; wherein each of said heterocycles may optionally be substituted with at least one substituent, in particular one, two, three, four or five substituents, each substituent independently being selected from hydroxyl; oxo; carboxyl; halo; C1-6alkyl optionally substituted with carboxyl, C1-4alkyloxycarbonyl or aryl-C(═O)—; hydroxyC1-6alkyl optionally substituted with aryl or aryl-C(═O)—; polyhaloC1-6alkyl; C1-6alkyloxy optionally substituted with C1-4alkyloxy; C1-6alkylthio; polyhaloC1-6alkyloxy; C1-6alkyloxy-carbonyl wherein C1-6alkyl may optionally be substituted with aryl; cyano; aminocarbonyl; mono-or di(C1-4alkyl)-aminocarbonyl; C1-6alkylcarbonyl; amino; mono-or di(C1-6alkyl)amino; R5R4N—C1-6alkyl; C3-6cycloalkyl-NRx—; aryl-NRx—; Het-NRx—; C3-6cycloalkyl-C1-4alkyl-NRx—; arylC1-4alkyl-NRx—; HetC1-4alkyl-NRx—; —S(═O)p—C1-4alkyl; C3-6cycloalkyl; C3-6cycloalkylC1-4alkyl; C3-6cycloalkyl-C(═O)—; aryl; aryloxy; arylC1-4alkyl; aryl-C(═O)—; aryl-C(═O)—C1-4alkyl; Het; HetC1-4alkyl; Het-C(═O)—; Het-C(═O)—C1-4alkyl; Het-O—;
      • R2 represents R3;
      • R3 represents C3-6cycloalkyl, phenyl, naphtalenyl, 2,3-dihydro-1,4-benzodioxinyl, 1,3-benzodioxolyl, 2,3-dihydrobenzo furanyl or a 6-membered aromatic heterocycle containing 1 or 2 N atoms, wherein said C3-6cycloalkyl, phenyl, naphtalenyl, 2,3-dihydro-1,4-benzodioxinyl, 1,3-benzodioxolyl, 2,3-dihydrobenzofuranyl or 6-membered aromatic heterocycle may optionally be substituted with at least one substituent, in particular one, two, three, four or five substituents, each substituent independently selected from hydroxyl; carboxyl; halo; C1-6alkyl optionally substituted with hydroxy; polyhaloC1-6alkyl; C1-6alkyloxy optionally substituted with C1-4alkyloxy; C1-6alkylthio; polyhalo-C1-6alkyloxy; C1-6alkyloxycarbonyl wherein C1-6alkyl may optionally be substituted with aryl; cyano; C1-6alkylcarbonyl; nitro; amino; mono-or di(C1-4alkyl)amino; C1-4alkylcarbonylamino; —S(═O)p—C1-4alkyl; R5R4N—C(═O)—; R5R4N—C1-6alkyl; C3-6cycloalkyl; C3-6cycloalkylC1-4alkyl; C3-6cycloalkyl-C(═O)—; aryl; aryloxy; arylC1-4alkyl; aryl-C(═O)—C1-4alkyl; aryl-C(═O)—; Het; HetC1-4alkyl; Het-C(═O)—C1-4alkyl; Het-C(═O)—; Het-O—;
      • R4 represents hydrogen; C1-4alkyl optionally substituted with hydroxyl or C1-4alkyloxy; R7R6N—C1-4alkyl; C1-4alkyloxy; Het; aryl; R7R6N—C(═O)—C1-4alkyl;
      • R5 represents hydrogen or C1-4alkyl;
      • R6 represents hydrogen; C1-4alkyl; C1-4alkylcarbonyl;
      • R7 represents hydrogen or C1-4alkyl; or
      • R6 and R7 may be taken together with the nitrogen to which they are attached to form a saturated monocyclic 5, 6 or 7-membered heterocycle which may further contain one or more heteroatoms selected from O, S, S(═O)p or N; and which heterocycle may optionally be substituted with C1-4alkyl;
      • R8 represents hydrogen, halo, C1-4alkyl, C1-4alkyl substituted with hydroxyl;
      • aryl represents phenyl or phenyl substituted with at least one substituent, in particular one, two, three, four or five substituents, each substituent independently being selected from hydroxyl; carboxyl; halo; C1-6alkyl optionally substituted with C1-4alkyloxy, amino or mono-or di(C1-4alkyl)amino; polyhaloC1-6alkyl; C1-6alkyloxy optionally substituted with C1-4alkyloxy; C1-6alkylthio; polyhaloC1-6alkyloxy; C1-6alkyloxycarbonyl; cyano; amino carbonyl; mono-or di(C1-4alkyl)aminocarbonyl; C1-6alkylcarbonyl; nitro; amino; mono-or di(C1-4alkyl)amino; —S(═O)p—C1-4alkyl;
      • Het represents a monocyclic non-aromatic or aromatic heterocycle containing at least one heteroatom selected from O, S, S(═O)p or N; or a bicyclic or tricyclic non-aromatic or aromatic heterocycle containing at least one heteroatom selected from O, S, S(═O)p or N; said monocyclic heterocycle or said bi-or tricyclic heterocycle optionally being substituted with at least one substituent, in particular one, two, three, four or five substituents, each substituent independently being selected from hydroxyl; oxo; carboxyl; halo; C1-6alkyl optionally substituted with C1-4alkyloxy, amino or mono-or di(C1-4alkyl)amino; polyhaloC1-6alkyl; C1-6alkyloxy optionally substituted with C1-4alkyloxy; C1-6alkylthio; polyhaloC1-6alkyloxy; C1-6alkyl-oxycarbonyl; cyano; aminocarbonyl; mono-or di(C1-4alkyl)aminocarbonyl; C1-6alkylcarbonyl; nitro; amino; mono-or di(C1-4alkyl)amino; —S(═O)p—C1-4alkyl
      • p represents 1 or 2;
      • a N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof.
  • The present invention also relates to the use of a compound of formula (I) or (I′″) for the manufacture of a medicament for the prevention or the treatment of a disease which can benefit from elevated levels of one or more satiety hormones, in particular GLP-1, in particular the present invention relates to the use of a compound of formula (I) for the manufacture of a medicament for the treatment of a disease which can benefit from elevated levels of GLP-1.
  • The present invention further relates to the use of a compound of formula (I) for the manufacture of a medicament for the prevention or the treatment of a disease mediated by DGAT, in particular the present invention relates to the use of a compound of formula (I) for the manufacture of a medicament for the prevention or the treatment of a disease which can benefit from inhibition of DGAT, in particular for the treatment of a disease which can benefit from inhibition of DGAT, in particular DGAT1.
  • As used hereinbefore or hereinafter C0-3alkyl as a group or part of a group defines straight or branched chain saturated hydrocarbon radicals having from 0 (then it represents a direct bond) to 3 carbon atoms such as methyl, ethyl, propyl, 1-methyl-ethyl; C1-2alkyl as a group or part of a group defines straight or branched chain saturated hydrocarbon radicals having 1 or 2 carbon atoms such as methyl, ethyl;
  • C1-4alkyl as a group or part of a group defines straight or branched chain saturated hydrocarbon radicals having from 1 to 4 carbon atoms such as methyl, ethyl, propyl, 1-methylethyl, butyl; C1-5alkyl as a group or part of a group defines straight or branched chain saturated hydrocarbon radicals having from 1 to 5 carbon atoms such as the group defined for C1-4alkyl and pentyl, 2-methylbutyl and the like; C1-6alkyl as a group or part of a group defines straight or branched chain saturated hydrocarbon radicals having from 1 to 6 carbon atoms such as the group defined for C1-4alkyl and for C1-5alkyl and hexyl, 2-methylpentyl and the like; C1-6alkanediyl defines straight or branched chain saturated bivalent hydrocarbon radicals having from 1 to 6 carbon atoms such as methylene, 1,2-ethanediyl or 1,2-ethylidene, 1,3-propanediyl or 1,3-propylidene, 1,4-butanediyl or 1,4-butylidene, 1,5-pentanediyl and the like; C2-6alkenyl as a group or part of a group defines straight or branched chain hydrocarbon radicals having from 2 to 6 carbon atoms and having a double bond such as ethenyl, propenyl, butenyl, pentenyl, hexenyl, 3-methylbutenyl and the like; C2-6alkenediyl defines straight or branched chain bivalent hydrocarbon radicals having from 2 to 6 carbon atoms and having a double bond such as 1,2-ethenediyl, 1,3-propenediyl, 1,4-butenediyl, 1,5-pentenediyl and the like; C2-6alkynediyl as a group or part of a group defines straight or branched chain bivalent hydrocarbon radicals having from 2 to 6 carbon atoms and having a triple bond such as 1,2-ethynediyl, 1,3-propynediyl, 1,4-butynediyl, 1,5-pentynediyl and the like; C3-6cycloalkyl is generic to cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
  • The term halo is generic to fluoro, chloro, bromo and iodo. As used hereinbefore or hereinafter, polyhaloC1-6alkyl as a group or part of a group is defined as C1-6alkyl substituted with one or more, such as for example 2, 3, 4 or 5 halo atoms, for example methyl substituted with one or more fluoro atoms, for example, difluoromethyl or trifluoromethyl, 1,1-difluoro-ethyl, 1,1-difluoro-2,2,2-trifluoro-ethyl and the like. In case more than one halogen atoms are attached to a C1-6alkyl group within the definition of polyhaloC1-6alkyl, they may be the same or different.
  • As used herein before, the term (═O) forms a carbonyl moiety when attached to a carbon atom, a sulfoxide moiety when attached to a sulfur atom and a sulfonyl moiety when two of said terms are attached to a sulfur atom. Oxo means ═O.
  • The radical R1 as defined hereinabove may be an optionally substituted 5-membered monocyclic heterocycle containing at least 2 heteroatoms, an optionally substituted 6-membered aromatic monocyclic heterocycle or an optionally substituted 5-membered heterocycle containing at least 2 heteroatoms fused with a phenyl, cyclohexyl or a 5- or 6-membered heterocycle.
  • A 5-membered monocyclic heterocycle as defined hereinabove or hereinafter may be a 5-membered monocyclic non-aromatic (fully saturated or partially saturated) or aromatic heterocycle containing at least 2 heteroatom, in particular 2 or 3 heteroatoms, each independently selected from O, S, S(═O)p or N. Examples of such unsubstituted monocyclic 5-membered heterocycles comprise, but are not limited to, non-aromatic (fully saturated or partially saturated) or aromatic 5-membered monocyclic heterocycles such as for example 1,3-dioxolanyl, imidazolidinyl, thiazolidinyl, dihydrooxazolyl, isothiazolidinyl, isoxazolidinyl, oxadiazolidinyl, triazolidinyl, thiadiazolidinyl, pyrazolidinyl, imidazolinyl, pyrazolinyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, triazolyl, thiadiazolyl, oxadiazolyl, tetrazolyl and the like. Optional substituents of the above heterocycles are hydroxyl; oxo; carboxyl; halo; C1-6alkyl optionally substituted with carboxyl, C1-4alkyloxy-carbonyl or aryl-C(═O)—; hydroxyC1-6alkyl optionally substituted with aryl or aryl-C(═O)—; polyhaloC1-6alkyl; C1-6alkyloxy optionally substituted with C1-4alkyloxy; C1-6alkylthio; polyhaloC1-6alkyloxy; C1-6alkyloxy-carbonyl wherein C1-6alkyl may optionally be substituted with aryl; cyano; aminocarbonyl; mono-or di(C1-4alkyl)-aminocarbonyl; C1-6alkylcarbonyl; amino; mono-or di(C1-6alkyl)amino; R5R4N—C1-6alkyl; C3-6cycloalkyl-NRx—; aryl-NRx—; Het-NRx—; C3-6cycloalkylC1-4alkyl-NRx—; arylC1-4alkyl-NRx—; HetC1-4alkyl-NRx—; —S(═O)p—C1-4alkyl; C3-6cycloalkyl; C3-6cycloalkylC1-4alkyl; C3-6cycloalkyl-C(═O)—; aryl; aryloxy; arylC1-4alkyl; aryl-C(═O)—; aryl-C(═O)—C1-4alkyl; Het; HetC1-4alkyl; Het-C(═O)—; Het-C(═O)—C1-4alkyl; Het-O—.
  • A 6-membered aromatic monocyclic heterocycle as defined hereinabove or hereinafter contains at least one heteroatom, in aprticular 1, 2 or 3 heteroatoms, each independently selected from O, S, S(═O)p or N. Examples of such unsubstituted monocyclic 6-membered aromatic heterocycles comprise, but are not limited to, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, pyranyl and the like. Optional substituents of the above heterocycles are hydroxyl; oxo; carboxyl; halo; C1-6alkyl optionally substituted with carboxyl, C1-4alkyloxycarbonyl or aryl-C(═O)—; hydroxyC1-6alkyl optionally substituted with aryl or aryl-C(═O)—; polyhaloC1-6alkyl; C1-6alkyloxy optionally substituted with C1-4alkyloxy; C1-6alkylthio; polyhaloC1-6alkyloxy; C1-6alkyloxy-carbonyl wherein C1-6alkyl may optionally be substituted with aryl; cyano; aminocarbonyl; mono-or di(C1-4alkyl)aminocarbonyl; C1-6alkylcarbonyl; amino; mono-or di(C1-6alkyl)amino; R5R4N—C1-6alkyl; C3-6cycloalkyl-NRx—; aryl-NRx—; Het-NRx—; C3-6cycloalkylC1-4alkyl-NRx—; arylC1-4alkyl-NRx—; HetC1-4alkyl-NRx—; —S(═O)p—C1-4alkyl; C3-6cycloalkyl; C3-6cycloalkylC1-4alkyl; C3-6cycloalkyl-C(═O)—; aryl; aryloxy; arylC1-4alkyl; aryl-C(═O)—; aryl-C(═O)—C1-4alkyl; Het; HetC1-4alkyl; Het-C(═O)—; Het-C(═O)—C1-4alkyl; Het-O—.
  • A 5-membered heterocycle containing at least 2 heteroatoms fused with phenyl, cyclohexyl or a 5- or 6-membered heterocycle as defined hereinabove or hereinafter may be a non-aromatic (fully saturated or partially saturated) or aromatic 5-membered heterocycle containing at least 2 heteroatoms, in particular 2 or 3 heteroatoms, each independently selected from O, S, S(═O)p or N, in particular O, S or N, more in particular O or N, fused with phenyl, cyclohexyl or a 5- or 6-membered non-aromatic (fully saturated or partially saturated) or aromatic heterocycle containing at least one heteroatom, in particular 1, 2 or3 heteroatoms, each independently selected from O, S, S(═O)p or N. Examples of such unsubstituted bicyclic heterocycles comprise, but are not limited to, non-aromatic (fully saturated or partially saturated) or aromatic 8- or 9-membered bicyclic heterocycles such as for example 1,3-benzodioxolyl, benzoxazolyl, benzimidazolyl, indazolyl, benzisoxazolyl, benzisothiazolyl, benzopyrazolyl, benzoxadiazolyl, benzothiadiazolyl, benzotriazolyl, purinyl, pyrrolopyridyl, thienopyridyl, furopyridyl, isothiazolopyridyl, thiazolopyridyl, isoxazolopyridyl, oxazolopyridyl, pyrazolopyridyl, imidazopyridyl, pyrrolopyrazinyl, thienopyrazinyl, furopyrazinyl, isothiazolopyrazinyl, thiazolopyrazinyl, isoxazolopyrazinyl, oxazolopyrazinyl, pyrazolopyrazinyl, imidazopyrazinyl, pyrrolopyrimidinyl, thienopyrimidinyl, furopyrimidinyl, isothiazolopyrimidinyl, thiazolopyrimidinyl, isoxazolopyrimidinyl, oxazolopyrimidinyl, pyrazolopyrimidinyl, imidazopyrimidinyl, pyrrolopyridazinyl, thienopyridazinyl, furopyridazinyl, isothiazolopyridazinyl, thiazolopyridazinyl, isoxazolopyridazinyl, oxazolopyridazinyl, pyrazolopyridazinyl, imidazopyridazinyl, oxadiazolopyridyl, thiadiazolopyridyl, triazolopyridyl, oxadiazolopyrazinyl, thiadiazolopyrazinyl, triazolopyrazinyl, oxadiazolopyrimidinyl, thiadiazolopyrimidinyl, triazolopyrimidinyl, oxadiazolopyridazinyl, thiadiazolopyridazinyl, triazolopyridazinyl, imidazooxazolyl, imidazothiazolyl, imidazoimidazolyl, imidazopyrazolyl, isoxazolotriazinyl, isothiazolotriazinyl, pyrazolotriazinyl, oxazolotriazinyl, thiazolotriazinyl, imidazotriazinyl, oxadiazolotriazinyl, thiadiazolotriazinyl, triazolotriazinyl and the like. Optional substituents of the above heterocycles are hydroxyl; oxo; carboxyl; halo; C1-6alkyl optionally substituted with carboxyl, C1-4alkyloxycarbonyl or aryl-C(═O)—; hydroxyC1-6alkyl optionally substituted with aryl or aryl-C(═O)—; polyhaloC1-6alkyl; C1-6alkyloxy optionally substituted with C1-4alkyloxy; C1-6alkylthio; polyhaloC1-6alkyloxy; C1-6alkyloxy-carbonyl wherein C1-6alkyl may optionally be substituted with aryl; cyano; aminocarbonyl; mono-or di(C1-4alkyl)aminocarbonyl; C1-6alkylcarbonyl; amino; mono-or di(C1-6alkyl)amino; R5R4N—C1-6alkyl; C3-6cycloalkyl-NRx—; aryl-NRx—; Het-NRx—; C3-6cycloalkylC1-4alkyl-NRx—; arylC1-4alkyl-NRx—; HetC1-4alkyl-NRx—; —S(═O)p—C1-4alkyl; C3-6cycloalkyl; C3-6cycloalkylC1-4alkyl; C3-6cycloalkyl-C(═O)—; aryl; aryloxy; arylC1-4alkyl; aryl-C(═O)—; aryl-C(═O)—C1-4alkyl; Het; HetC1-4alkyl; Het-C(═O)—; Het-C(═O)—C1-4alkyl; Het-O—.
  • The radical Het as defined hereinabove may be an optionally substituted monocyclic non-aromatic or aromatic heterocycle containing at least one heteroatom selected from O, S, S(═O)p or N; or a optionally substituted bi- or tricyclic non-aromatic or aromatic heterocycle containing at least one heteroatom selected from O, S, S(═O)p or N. Examples of such unsubstituted monocyclic heterocycles comprise, but are not limited to, non-aromatic (fully saturated or partially saturated) or aromatic 4-, 5-, 6- or 7-membered monocyclic heterocycles such as for example azetidinyl, tetrahydrofuranyl, pyrrolidinyl, dioxolanyl, imidazolidinyl, thiazolidinyl, tetrahydrothienyl, dihydrooxazolyl, isothiazolidinyl, isoxazolidinyl, oxadiazolidinyl, triazolidinyl, thiadiazolidinyl, pyrazolidinyl, piperidinyl, hexahydropyrimidinyl, hexahydropyrazinyl, dioxanyl, morpholinyl, dithianyl, thiomorpholinyl, piperazinyl, trithianyl, pyrrolinyl, imidazolinyl, pyrazolinyl, pyrrolyl, furyl, thienyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, triazolyl, thiadiazolyl, oxadiazolyl, tetrazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, pyranyl and the like. Examples of such unsubstituted bicyclic or tricyclic heterocycles comprise, but are not limited to, non-aromatic (fully saturated or partially saturated) or aromatic 8- to 17-membered bicyclic or tricyclic heterocycles such as for example decahydroquinolinyl, octahydroindolyl, 2,3-dihydrobenzo furanyl, 1,3-benzodioxolyl, 2,3-dihydro-1,4-benzodioxinyl, indolinyl, benzofuryl, isobenzofuryl, benzothienyl, isobenzothienyl, indolizinyl, indolyl, isoindolyl, benzoxazolyl, benzimidazolyl, indazolyl, benzisoxazolyl, benzisothiazolyl, benzopyrazolyl, benzoxadiazolyl, benzothiadiazolyl, benzotriazolyl, purinyl, quinolinyl, isoquinolinyl, cinnolinyl, quinolizinyl, phthalazinyl, quinoxalinyl, quinazolinyl, naphthiridinyl, pteridinyl, benzopyranyl, pyrrolopyridyl, thienopyridyl, furopyridyl, isothiazolopyridyl, thiazolopyridyl, isoxazolopyridyl, oxazolopyridyl, pyrazolopyridyl, imidazopyridyl, pyrrolopyrazinyl, thienopyrazinyl, furopyrazinyl, isothiazolopyrazinyl, thiazolopyrazinyl, isoxazolopyrazinyl, oxazolopyrazinyl, pyrazolopyrazinyl, imidazopyrazinyl, pyrrolopyrimidinyl, thienopyrimidinyl, furopyrimidinyl, isothiazolopyrimidinyl, thiazolopyrimidinyl, isoxazolopyrimidinyl, oxazolopyrimidinyl, pyrazolopyrimidinyl, imidazopyrimidinyl, pyrrolopyridazinyl, thienopyridazinyl, furopyridazinyl, isothiazolopyridazinyl, thiazolopyridazinyl, isoxazolopyridazinyl, oxazolopyridazinyl, pyrazolopyridazinyl, imidazopyridazinyl, oxadiazolopyridyl, thiadiazolopyridyl, triazolopyridyl, oxadiazolopyrazinyl, thiadiazolopyrazinyl, triazolopyrazinyl, oxadiazolopyrimidinyl, thiadiazolopyrimidinyl, triazolopyrimidinyl, oxadiazolopyridazinyl, thiadiazolopyridazinyl, triazolopyridazinyl, imidazooxazolyl, imidazothiazolyl, imidazoimidazolyl, imidazopyrazolyl; isoxazolotriazinyl, isothiazolotriazinyl, pyrazolotriazinyl, oxazolotriazinyl, thiazolotriazinyl, imidazotriazinyl, oxadiazolotriazinyl, thiadiazolotriazinyl, triazolotriazinyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl, phenoxazinyl and the like. Optional substituents of the above heterocycles are hydroxyl; oxo; carboxyl; halo; C1-6alkyl optionally substituted with C1-4alkyloxy, amino or mono-or di-(C1-4alkyl)amino; polyhaloC1-6alkyl; C1-6alkyloxy optionally substituted with C1-4alkyloxy; C1-6alkylthio; polyhaloC1-6alkyloxy; C1-6alkyl-oxycarbonyl; cyano; aminocarbonyl; mono-or di(C1-4alkyl)aminocarbonyl; C1-6alkylcarbonyl; nitro; amino; mono-or di(C1-4alkyl)amino; —S(═O)p—C1-4alkyl.
  • Examples of a 6-membered aromatic heterocycle containing 1 or 2 N atoms in the definition of R3 are pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl.
  • When any variable occurs more than one time in any constituent (e.g. aryl, Het), each definition is independent.
  • The term Het or R1 is meant to include all the possible isomeric forms of the heterocycles, for instance, pyrrolyl comprises 1H-pyrrolyl and 2H-pyrrolyl.
  • The carbocycles or heterocycles covered by the terms aryl, Het, R1 or R3 may be attached to the remainder of the molecule of formula (I) through any ring carbon or heteroatom as appropriate, if not otherwise specified. Thus, for example, when the heterocycle is imidazolyl, it may be 1-imidazolyl, 2-imidazolyl, 4-imidazolyl and the like, or when the carbocycle is naphthalenyl, it may be 1-naphthalenyl, 2-naphthalenyl and the like.
  • Lines drawn from substituents into ring systems indicate that the bond may be attached to any of the suitable ring atoms.
  • When X is defined as for instance —NRx—C(═O)—, this means that the nitrogen of NRx is linked to the R2 substituent and the carbon atom of C(═O) is linked to the nitrogen of the ring
  • Figure US20100216809A1-20100826-C00201
  • Thus the left part of the bivalent radical in the definition of X is linked to the R2 substituent and the right part of the bivalent radical in the definition of
  • X is linked to the ring moiety
  • Figure US20100216809A1-20100826-C00202
  • Some of the compounds of formula (I) may also exist in their tautomeric form. Such forms although not explicitly indicated in the above formula are intended to be included within the scope of the present invention.
  • Whenever used hereinbefore or hereinafter that substituents can be selected each independently out of a list of numerous definitions, such as for example for R4 and R5, all possible combinations are intended which are chemically possible.
  • For therapeutic use, salts of the compounds of formula (I) are those wherein the counterion is pharmaceutically acceptable. However, salts of acids and bases which are non-pharmaceutically acceptable may also find use, for example, in the preparation or purification of a pharmaceutically acceptable compound. All salts, whether pharmaceutically acceptable or not are included within the ambit of the present invention.
  • The pharmaceutically acceptable salts as mentioned hereinbefore or hereinafter are meant to comprise the therapeutically active non-toxic acid addition salt forms which the compounds of formula (I) are able to form. The latter can conveniently be obtained by treating the base form with such appropriate acids as inorganic acids, for example, hydrohalic acids, e.g. hydrochloric, hydrobromic and the like; sulfuric acid; nitric acid; phosphoric acid and the like; or organic acids, for example, acetic, propanoic, hydroxy-acetic, 2-hydroxypropanoic, 2-oxopropanoic, oxalic, malonic, succinic, maleic, fumaric, malic, tartaric, 2-hydroxy-1,2,3-propanetricarboxylic, methanesulfonic, ethanesulfonic, benzenesulfonic, 4-methylbenzenesulfonic, cyclohexanesulfonic, 2-hydroxybenzoic, 4-amino-2-hydroxybenzoic and the like acids. Conversely the salt form can be converted by treatment with alkali into the free base form.
  • The compounds of formula (I) containing acidic protons may be converted into their therapeutically active non-toxic metal or amine addition salt forms by treatment with appropriate organic and inorganic bases. The pharmaceutically acceptable salts as mentioned hereinbefore or hereinafter are meant to also comprise the therapeutically active non-toxic metal or amine addition salt forms (base addition salt forms) which the compounds of formula (I) are able to form. Appropriate base addition salt forms comprise, for example, the ammonium salts, the alkali and earth alkaline metal salts, e.g. the lithium, sodium, potassium, magnesium, calcium salts and the like, salts with organic bases, e.g. primary, secondary and tertiary aliphatic and aromatic amines such as methylamine, ethylamine, propylamine, isopropylamine, the four butylamine isomers, dimethylamine, diethylamine, diethanolamine, dipropylamine, diisopropylamine, di-n-butylamine, pyrrolidine, piperidine, morpholine, trimethylamine, triethylamine, tripropylamine, quinuclidine, pyridine, quinoline and isoquino line, the benzathine, N-methyl-D-glucamine, 2-amino-2-(hydroxymethyl)-1,3-propanediol, hydrabamine salts, and salts with amino acids such as, for example, arginine, lysine and the like.
  • Conversely the salt form can be converted by treatment with acid into the free acid form.
  • The term salt also comprises the quaternary ammonium salts (quaternary amines) which the compounds of formula (I) are able to form by reaction between a basic nitrogen of a compound of formula (I) and an appropriate quaternizing agent, such as, for example, an optionally substituted C1-6alkylhalide, arylhalide, C1-6alkyl-carbonylhalide, arylcarbonylhalide, or arylC1-6alkylhalide, e.g. methyliodide or benzyliodide. Other reactants with good leaving groups may also be used, such as for example C1-6alkyl trifluoromethanesulfonates, C1-6alkyl methanesulfonates, and C1-6alkyl p-toluenesulfonates. A quaternary amine has a positively charged nitrogen. Pharmaceutically acceptable counterions include chloro, bromo, iodo, trifluoroacetate, acetate, triflate, sulfate, sulfonate. The counterion of choice can be introduced using ion exchange resins.
  • The term solvate comprises the hydrates and solvent addition forms which the compounds of formula (I) are able to form, as well as salts thereof. Examples of such forms are e.g. hydrates, alcoholates and the like.
  • The N-oxide forms of the present compounds are meant to comprise the compounds of formula (I) wherein one or several tertiary nitrogen atoms are oxidized to the so-called N-oxide.
  • It will be appreciated that some of the compounds of formula (I) and their N-oxides, salts, and solvates may contain one or more centers of chirality and exist as stereochemically isomeric forms.
  • The term “stereochemically isomeric forms” as used hereinbefore or hereinafter defines all the possible stereoisomeric forms which the compounds of formula (I), and their N-oxides, salts, or solvates may possess. Unless otherwise mentioned or indicated, the chemical designation of compounds denotes the mixture of all possible stereochemically isomeric forms, said mixtures containing all diastereomers and enantiomers of the basic molecular structure as well as each of the individual isomeric forms of formula (I) and their N-oxides, salts or solvates, substantially free, i.e. associated with less than 10%, preferably less than 5%, in particular less than 2% and most preferably less than 1% of the other isomers. Thus, when a compound of formula (I) is for instance specified as (E), this means that the compound is substantially free of the (Z) isomer.
  • In particular, stereogenic centers may have the R- or S-configuration; substituents on bivalent cyclic (partially) saturated radicals may have either the cis- or trans-configuration. Compounds encompassing double bonds can have an E (entgegen) or Z (zusammen) -stereochemistry at said double bond. The terms cis, trans, R, S, E and Z are well known to a person skilled in the art.
  • Stereochemically isomeric forms of the compounds of formula (I) are obviously intended to be embraced within the scope of this invention.
  • Following CAS-nomenclature conventions, when two stereogenic centers of known absolute configuration are present in a molecule, an R or S descriptor is assigned (based on Cahn-Ingold-Prelog sequence rule) to the lowest-numbered chiral center, the reference center. The configuration of the second stereogenic center is indicated using relative descriptors [R*,R* ] or [R*,S*], where the first R* is always specified as the reference center and [R*,R*] indicates centers with the same chirality and [R *,S*] indicates centers of unlike chirality. For example, if the lowest-numbered chiral center in the molecule has an S configuration and the second center is R, the stereo descriptor would be specified as S—[R*,S*]. If “α” and “β” are used: the position of the highest priority substituent on the asymmetric carbon atom in the ring system having the lowest ring number, is arbitrarily always in the “α” position of the mean plane determined by the ring system. The position of the highest priority substituent on the other asymmetric carbon atom in the ring system relative to the position of the highest priority substituent on the reference atom is denominated “α”, if it is on the same side of the mean plane determined by the ring system, or “β”, if it is on the other side of the mean plane determined by the ring system.
  • The compounds of (I) may be synthesized in the form of racemic mixtures of enantiomers which can be separated from one another following art-known resolution procedures. The racemic compounds of formula (I) may be converted into the corresponding diastereomeric salt forms by reaction with a suitable chiral acid. Said diastereomeric salt forms are subsequently separated, for example, by selective or fractional crystallization and the enantiomers are liberated therefrom by alkali. An alternative manner of separating the enantiomeric forms of the compounds of formula (I) involves liquid chromatography using a chiral stationary phase. Said pure stereochemically isomeric forms may also be derived from the corresponding pure stereochemically isomeric forms of the appropriate starting materials, provided that the reaction occurs stereospecifically. Preferably if a specific stereoisomer is desired, said compound will be synthesized by stereospecific methods of preparation. These methods will advantageously employ enantiomerically pure starting materials.
  • Whenever used hereinafter, the term “compounds of formula (I)” or any subgroup thereof, is meant to also include their N-oxide forms, their salts, their stereochemically isomeric forms and their solvates. Of special interest are those compounds of formula (I) which are stereochemically pure.
  • A first embodiment of the present invention are those compounds of formula (I) having the following formula
  • Figure US20100216809A1-20100826-C00203
      • including any stereochemically isomeric form thereof, wherein
      • A represents CH or N;
      • the dotted line represents an optional bond in case A represents a carbon atom;
      • X represents —NRx—C(═O)—; —Z—C(═O)—; —Z—NRx—C(═O)—; —S(═O)p-; —C(═S)—;
      • —NRx—C(═S)—; —Z—C(═S)—; —Z—NRx—C(═S)—;
      • Z represents a bivalent radical selected from C1-6alkanediyl, C2-6alkenediyl or C2-6alkynediyl; wherein each of said C1-6alkanediyl, C2-6alkenediyl or C2-6alkynediyl may optionally be substituted with hydroxyl;
      • Rx represents hydrogen or C1-4alkyl;
  • R1 represents a 5-membered monocyclic heterocycle containing at least 2 heteroatoms; a 6-membered aromatic monocyclic heterocycle; or a 5-membered heterocycle containing at least 2 heteroatoms fused with phenyl, cyclohexyl or a 5- or 6-membered heterocycle; wherein each of said heterocycles may optionally be substituted with at least one substituent, in particular one, two, three, four or five substituents, each substituent independently being selected from hydroxyl; oxo; carboxyl; halo; C1-6alkyl optionally substituted with aryl-C(═O)—; hydroxyC1-6alkyl optionally substituted with aryl or aryl-C(═O)—; polyhaloC1-6alkyl; C1-6alkyloxy optionally substituted with C1-4alkyloxy; C1-6alkylthio; polyhaloC1-6alkyloxy; C1-6alkyloxy-carbonyl wherein C1-6alkyl may optionally be substituted with aryl; cyano; aminocarbonyl; mono-or di(C1-4alkyl)aminocarbonyl; C1-6alkylcarbonyl; nitro; amino; mono-or di(C1-6alkyl)amino; C3-6cycloalkyl-NRx—; aryl-NRx—; Het-NRx—; C3-6cycloalkylC1-4alkyl-NRx—; arylC1-4alkyl-NRx—; HetC1-4alkyl-NRx—; —S(═O)p—C1- 4alkyl; C3-6cycloalkyl; C3-6cycloalkylC1-4alkyl; C3-6cycloalkyl-C(═O)—; aryl; aryloxy; arylC1-4alkyl; aryl-C(═O)—; Het; HetC1-4alkyl; Het-C(═O)—; Het-O—;
      • R2 represents R3;
      • R3 represents C3-6cycloalkyl, phenyl, naphtalenyl, 2,3-dihydro-1,4-benzodioxinyl, 1,3-benzodioxolyl, wherein said C3-6cycloalkyl, phenyl, naphtalenyl, 2,3-dihydro-1,4-benzodioxinyl, 1,3-benzodioxolyl may optionally be substituted with at least one substituent, in particular one, two, three, four or five substituents, each substituent independently selected from hydroxyl; carboxyl; halo; C1-6alkyl optionally substituted with hydroxy; polyhaloC1-6alkyl; C1-6alkyloxy optionally substituted with C1-4alkyloxy; C1-6alkylthio; polyhalo-C1-6alkyloxy; C1-6alkyloxy-carbonyl wherein C1-6alkyl may optionally be substituted with aryl; cyano; C1-6alkylcarbonyl; nitro; amino; mono-or di(C1-4alkyl)amino; —S(═O)p—C1-4alkyl; R5R4N—C(═O)—; R5R4N—C1-6alkyl; C3-6cycloalkyl; C3-6cycloalkylC1-4alkyl; C3-6cycloalkyl-C(═O)—; aryl; aryloxy; arylC1-4alkyl; aryl-C(═O)—; Het; HetC1-4alkyl; Het-C(═O)—; Het-O—;
      • R4 represents hydrogen; C1-4alkyl optionally substituted with hydroxyl or C1-4alkyloxy; R7R6N—C1-4alkyl; C1-4alkyloxy; Het; aryl; R7R6N—C(═O)—C1-4alkyl;
      • R5 represents hydrogen or C1-4alkyl;
      • R6 represents hydrogen; C1-4alkyl; C1-4alkylcarbonyl;
      • R7 represents hydrogen or C1-4alkyl; or
      • R6 and R7 may be taken together with the nitrogen to which they are attached to form a saturated monocyclic 5, 6 or 7-membered heterocycle which may further contain one or more heteroatoms selected from O, S, S(═O)p or N; and which heterocycle may optionally be substituted with C1-4alkyl;
      • aryl represents phenyl or phenyl substituted with at least one substituent, in particular one, two, three, four or five substituents, each substituent independently being selected from hydroxyl; carboxyl; halo; C1-6alkyl optionally substituted with C1-4alkyloxy, amino or mono-or di(C1-4alkyl)amino; polyhaloC1-6alkyl; C1-6alkyloxy optionally substituted with C1-4alkyloxy; C1-6alkylthio; polyhaloC1-6alkyloxy; C1-6alkyloxycarbonyl; cyano; amino carbonyl; mono-or di(C1-4alkyl)aminocarbonyl; C1-6alkylcarbonyl; nitro; amino; mono-or di(C1-4alkyl)amino; —S(═O)p—C1-4alkyl;
      • Het represents a monocyclic non-aromatic or aromatic heterocycle containing at least one heteroatom selected from O, S, S(═O)p or N; or a bicyclic or tricyclic non-aromatic or aromatic heterocycle containing at least one heteroatom selected from O, S, S(═O)p or N; said monocyclic heterocycle or said bi-or tricyclic heterocycle optionally being substituted with at least one substituent, in particular one, two, three, four or five substituents, each substituent independently being selected from hydroxyl; oxo; carboxyl; halo; C1-6alkyl optionally substituted with C1-4alkyloxy, amino or mono-or di(C1-4alkyl)amino; polyhaloC1-6alkyl; C1-6alkyloxy optionally substituted with C1-4alkyloxy; C1-6alkylthio; polyhaloC1-6alkyloxy; C1-6alkyl-oxycarbonyl; cyano; aminocarbonyl; mono-or di(C1-4alkyl)aminocarbonyl; C1-6alkylcarbonyl; nitro; amino; mono-or di(C1-4alkyl)amino; —S(═O)p—C1-4alkyl;
      • p represents 1 or 2;
      • provided that the following compounds
  • Figure US20100216809A1-20100826-C00204
    X R1 R2
    Figure US20100216809A1-20100826-C00205
    Figure US20100216809A1-20100826-C00206
    Figure US20100216809A1-20100826-C00207
    Figure US20100216809A1-20100826-C00208
    Figure US20100216809A1-20100826-C00209
    Figure US20100216809A1-20100826-C00210
    Figure US20100216809A1-20100826-C00211
    Figure US20100216809A1-20100826-C00212
    Figure US20100216809A1-20100826-C00213
    Figure US20100216809A1-20100826-C00214
    Figure US20100216809A1-20100826-C00215
    Figure US20100216809A1-20100826-C00216
    Figure US20100216809A1-20100826-C00217
    Figure US20100216809A1-20100826-C00218
    Figure US20100216809A1-20100826-C00219
    Figure US20100216809A1-20100826-C00220
    Figure US20100216809A1-20100826-C00221
    Figure US20100216809A1-20100826-C00222
    Figure US20100216809A1-20100826-C00223
    Figure US20100216809A1-20100826-C00224
    Figure US20100216809A1-20100826-C00225
    Figure US20100216809A1-20100826-C00226
    Figure US20100216809A1-20100826-C00227
    Figure US20100216809A1-20100826-C00228
    Figure US20100216809A1-20100826-C00229
    Figure US20100216809A1-20100826-C00230
    Figure US20100216809A1-20100826-C00231
    Figure US20100216809A1-20100826-C00232
    Figure US20100216809A1-20100826-C00233
    Figure US20100216809A1-20100826-C00234
    Figure US20100216809A1-20100826-C00235
    Figure US20100216809A1-20100826-C00236
    Figure US20100216809A1-20100826-C00237
    Figure US20100216809A1-20100826-C00238
    Figure US20100216809A1-20100826-C00239
    Figure US20100216809A1-20100826-C00240
    Figure US20100216809A1-20100826-C00241
    Figure US20100216809A1-20100826-C00242
    Figure US20100216809A1-20100826-C00243
      • are excluded;
      • a N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof.
  • The invention also relates to a compound of formula (I) as described in the above embodiment, provided that the following compounds
  • Figure US20100216809A1-20100826-C00244
    X R1 R2 Salt
    Figure US20100216809A1-20100826-C00245
    Figure US20100216809A1-20100826-C00246
    Figure US20100216809A1-20100826-C00247
    Figure US20100216809A1-20100826-C00248
    Figure US20100216809A1-20100826-C00249
    Figure US20100216809A1-20100826-C00250
    Figure US20100216809A1-20100826-C00251
    Figure US20100216809A1-20100826-C00252
    Figure US20100216809A1-20100826-C00253
    Figure US20100216809A1-20100826-C00254
    Figure US20100216809A1-20100826-C00255
    Figure US20100216809A1-20100826-C00256
    Figure US20100216809A1-20100826-C00257
    Figure US20100216809A1-20100826-C00258
    Figure US20100216809A1-20100826-C00259
    Figure US20100216809A1-20100826-C00260
    Figure US20100216809A1-20100826-C00261
    Figure US20100216809A1-20100826-C00262
    Figure US20100216809A1-20100826-C00263
    Figure US20100216809A1-20100826-C00264
    Figure US20100216809A1-20100826-C00265
    Figure US20100216809A1-20100826-C00266
    Figure US20100216809A1-20100826-C00267
    Figure US20100216809A1-20100826-C00268
    Figure US20100216809A1-20100826-C00269
    Figure US20100216809A1-20100826-C00270
    Figure US20100216809A1-20100826-C00271
    Figure US20100216809A1-20100826-C00272
    Figure US20100216809A1-20100826-C00273
    Figure US20100216809A1-20100826-C00274
    Figure US20100216809A1-20100826-C00275
    Figure US20100216809A1-20100826-C00276
    Figure US20100216809A1-20100826-C00277
    Figure US20100216809A1-20100826-C00278
    Figure US20100216809A1-20100826-C00279
    Figure US20100216809A1-20100826-C00280
    Figure US20100216809A1-20100826-C00281
    Figure US20100216809A1-20100826-C00282
    Figure US20100216809A1-20100826-C00283
    Figure US20100216809A1-20100826-C00284
    Figure US20100216809A1-20100826-C00285
    Figure US20100216809A1-20100826-C00286
    Figure US20100216809A1-20100826-C00287
    Figure US20100216809A1-20100826-C00288
    Figure US20100216809A1-20100826-C00289
    Figure US20100216809A1-20100826-C00290
    Figure US20100216809A1-20100826-C00291
    Figure US20100216809A1-20100826-C00292
    Figure US20100216809A1-20100826-C00293
    Figure US20100216809A1-20100826-C00294
    Figure US20100216809A1-20100826-C00295
    Figure US20100216809A1-20100826-C00296
    Figure US20100216809A1-20100826-C00297
    Figure US20100216809A1-20100826-C00298
    Figure US20100216809A1-20100826-C00299
    Figure US20100216809A1-20100826-C00300
    Figure US20100216809A1-20100826-C00301
    Figure US20100216809A1-20100826-C00302
    Figure US20100216809A1-20100826-C00303
    Figure US20100216809A1-20100826-C00304
    Figure US20100216809A1-20100826-C00305
    Figure US20100216809A1-20100826-C00306
    Figure US20100216809A1-20100826-C00307
    Figure US20100216809A1-20100826-C00308
    Figure US20100216809A1-20100826-C00309
    Figure US20100216809A1-20100826-C00310
    Figure US20100216809A1-20100826-C00311
    Figure US20100216809A1-20100826-C00312
    Figure US20100216809A1-20100826-C00313
    Figure US20100216809A1-20100826-C00314
    Figure US20100216809A1-20100826-C00315
    Figure US20100216809A1-20100826-C00316
    Figure US20100216809A1-20100826-C00317
    Figure US20100216809A1-20100826-C00318
    Figure US20100216809A1-20100826-C00319
    Figure US20100216809A1-20100826-C00320
    Figure US20100216809A1-20100826-C00321
    Figure US20100216809A1-20100826-C00322
    Figure US20100216809A1-20100826-C00323
    Figure US20100216809A1-20100826-C00324
    Figure US20100216809A1-20100826-C00325
    Figure US20100216809A1-20100826-C00326
    Figure US20100216809A1-20100826-C00327
    Figure US20100216809A1-20100826-C00328
    Figure US20100216809A1-20100826-C00329
    Figure US20100216809A1-20100826-C00330
    Figure US20100216809A1-20100826-C00331
    Figure US20100216809A1-20100826-C00332
    Figure US20100216809A1-20100826-C00333
    Figure US20100216809A1-20100826-C00334
    Figure US20100216809A1-20100826-C00335
    Figure US20100216809A1-20100826-C00336
    Figure US20100216809A1-20100826-C00337
    Figure US20100216809A1-20100826-C00338
    Figure US20100216809A1-20100826-C00339
    Figure US20100216809A1-20100826-C00340
    Figure US20100216809A1-20100826-C00341
    Figure US20100216809A1-20100826-C00342
    Figure US20100216809A1-20100826-C00343
    Figure US20100216809A1-20100826-C00344
    Figure US20100216809A1-20100826-C00345
    Figure US20100216809A1-20100826-C00346
    Figure US20100216809A1-20100826-C00347
    Figure US20100216809A1-20100826-C00348
    Figure US20100216809A1-20100826-C00349
    Figure US20100216809A1-20100826-C00350
    Figure US20100216809A1-20100826-C00351
    Figure US20100216809A1-20100826-C00352
    Figure US20100216809A1-20100826-C00353
    Figure US20100216809A1-20100826-C00354
    Figure US20100216809A1-20100826-C00355
    Figure US20100216809A1-20100826-C00356
    Figure US20100216809A1-20100826-C00357
    Figure US20100216809A1-20100826-C00358
    Figure US20100216809A1-20100826-C00359
    Figure US20100216809A1-20100826-C00360
    Figure US20100216809A1-20100826-C00361
    Figure US20100216809A1-20100826-C00362
    Figure US20100216809A1-20100826-C00363
    Figure US20100216809A1-20100826-C00364
    Figure US20100216809A1-20100826-C00365
    Figure US20100216809A1-20100826-C00366
    Figure US20100216809A1-20100826-C00367
    Figure US20100216809A1-20100826-C00368
    Figure US20100216809A1-20100826-C00369
    Figure US20100216809A1-20100826-C00370
    Figure US20100216809A1-20100826-C00371
    Figure US20100216809A1-20100826-C00372
    Figure US20100216809A1-20100826-C00373
    Figure US20100216809A1-20100826-C00374
    Figure US20100216809A1-20100826-C00375
    Figure US20100216809A1-20100826-C00376
    Figure US20100216809A1-20100826-C00377
    Figure US20100216809A1-20100826-C00378
    Figure US20100216809A1-20100826-C00379
    Figure US20100216809A1-20100826-C00380
    Figure US20100216809A1-20100826-C00381
    Figure US20100216809A1-20100826-C00382
    Figure US20100216809A1-20100826-C00383
    Figure US20100216809A1-20100826-C00384
    Figure US20100216809A1-20100826-C00385
    Figure US20100216809A1-20100826-C00386
    Figure US20100216809A1-20100826-C00387
    Figure US20100216809A1-20100826-C00388
    Figure US20100216809A1-20100826-C00389
    Figure US20100216809A1-20100826-C00390
    Figure US20100216809A1-20100826-C00391
         		trifluoroacetate salt
    Figure US20100216809A1-20100826-C00392
    Figure US20100216809A1-20100826-C00393
    Figure US20100216809A1-20100826-C00394
    Figure US20100216809A1-20100826-C00395
    Figure US20100216809A1-20100826-C00396
    Figure US20100216809A1-20100826-C00397
      • are excluded.
  • A second embodiment of the present invention are those compounds of formula (I) or, whenever possible, any subgroup thereof as mentioned hereinbefore as embodiment wherein X represents —NRx—C(═O)—; —Z—C(═O)—; —Z—NRx—C(═O)—; —S(═O)p-; —NRx—C(═S)— or —O—C(═O)—; in particular X represents —NRx—C(═O)—; —Z—C(═O)—; —Z—NRx—C(═O)—; more in particular X represents —NRx—C(═O— or —Z—C(═O)—.
  • A third embodiment of the present invention are those compounds of formula (I) or, whenever possible, any subgroup thereof as mentioned hereinbefore as embodiment wherein A represents N.
  • A fourth embodiment of the present invention are those compounds of formula (I) or, whenever possible, any subgroup thereof as mentioned hereinbefore as embodiment wherein A represents CH, in particular wherein A represents CH and the dotted line does not represent a bond.
  • A fifth embodiment of the present invention are those compounds of formula (I) or, whenever possible, any subgroup thereof as mentioned hereinbefore as embodiment wherein R1 represents a 5-membered monocyclic heterocycle containing at least 2 heteroatoms, in particular pyrazolyl, triazolyl or oxadiazolyl; a 6-membered monocyclic aromatic heterocycle, in particular pyrimidinyl; or a 5-membered aromatic heterocycle containing at least 2 heteroatoms fused with a 5-membered heterocycle, in particular imidazopyrazolyl or imidazothiazolyl; wherein each of said heterocycles may optionally be substituted, preferably with one or two substituents. Particular substituents of said heterocycles include oxo, C1-6alkyl optionally substituted with aryl-C(═O)— or C1-4alkyloxycarbonyl; hydroxyC1-6alkyl optionally substituted with aryl or aryl-C(═O)—; amino; mono-or di(C1-6alkyl)amino; R5R4N—C1-6alkyl; C3-6cycloalkyl-NRx—; aryl-NRx—; Het-NRx—; C3-6cycloalkylC1-4alkyl-NRx—; arylC1-4alkyl-NRx—; HetC1-4alkyl-NRx—; C3-6cycloalkyl; C3-6cycloalkylC1-4alkyl; aryl; aryloxy; arylC1-4alkyl; aryl-C(═O)—; aryl-C(═O)—C1-4alkyl; Het; HetC1-4alkyl; Het-C(═O)—; Het-C(═O)—C1-4alkyl; Het-O—; more in particular C1-6alkyl optionally substituted with aryl-C(═O)— or C1-4alkyloxycarbonyl; hydroxyC1-6alkyl optionally substituted with aryl; mono-or di(C1-6alkyl)amino; R5R4N—C1-6alkyl; C3-6cycloalkyl-NRx—; Het-NRx—; arylC1-4alkyl-NRx—; C3-6cycloalkyl; C3-6cycloalkylC1-4alkyl; aryl; arylC1-4alkyl; aryl-C(═O)—C1-4alkyl or Het.
  • A sixth embodiment of the present invention are those compounds of formula (I) or, whenever possible, any subgroup thereof as mentioned hereinbefore as embodiment wherein the compound of formula (I) is a compound of formula (I′)
  • Figure US20100216809A1-20100826-C00398
      • wherein R3a and R3b each independently represent hydrogen; hydroxyl; carboxyl; halo; C1-6alkyl optionally substituted with hydroxyl; polyhaloC1-6alkyl; C1-6alkyloxy optionally substituted with C1-4alkyloxy; C1-6alkylthio; polyhaloC1-6alkyloxy; C1-6alkyloxycarbonyl; cyano; aminocarbonyl; mono-or di(C1-4alkyl)aminocarbonyl; C1-6alkylcarbonyl; nitro; amino; mono-or di(C1-4alkyl)amino; C1-4alkylcarbonylamino; —S(═O)p—C1-4alkyl; and wherein R3c represents hydrogen; hydroxyl; carboxyl; halo; C1-6alkyl; polyhaloC1-6alkyl; C1-6alkyloxy optionally substituted with C1-4alkyloxy; C1-6alkylthio; polyhalo-C1-6alkyloxy; C1-6alkyloxycarbonyl wherein C1-6alkyl may optionally be substituted with aryl; cyano; C1-6alkylcarbonyl; nitro; amino; mono-or di(C1-4alkyl)amino; —S(═O)p—C1-4alkyl; R5R4N—C(═O)—; R5R4N—C1-6alkyl; C3-6cycloalkyl; aryl; aryloxy; arylC1-4alkyl; aryl-C(═O)—; Het; HetC1-4alkyl; Het-C(═O)—; Het-O—.
  • A seventh embodiment of the present invention are those compounds of formula (I) or, whenever possible, any subgroup thereof as mentioned hereinbefore as embodiment wherein the compound of formula (I) is a compound of formula (I″)
  • Figure US20100216809A1-20100826-C00399
      • wherein R3a and R3b each independently represent hydrogen; hydroxyl; carboxyl; halo; C1-6alkyl; polyhaloC1-6alkyl; C1-6alkyloxy optionally substituted with C1-4alkyloxy; C1-6alkylthio; polyhaloC1-6alkyloxy; C1-6alkyloxycarbonyl; cyano; aminocarbonyl; mono-or di(C1-4alkyl)aminocarbonyl; C1-6alkylcarbonyl; nitro; amino; mono-or di(C1-4alkyl)amino; —S(═O)p—C1-4alkyl; and wherein R3c represents hydrogen; hydroxyl; carboxyl; halo; C1-6alkyl optionally substituted with hydroxyl; polyhaloC1-6alkyl; C1-6alkyloxy optionally substituted with C1-4alkyloxy; C1-6alkylthio; polyhalo-C1-6alkyl-oxy; C1-6alkyloxycarbonyl wherein C1-6alkyl may optionally be substituted with aryl; cyano; C1-6alkylcarbonyl; nitro; amino; mono-or di(C1-4alkyl)amino; C1-4alkylcarbonylamino; —S(═O)p—C1-4alkyl; R5R4N—C(═O)—; R5R4N—C1-6alkyl; C3-6cycloalkyl; aryl; aryloxy; arylC1-4alkyl; aryl-C(═O)—; Het; HetC1-4alkyl; Het-C(═O)—; Het-O—.
  • An eighth embodiment of the present invention are those compounds of formula (I) or, whenever possible, any subgroup thereof as mentioned hereinbefore as embodiment wherein the compound of formula (I) is a compound of formula (I′) or (I″) and wherein R3a and R3b each independently represent halo, polyhaloC1-6alkyl, C1-6alkyl or C1-6alkyloxy, in particular both R3a and R3b represent halo, more in particular both R3a and R3b represent chloro.
  • A ninth embodiment of the present invention are those compounds of formula (I) or, whenever possible, any subgroup thereof as mentioned hereinbefore as embodiment wherein the compound of formula (I) is a compound of formula (I′) or (I″) and wherein R3c represents hydrogen, hydroxyl, carboxyl; halo; amino; mono-or di-(C1-4alkyl)amino; C1-6alkyl; C1-6alkyloxy; C1-6alkyloxycarbonyl; C1-6alkylthio; C1-4alkylcarbonylamino; R5R4N—C(═O)—; R5R4N—C1-6alkyl; Het-C(═O)— or HetC1-4alkyl; or R3c represents hydrogen.
  • A tenth embodiment of the present invention are those compounds of formula (I) or, whenever possible, any subgroup thereof as mentioned hereinbefore as embodiment wherein p represents 2.
  • An eleventh embodiment of the present invention are those compounds of formula (I) or, whenever possible, any subgroup thereof as mentioned hereinbefore as embodiment wherein Z represents C1-6alkanediyl, in particular CH2 or CH2-CH2.
  • A twelfth embodiment of the present invention are those compounds of formula (I) or, whenever possible, any subgroup thereof as mentioned hereinbefore as embodiment wherein Rx represents hydrogen.
  • A thirteenth embodiment of the present invention are those compounds of formula (I) or, whenever possible, any subgroup thereof as mentioned hereinbefore as embodiment wherein R8 represents hydrogen.
  • A fourteenth embodiment of the present invention are those compounds of formula (I) or, whenever possible, any subgroup thereof as mentioned hereinbefore as embodiment wherein R8 represents halo, C1-4alkyl or C1-4alkyl substituted with hydroxyl; in particular R8 represents halo or C1-4alkyl.
  • A fifteenth embodiment of the present invention are those compounds of formula (I) or, whenever possible, any subgroup thereof as mentioned hereinbefore as embodiment wherein R3 represents C3-6cycloalkyl, phenyl, naphtalenyl, 1,3-benzodioxolyl or a 6-membered aromatic heterocycle containing 1 or 2 N atoms, wherein said C3-6cycloalkyl, phenyl, naphtalenyl, 1,3-benzodioxolyl or 6-membered aromatic heterocycle may optionally be substituted with at least one substituent, in particular one or two substituents, preferably each substituent independently selected from hydroxyl; carboxyl; halo; C1-6alkyl optionally substituted with hydroxy; polyhaloC1-6alkyl; C1-6alkyloxy; C1-6alkylthio; C1-6alkyloxycarbonyl; amino; mono-or di(C1-4alkyl)amino; C1 -4alkylcarbonylamino; Het; HetC1 -4alkyl.
  • A sixteenth embodiment of the present invention are those compounds of formula (I) or any subgroup thereof as mentioned hereinbefore as embodiment wherein one or more, preferably all, of the following restrictions apply:
      • a) X represents —NRx—C(═O)—; or —Z—C(═O)—;
      • b) the compound of formula (I) is a compound of formula (I″), in particular a compound of formula (I″) wherein R3a and R3b represent halo; more in particular chloro; and wherein R3c represents hydrogen;
      • c) A represents N;
      • d) A represents CH;
      • e) the dotted line does not represent a bond;
      • f) Z represents C1-6alkanediyl;
      • g) R1 represents a 5-membered monocyclic aromatic heterocycle containing at least 2 heteroatoms, in particular pyrazolyl or triazolyl; a 6-membered monocyclic aromatic heterocycle; or a 5-membered aromatic heterocycle containing at least 2 heteroatoms fused with a 5-membered heterocycle; each of said heterocycles optionally being substituted, in particular substituted with oxo, C1-6alkyl optionally substituted with aryl-C(═O)—; hydroxyC1-6alkyl optionally substituted with aryl; C3-6cycloalkyl-NRx—; Het-NRx—; arylC1-4alkyl-NRx—; aryl; arylC1-4alkyl.
      • h) Rx represents hydrogen.
  • A seventeenth embodiment of the present invention are those compounds of formula (I) or any subgroup thereof as mentioned hereinbefore as embodiment wherein one or more, preferably all, of the following restrictions apply:
      • a) A represents CH or N;
      • b) the dotted line does not represents a bond in case A represents a carbon atom;
      • c) X represents —NRx—C(═O)—; —Z—C(═O)—; —Z—NRx—C(═O)—;
      • d) Z represents a bivalent radical selected from C1-6alkanediyl;
      • e) Rx represents hydrogen;
      • f) R1 represents a 5-membered monocyclic heterocycle containing at least 2 heteroatoms; a 6-membered aromatic monocyclic heterocycle; or a 5-membered heterocycle containing at least 2 heteroatoms fused with a 5-membered heterocycle; wherein each of said heterocycles such as for example pyrazolyl, triazolyl, oxadiazolyl, pyrimidinyl, imidazopyrazolyl or imidazothienyl, may optionally be substituted with at least one substituent, in particular one or two substituents, each substituent independently being selected from oxo; C1-6alkyl optionally substituted with C1-4alkyloxycarbonyl; hydroxyC1-6alkyl optionally substituted with aryl; mono-or di(C1-6alkyl)amino; R5R4N—C1-6alkyl; Het-NRx—; arylC1-4alkyl-NRx—; C3-6cycloalkyl; C3-6cycloalkylC1-4alkyl; aryl; arylC1-4alkyl; aryl-C(═O)—C1-4alkyl; Het;
      • g) R3 represents C3-6cycloalkyl, phenyl, naphtalenyl, 1,3-benzodioxolyl, or a 6-membered aromatic heterocycle containing 1 or 2 N atoms, wherein said C3-6cycloalkyl, phenyl, naphtalenyl, 1,3-benzodioxolyl or 6-membered aromatic heterocycle may optionally be substituted with at least one substituent, in particular one or two substituents, each substituent independently selected from hydroxyl; carboxyl; halo; C1-6alkyl optionally substituted with hydroxy; polyhaloC1-6alkyl; C1-6alkyloxy; C1-6alkylthio; C1-6alkyloxycarbonyl; mono-or di(C1-4alkyl)amino; C1-4alkylcarbonylamino; Het; HetC1-4alkyl;
      • h) R4 represents hydrogen or C1-4alkyl;
      • i) R5 represents hydrogen or C1-4alkyl;
      • j) R8 represents hydrogen;
      • k) aryl represents phenyl or phenyl substituted with at least one substituent, in particular one substituent, said substituent being selected from halo; C1-6alkyl; C1-6alkyloxy;
      • l) Het represents a monocyclic non-aromatic or aromatic heterocycle containing at least one heteroatom selected from O, S, S(═O)p or N; said monocyclic heterocycle optionally being substituted with C1-6alkyloxycarbonyl.
  • Preferred compounds of formula (I) are selected from
  • Figure US20100216809A1-20100826-C00400
    A X R1 Rq
    N
    Figure US20100216809A1-20100826-C00401
    Figure US20100216809A1-20100826-C00402
         		H- - - 
    N
    Figure US20100216809A1-20100826-C00403
    Figure US20100216809A1-20100826-C00404
         		H- - - 
    N
    Figure US20100216809A1-20100826-C00405
    Figure US20100216809A1-20100826-C00406
         		H- - - 
    N
    Figure US20100216809A1-20100826-C00407
    Figure US20100216809A1-20100826-C00408
    Figure US20100216809A1-20100826-C00409
    N
    Figure US20100216809A1-20100826-C00410
    Figure US20100216809A1-20100826-C00411
    Figure US20100216809A1-20100826-C00412
    N
    Figure US20100216809A1-20100826-C00413
    Figure US20100216809A1-20100826-C00414
         		HOCH2- - - 
      • a N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof.
  • In general, compounds of formula (I) wherein X represents Xi—NH—C(═O)— with X1 representing a direct bond or Z, said compounds being represented by formula (I-a), can be prepared by reacting an intermediate of formula (II) with an intermediate of formula (III) in the presence of a suitable solvent, such as for example N,N-dimethylformamide or dichloromethane or acetonitrile, optionally in the presence of a suitable base, such as for example N,N-diethyl-ethanamine. Intermediates of formula (II) are commercially available or can be prepared by reacting R2—X1—NH2 with phosgene in the presence of a suitable solvent, such as for example toluene.
  • Figure US20100216809A1-20100826-C00415
  • The above reaction can also be performed as a fast synthesis reaction thereby using appropriate reagents well-known for fast synthesis, such as for example for the purification of the reaction mixture 1-ethenyl-4-(isocyanatomethyl)-benzene polymer with ethenylbenzene and tris-2-aminoethylamine linked to polystyrene can be used.
  • Compounds of formula (I-a) wherein Xi represents a direct bond, said compounds being represented by formula (I-a-1), can be prepared by reacting an intermediate of formula (II′) with Cl3COC(═O)—Cl or C(═O)Cl2, optionally in the presence of HCl in diethylether, and in the presence of a suitable solvent, such as for example toluene or acetonitrile, followed by reaction with an intermediate of formula (III) in the presence of a suitable solvent, such as for example acetonitrile, N,N-dimethylformamide or dichloromethane, optionally in the presence of a suitable base, such as for example N,N-diethyl-ethanamine or N,N-diisopropyl-ethanamine.
  • Figure US20100216809A1-20100826-C00416
  • Compounds of formula (I) wherein X represents —X1—C(═O)— with X1 representing a direct bond or Z, said compounds being represented by formula (I-b), can be prepared by reacting an intermediate of formula (IV) with an intermediate of formula (III) in the presence of a suitable dehydrating (coupling) agent, such as for example N′-(ethylcarbonimidoyl)-N,N-dimethyl-1,3-propanediamine monohydrochloride (EDCI), dicyclohexylcarbodiimide (DCC), carbonyl diimidazole (CDI), 1-[bis(di-methylamino)methylene]-1H-benzotriazoliumhexafluorophosphate(1-)3-oxide (HBTU), 1-[bis(dimethyl-amino)methylene]-5-chloro-1H-benzotriazolium-hexafluoro-phosphate(1-) 3-oxide (HCTU), O-benzotriazolyltetramethylisouronium tetrafluoroborate (TBTU) or diethyl cyanophosphonate (DECP), optionally combined with hydroxy benzotriazole or chloro hydroxybenzotriazole, in the presence of a suitable solvent, such as for example N,N-dimethylformamide, tetrahydrofuran or dichloromethane, and optionally in the presence of a suitable base, such as for example N,N-diisopropyl-ethanamine or N,N-diethyl-ethanamine. This reaction of an intermediate of formula (IV) with an intermediate of formula (III) can also be performed in the presence of a suitable activating agent, such as for example Cl—C(═O)—C(═O)—Cl, a suitable base, such as for example N,N-diethyl-ethanamine, and a suitable solvent, such as for example N,N-dimethylformamide.
  • Figure US20100216809A1-20100826-C00417
  • Compounds of formula (I-b) wherein X1 represents a direct bond, said compounds being represented by formula (I-b-1), can be prepared by reacting an intermediate of formula (IV′) wherein W1 represents a suitable leaving group, such as for example halo, e.g. chloro and the like, with an intermediate of formula (III) in the presence of a suitable base, such as for example N-methyl morpholine, and a suitable solvent, such as for example N,N-dimethylformamide.
  • Figure US20100216809A1-20100826-C00418
  • Compounds of formula (I) wherein X represents X1—NH—C(═S)— with X1 representing a direct bond or Z, said compounds being represented by formula (I-c), can be prepared by reacting an intermediate of formula (XV) with an intermediate of formula (III) in the presence of a suitable solvent, such as for example tetrahydrofuran or dichloromethane, optionally in the presence of a suitable base, such as for example N,N-diethylethanamine.
  • Figure US20100216809A1-20100826-C00419
  • Compounds of formula (I) wherein X represents —S(═O)p—, said compounds being represented by formula (I-d), can be prepared by reacting an intermediate of formula (XIV) wherein W3 represents a suitable leaving group, such as for example halo, e.g. chloro and the like, with an intermediate of formula (III) in the presence of a suitable base, such as for example N,N-diisopropyl-ethanamine or N,N-diethyl-ethanamine, and a suitable solvent, such as for example dichloromethane.
  • Figure US20100216809A1-20100826-C00420
  • Compounds of formula (I) wherein X represents —C(═O)—C2-6alkenediyl-, said compounds being represented by formula (I-e), can be prepared by reacting an intermediate of formula (XV) with an intermediate of formula (III) in the presence of a suitable solvent, such as for example an alcohol, e.g. ethanol.
  • Figure US20100216809A1-20100826-C00421
  • Compounds of formula (I) wherein R2 represents R3, said R3 being substituted with R5R4N—C1-6alkyl, said R2 being represented by —R3′—C1-6alkyl-NR4R5 and said compounds being represented by formula (I-f), can be prepared by reacting an intermediate of formula (XVI) wherein W4 represents a suitable leaving group, such as for example CH3—S(═O)2—O—, with NHR4R5 in the presence of a suitable solvent, such as for example acetonitrile. Intermediates of formula (XVI) can be prepared by reacting the corresponding OH derivatives with CH3—S(═O)2—Cl in the presence of a suitable base, such as for example pyridine, and a suitable solvent, such as for example dichloromethane.
  • Figure US20100216809A1-20100826-C00422
  • Compounds of formula (I) wherein the R1 substituent is substituted with amino can be prepared from the corresponding compound wherein the amino function is protected by a suitable protecting group, such as for example a tertiair butyloxycarbonyl group, in the presence of a suitable acid, such as for example trifluoroacetic acid, and a suitable solvent, such as for example dichloromethane. Said protected compounds can be prepared according to the synthesis protocol described hereinabove.
  • Compounds of formula (I) wherein X contains Z, said Z being substituted with amino, said X being represented by Z1(NH2)—X2, wherein X2 represents the remainder of the linker X, and said compounds being represented by formula (I-g), can be prepared by deprotecting an intermediate of formula (XVIII) wherein P represents a suitable leaving group, such as for example tert butoxycarbonyl, with a suitable acid, such as for example trifluoroacetic acid, in the presence of a suitable solvent, such as for example dichloromethane.
  • Figure US20100216809A1-20100826-C00423
  • The compounds of formula (I) may further be prepared by converting compounds of formula (I) into each other according to art-known group transformation reactions.
  • The compounds of formula (I) may be converted to the corresponding N-oxide forms following art-known procedures for converting a trivalent nitrogen into its N-oxide form. Said N-oxidation reaction may generally be carried out by reacting the starting material of formula (I) with an appropriate organic or inorganic peroxide. Appropriate inorganic peroxides comprise, for example, hydrogen peroxide, alkali metal or earth alkaline metal peroxides, e.g. sodium peroxide, potassium peroxide; appropriate organic peroxides may comprise peroxy acids such as, for example, benzenecarboperoxoic acid or halo substituted benzenecarboperoxoic acid, e.g. 3-chlorobenzenecarboperoxoic acid, peroxoalkanoic acids, e.g. peroxoacetic acid, alkylhydroperoxides, e.g. tert.butyl hydro-peroxide. Suitable solvents are, for example, water, lower alcohols, e.g. ethanol and the like, hydrocarbons, e.g. toluene, ketones, e.g. 2-butanone, halogenated hydrocarbons, e.g. dichloromethane, and mixtures of such solvents.
  • Compounds of formula (I) wherein R1 or R2 is unsubstituted, can be converted into a compound wherein R1 or R2 contain a C1-4alkyl-S(═O)p— substituent, by reaction with C1-4alkyl-S(═O)p—W5 wherein W5 represents a suitable leaving group, such as for example halo, e.g. chloro and the like, in the presence of a suitable base, such as for example N,N-diethyl-ethanamine, and in the presence of a suitable solvent, such as for example acetonitrile.
  • Compounds of formula (I) wherein R1 or R2 contains a C1-6alkyloxycarbonyl substituent, can be converted into a compound of formula (I) wherein R1 or R2 contain a carboxyl substituent, by reaction with a suitable base, such as for example sodium hydroxide, in the presence of a suitable solvent, such as for example dioxane.
  • Compounds of formula (I) wherein R1 or R2 contain a C1-6alkyloxycarbonyl substituent, can also be converted into a compound of formula (I) wherein R1 or R2 contain a CH2—OH substituent, by reaction with a suitable reducing agent, such as for example LiBH, in the presence of a suitable solvent, such as for example tetrahydrofuran or dioxane.
  • Compounds of formula (I) wherein R1 or R2 contain a C1-6alkyloxycarbonyl substituent, can also be converted into a compound of formula (I) wherein R1 or R2 are unsubstituted by reaction with a suitable acid, such as for example hydrochloric acid and the like.
  • Compounds of formula (I) wherein R1 or R2 contain a C1-5alkyl-carbonyl substituent, can be converted into a compound of formula (I) wherein R1 or R2 contain a C1-5alkyl-CH(OH)— substituent, by reaction with a suitable reducing agent, such as for example NaBH4, in the presence of a suitable solvent, such as for example an alcohol, e.g. methanol.
  • Compounds of formula (I) wherein R1 or R2 contain a C1-6alkyloxy substituent, can be converted into a compound of formula (I) wherein R1 or R2 contain a OH substituent, by reaction with a suitable reducing agent, such as for example BBr3, in the presence of a suitable solvent, such as for example dichloromethane or dichloroethane.
  • Compounds of formula (I) wherein R1 or R2 contain a carboxyl substituent, can be converted into a compound of formula (I) wherein R1 or R2 contain a Het-C(═O)— substituent wherein Het represents an optionally substituted monocyclic saturated heterocycle containing at least one N atom, said heterocycle being linked via the N atom to the C(═O) group, by reaction with said heterocycle in the presence a suitable dehydrating (coupling) agent, such as for example N-(ethylcarbonimidoyl)-N,N-dimethyl-1,3-propanediamine monohydrochloride (EDCI), dicyclohexylcarbodiimide (DCC), carbonyl diimidazole (CDI), 1-[bis(di-methylamino)methylene]-1H-benzo-triazoliumhexafluorophosphate(1-)3-oxide (HBTU), 1-[bis(dimethyl-amino)-methylene]-5-chloro-1H-benzotriazolium-hexafluorophosphate(1-) 3-oxide (HCTU), O-benzotriazolyl tetramethylisouronium tetrafluoroborate (TBTU) or diethyl cyanophosphonate (DECP), optionally combined with hydroxy benzotriazole or chloro hydroxybenzotriazole, in the presence of a suitable solvent, such as for example N,N-dimethylformamide, dichloromethane, acetonitrile or tetrahydrofuran, and optionally in the presence of a suitable base, such as for example N,N-diisopropyl-ethanamine or N,N-diethyl-ethanamine. This reaction can also be performed as a fast synthesis reaction thereby using appropriate reagents well-known for fast synthesis, such as for example dicyclohexylcarbodiimide (DCC) or carbonyl diimidazole (CDI), linked to an appropriate carrier, e.g. polystyrene. Also for the purification of the reaction mixture, appropriate fast-synthesis reagents can be used, such as for example 1-ethenyl-4-(isocyanatomethyl)-benzene polymer with ethenylbenzene.
  • The compounds of formula (I) and some of the intermediates in the present invention may contain an asymmetric carbon atom. Pure stereochemically isomeric forms of said compounds and said intermediates can be obtained by the application of art-known procedures. For example, diastereoisomers can be separated by physical methods such as selective crystallization or chromatographic techniques, e.g. counter current distribution, chiral liquid chromatography and the like methods. Enantiomers can be obtained from racemic mixtures by first converting said racemic mixtures with suitable resolving agents such as, for example, chiral acids, to mixtures of diastereomeric salts or compounds; then physically separating said mixtures of diastereomeric salts or compounds by, for example, selective crystallization or chromatographic techniques, e.g. liquid chromatography and the like methods; and finally converting said separated diastereomeric salts or compounds into the corresponding enantiomers. Pure stereochemically isomeric forms may also be obtained from the pure stereochemically isomeric forms of the appropriate intermediates and starting materials, provided that the intervening reactions occur stereospecifically.
  • An alternative manner of separating the enantiomeric forms of the compounds of formula (I) and intermediates involves liquid chromatography or SCF (Super Critical Fluid) chromatography, in particular using a chiral stationary phase.
  • Some of the intermediates and starting materials are known compounds and may be commercially available or may be prepared according to art-known procedures.
  • Intermediates of formula (III) can be prepared by deprotecting an intermediate of formula (V) wherein P represents a suitable protective group, such as for example benzyl or C1-4alkyloxycarbonyl, e.g. CH3CH2—O—C(═O)— or (CH3)3C—O—C(═O)—.
  • Figure US20100216809A1-20100826-C00424
  • In the above reaction, when P represents for instance benzyl, appropriate deprotection conditions are deprotection in the presence of H2, a suitable catalyst, such as for example palladium on charcoal or Pd(OH)2, a suitable solvent, such as for example tetrahydrofuran or an alcohol, e.g. methanol. When P represents for instance (CH3)3C—O—C(═O)—, appropriate deprotection conditions are deprotection in the presence of a suitable acid, such as for example HCl or trifluoroacetic acid, in the presence of a suitable solvent, such as for example acetonitrile, dichloromethane or an alcohol, e.g. propanol. When P represents for instance CH3CH2—O—C(═O)—, appropriate deprotection conditions are deprotection in the presence of a suitable acid, such as for example HBr, in the presence of Na2SO3, or deprotection in the presence of a suitable base, such as for example KOH, in the presence of a suitable solvent, such as for example water, ethylene glycol or an alcohol, e.g. propanol.
  • Intermediates of formula (V) wherein R1 represents optionally substituted pyrazolyl, said intermediates being represented by formula (V-a) wherein R1a represents the optional substituent, can be prepared by reacting an intermediate of formula (VI) with an intermediate of formula (VII) in the presence of a suitable solvent, such as for example an alcohol, e.g. ethanol, and optionally in the presence of sodium.
  • Figure US20100216809A1-20100826-C00425
  • Intermediates of formula (V) wherein R1 represents optionally substituted triazolyl, said intermediates being represented by formula (V-b) wherein R1a represents the optional substituent, can be prepared by reacting an intermediate of formula (VIII) with an intermediate of formula (VII) in the presence of a suitable solvent, such as for example an alcohol, e.g. ethanol, and in the presence of a suitable base, such as for example sodium, or in the Presence of a suitable acid, such as for example acetic acid.
  • Figure US20100216809A1-20100826-C00426
  • Intermediates of formula (V) wherein R1 represents optionally substituted pyrimidinyl, said intermediates being represented by formula (V-c) wherein R1a represents the optional substituent, can be prepared by reacting an intermediate of formula (VI) with an intermediate of formula (IX) in the presence of a suitable solvent, such as for example an alcohol, e.g. ethanol, and optionally in the presence of sodium.
  • Figure US20100216809A1-20100826-C00427
  • Intermediates of formula (V) wherein R1 represents optionally substituted imidazopyrazolyl, said intermediates being represented by formula (V-d) wherein R1a represents the optional substituent, can be prepared by reacting an intermediate of formula (X) with an intermediate of formula (XI) in the presence of a suitable solvent, such as for example N,N-dimethylformamide, a suitable base, such as for example DIPEA, and a suitable dehydrating (coupling) agent, such as for example N′-(ethylcarbonimidoyl)-N,N-dimethyl-1,3-propanediamine monohydrochloride (EDCI), dicyclohexylcarbodiimide (DCC), carbonyl diimidazole (CDI), 1-[bis(di-methylamino)methylene]-1H-benzotriazoliumhexafluorophosphate(1-)3-oxide (HBTU), 1-[bis(dimethyl-amino)methylene]-5-chloro-1H-benzotriazolium-hexafluorophosphate(1-) 3-oxide (HCTU), O-benzotriazolyltetramethylisouronium tetrafluoroborate (TBTU) or diethyl cyanophosphonate (DECP), optionally combined with hydroxy benzotriazole or chloro hydroxybenzotriazole, followed by reaction with POCl3 in the presence of a suitable solvent, such as for example dioxane. This reaction of an intermediate of formula (X) with an intermediate of formula (XI) can also be performed in the presence of a suitable activating agent, such as for example Cl—C(═O)—C(═O)—Cl, a suitable base, such as for example N,N-diethyl-ethanamine, and a suitable solvent, such as for example N,N-dimethylformamide. Alternatively, intermediates of formula (V-d) can also be directly prepared from an intermediate of formula (X) and an intermediate of formula (XI) in the presence of POCl3.
  • Figure US20100216809A1-20100826-C00428
  • Intermediates of formula (V) wherein R1 represents optionally substituted oxadiazole, said intermediates being represented by formula (V-e-1) wherein R1a represents the optional substituent, can be prepared by reacting an intermediate of formula (X) with an intermediate of formula (XXI) in the presence of a suitable solvent, such as for example N,N-dimethylformamide, a suitable base, such as for example DIPEA, and a suitable dehydrating (coupling) agent, such as for example N′-(ethylcarbonimidoyl)-N,N-dimethyl-1,3-propanediamine monohydrochloride (EDCI), dicyclohexylcarbodiimide (DCC), carbonyl diimidazole (CDI), 1-[bis(di-methylamino)methylene]-1H-benzotriazoliumhexafluorophosphate(1-)3-oxide (HBTU), 1-[bis(dimethyl-amino)methylene]-5-chloro-1H-benzotriazolium-hexafluorophosphate(1-) 3-oxide (HCTU), O-benzotriazolyltetramethylisouronium tetrafluoroborate (TBTU) or diethyl cyanophosphonate (DECP), optionally combined with hydroxy benzotriazole or chloro hydroxybenzotriazole, followed by reaction of the resulting intermediate of formula (XXII) with Burgess'reagent (CAS 29684-56-8) in the presence of a suitable solvent, such as for example tetrahydrofuran.
  • Figure US20100216809A1-20100826-C00429
  • Intermediates of formula (V) wherein R1 represents optionally substituted oxadiazole, said intermediates being represented by formula (V-e-2) wherein R1a represents the optional substituent, can be prepared by reacting an intermediate of formula (XOH) with an intermediate of formula (XXIV) in the presence of a suitable base, such as for example sodium hydride, and a suitable solvent, such as for example tetrahydrofuran.
  • Figure US20100216809A1-20100826-C00430
  • Intermediates of formula (V) wherein R1 represents optionally substituted imidazothiazole, said intermediates being represented by formula (V-f) wherein R1a represents the optional substituent, can be prepared by reacting an intermediate of formula (XII) (see below) with Br2 in the presence of HBr/acetic acid, followed by reacting the resulting intermediate of formula (XXV) with 2-amino-thiazole in the presence of a suitable solvent, such as for example an alcohol, e.g. ethanol.
  • Figure US20100216809A1-20100826-C00431
  • When R1 in an intermediate of formula (V) represents an unsubstituted heterocycle or triazolone an appropriate substituent R1a can be introduced by reaction with W1—R1a, wherein W1 represents a suitable leaving group, such as for example halo, e.g. chloro or bromo, in the presence of a suitable base, such as for example NaH, KOH, Na2CO3 or Cs2CO3, and a suitable solvent, such as for example N,N-dimethylformamide or N,N-dimethylacetamide.
  • Intermediates of formula (X) wherein P is for instance benzyl can be prepared by hydrolysis of the corresponding ester in the presence of a suitable acid, such as for example HCl, or a suitable base, such as for example sodium hydroxide, in the presence of a suitable solvent, such as for example dioxane. Or intermediates of formula (X) wherein P is (CH3)3C—O—C(═O)— can be prepared by hydrolysis of the corresponding ester in the presence of a suitable base, such as for example sodium hydroxide, and a suitable solvent, such as for example tetrahydrofuran, dioxane or an alcohol, e.g. methanol. The corresponding esters can be prepared by reacting the protected piperidine/piperazine with ethyl benzoate substituted in position 4 with a suitable leaving group, such as for example halo, e.g. fluoro and the like, in a suitable solvent, such as for example N,N-dimethylacetamide.
  • Intermediates of formula (VI) can be prepared by reacting an intermediate of formula (XII) with CH3O—CH(OCH3)—N(CH3)2.
  • Figure US20100216809A1-20100826-C00432
  • Intermediates of formula (VIII) can be prepared by reacting an intermediate of formula (XIII) with CH3O—CH(OCH3)—N(CH3)2.
  • Figure US20100216809A1-20100826-C00433
  • Intermediates of formula (XII) wherein P represents tertiair butyloxycarbonyl, can be prepared by reacting 1-[4-(1-piperazinyl)phenyl]ethanone with C,C′-bis(1,1-dimethylethyl) dicarbonic acid ester in the presence of a suitable solvent, such as for example dichloromethane. Intermediates of formula (XII) wherein P represents benzyl can be prepare by reacting 1-[4-(1-piperazinyl)phenyl]ethanone with benzylbromide in the presence of a suitable base, such as for example Na2CO3, and a suitable solvent, such as for example tetrahydrofuran.
  • Intermediates of formula (XIII) can be prepared by reacting an intermediate of formula (X) with NH3 in the presence of a suitable solvent, such as for example N,N-dimethylformamide, and in the presence of a suitable dehydrating (coupling) agent, such as for example N-(ethylcarbonimidoyl)-N,N-dimethyl-1,3-propanediamine monohydrochloride (EDCI), dicyclohexylcarbodiimide (DCC), carbonyl diimidazole (CDI), 1-[bis(di-methylamino)methylene]-1H-benzotriazoliumhexafluorophosphate(1-)3-oxide (HBTU), 1-[bis(dimethyl-amino)methylene]-5-chloro-1H-benzotriazoliumhexafluorophosphate(1-) 3-oxide (HCTU), O-benzotriazolyltetramethylisouronium tetrafluoroborate (TBTU) or diethyl cyanophosphonate (DECP), optionally combined with hydroxy benzotriazole or chloro hydroxybenzotriazole.
  • Intermediates of formula (II) wherein X1 represents a direct bond and R2 contains a Het-C1-4alkyl substituent, wherein Het represents a monocyclic, saturated N containing heterocycle represented by formula (XXXII), said intermediate of formula (IV) being represented by formula (II-a), can be prepared by reacting an intermediate of formula (XXI) with an intermediate of formula (XXVI) in the represence of a suitable dehydrating (coupling) agent, such as for example N-(ethylcarbonimidoyl)-N,N-dimethyl-1,3-propanediamine monohydrochloride (EDCI), dicyclohexylcarbodiimide (DCC), carbonyl diimidazole (CDI), 1-[bis(di-methylamino)methylene]-1H-benzotriazoliumhexafluorophosphate(1-)3-oxide (HBTU), 1-[bis(dimethylamino)-methylene]-5-chloro-1H-benzotriazolium-hexafluorophosphate(1-) 3-oxide (HCTU), O-benzotriazolyl tetramethylisouronium tetrafluoroborate (TBTU) or diethyl cyanophosphonate (DECP), optionally combined with hydroxy benzotriazole or chloro hydroxybenzotriazole, in the presence of a suitable solvent, such as for example N,N-dimethylformamide, dichloromethane, acetonitrile or tetrahydrofuran, and optionally in the presence of a suitable base, such as for example N,N-diisopropylethanamine or N,N-diethyl-ethanamine. The resulting intermediate of formula (XXVII) can then be reduced in a next step in the presence of a suitable reducing agent, such as for example borane, in the presence of a suitable solvent, such as for example tetrahydrofuran, to an intermediate of formula (XXVIII), which can then be converted into an intermediate of formula (II-a) with phosgene in the presence of HCl in diethylether and a suitable solvent, such as for example toluene or acetonitrile. Intermediates of formula (XXVII) can also be converted into an intermediate of formula (II-b) with phosgene in the presence of HCl in diethylether and a suitable solvent, such as for example toluene or acetonitrile or dichloromethane.
  • Figure US20100216809A1-20100826-C00434
  • Intermediates of formula (II′) wherein R2 contains a Het-C1-4alkyl substituent, said intermediate being represented by formula (II′-a), can be prepared by reacting an intermediate of formula (XIX) with an intermediate of formula (XX) wherein W6 represents a suitable leaving group, such as for example halo, e.g. chloro and the like, in the presence of a suitable solvent, such as for example acetonitrile, resulting in an intermediate of formula (II′-a) with can be converted into an intermediate of formula (II-a) as described hereinabove for intermediate (XXVIII).
  • Figure US20100216809A1-20100826-C00435
  • Intermediates of formula (IV) can be prepared by hydrolysis of an intermediate of formula (XXIX)) in the presence of LiOH, an acid, such as for example HCl, and a suitable solvent, such as for example an alcohol, e.g. methanol. Intermediates of formula (XXIX)) wherein R2 contains Het-C1-4alkyl as substituent, said intermediates being represented by formula (XXIX-a) can be prepared by reacting an intermediate of formula (XXX) wherein W7 represents a suitable leaving group, such as for example halo, e.g. bromo and the like, with an intermediate of formula (XXI). Intermediates of formula (XXX-a) as depicted below, can be prepared by reacting an intermediate of formula (XXXI) with N-bromosuccinimide in the presence of 2,2′-(1,2-diazenediyl)-bis[2-methylpropanenitrile] and a suitable solvent, such as for example CCl4. Intermediates of formula (XXXI) wherein X1 represents CH2, said intermediates being represented by formula (XXXI-a), can be prepared by reacting an intermediate of formula (XXXII) with sodium metal, in the presence of a suitable alcohol of formula C1-4alkyl-OH, followed by adding a suitable acid, such as for example sulfuric acid. Intermediates of formula (XXXII) can be prepared by reacting an intermediate of formula (II′-b) with 1,1-dimethylethyl-nitrous acid ester, CuCl2, 1,1-dichloroethene in a suitable solvent, such as for example acetonitrile.
  • Figure US20100216809A1-20100826-C00436
  • Intermediates of formula (XXVIII-a) can be prepared by reacting an intermediate of formula (IV) wherein X1 is substituted with a protected (P, such as for example tertiair butyloxycarbonyl) amino group, said intermediate being represented by formula (IV-a), with an intermediate of formula (III) in the presence of a suitable dehydrating (coupling) agent, such as for example N′-(ethylcarbonimidoyl)-N,N-dimethyl-1,3-propanediamine monohydrochloride (EDCI), dicyclohexylcarbodiimide (DCC), carbonyl diimidazole (CDI), 1-[bis(di-methylamino)methylene]-1H-benzotriazoliumhexafluorophosphate(1-)3-oxide (HBTU), 1-[bis(dimethyl-amino)-methylene]-5-chloro-1H-benzotriazolium-hexafluorophosphate(1-) 3-oxide (HCTU), O-benzotriazolyl tetramethylisouronium tetrafluoroborate (TBTU) or diethyl cyanophosphonate (DECP), optionally combined with hydroxy benzotriazole or chloro hydroxybenzotriazole, in the presence of a suitable solvent, such as for example N,N-dimethylformamide, dichloromethane, acetonitrile or tetrahydrofuran, and optionally in the presence of a suitable base, such as for example N,N-diisopropyl-ethanamine or N,N-diethyl-ethanamine.
  • Figure US20100216809A1-20100826-C00437
  • Intermediates of formula (IV) wherein X1 represents CHOH, said intermediates being represented by formula (IV-b) can be prepared by reducing an intermediate of formula (XVII) in the presence of ZnBr2, Si(CH3)3—CN and an acid, such as for example HCl, in the presence of a suitable solvent, such as for example dichloromethane. Intermediates of formula (XVII) can be prepared by reacting an intermediate of formula (XOCH) wherein W8 represents a suitable leaving group, such as for example halo, e.g. bromo and the like, with N,N-dimethylformamide in the presence of BuLi and a suitable solvent such as for example tetrahvdrofuran
  • Figure US20100216809A1-20100826-C00438
  • Pharmacological Part
  • As already indicated above, the present invention relates to the use of a DGAT inhibitor, in particular a DGAT1 inhibitor, to elevate levels of one or more satiety hormones, in particular GLP-1 levels. The present invention also relates to the use of a DGAT inhibitor, in particular a DGAT1 inhibitor, for the manufacture of a medicament for the prevention or the treatment, in particular for the treatment, of a disease which can benefit from an elevated level of one or more satiety hormones, in particular a disease which can benefit from an elevated GLP-1 level. In particular, GLP-1 levels are elevated in plasma or in portal blood, more in particular in plasma. By elevated GLP-1 levels, e.g. elevated GLP-1 plasma level or an elevated GLP-1 level in portal blood, it is meant that the GLP-1 level of a subject having taken a DGAT1 inhibitor is elevated or increased compared to the subject under the same conditions but not having taken the DGAT1 inhibitor. In particular GLP-1 levels are elevated in fasting conditions or postprandial, more in particular postprandial.
  • Therapeutic uses for a compound which elevates GLP-1 level include, but are not limited to, improving learning, enhancing neuro-protection, and/or alleviating a symptom of a disease or disorder of the central nervous system, e.g., through modulation of neurogenesis, and e.g., Parkinson's Disease, Alzheimer's Disease, Huntington's Disease, ALS, stroke, hemorrhage, cerebrovascular accident, ADD, and neuropsychiatric syndromes; converting liver stem/progenitor cells into functional pancreatic cells; preventing beta-cell deterioration and stimulation of beta-cell proliferation; treating pancreatitis; treating obesity; suppressing appetite and inducing satiety; treating irritable bowel syndrome or inflammatory bowel disease such as Crohn's disease and ulcerative colitis; reducing the morbidity and/or mortality associated with myocardial infarction and stroke; treating acute coronary syndrome characterized by an absence of Q-wave myocardial infarction; attenuating post-surgical catabolic changes; treating hibernating myocardium or diabetic cardiomyopathy; suppressing plasma blood levels of norepinepherine; increasing urinary sodium excretion, decreasing urinary potassium concentration; treating conditions or disorders associated with toxic hypervolemia, e.g., renal failure, congestive heart failure, nephrotic syndrome, cirrhosis, pulmonary edema, and hypertension; inducing an inotropic response and increasing cardiac contractility; treating polycystic ovary syndrome; treating respiratory distress; improving nutrition via a non-alimentary route, i.e., via intravenous, subcutaneous, intramuscular, peritoneal, or other injection or infusion; treating nephropathy; treating left ventricular systolic dysfunction, e.g., with abnormal left ventricular ejection fraction; inhibiting antro-duodenal motility, e.g., for the treatment or prevention of gastrointestinal disorders such as diarrhea, postoperative dumping syndrome and irritable bowel syndrome, and as premedication in endoscopic procedures; treating critical illness polyneuropathy (CIPN) and systemic inflammatory response syndrome (SIRS); modulating triglyceride levels and treating dyslipidemia; treating organ tissue injury (e.g. brain tissue injury) caused by reperfusion of blood flow following ischemia; improving the function of ischemic and reperfused brain tissue; treating coronary heart disease risk factor (CHDRF) syndrome. Further diseases which can benefit from an elevated GLP-1 level, include, but are not limited to, ischemic myocardial stunning; ishemic/reperfusion injury; acute myocardial infarction; left ventricular dysfunction; vascular disease; neuropathy, including periphere sensoric neuropathy associated with type II diabetes; bone-related disorders, including osteoporosis, obesity, diabetes. Because of the effect on GLP-1, the DGAT inhibitors can also be used to provide cardioprotection.
  • References supporting the above indications include Experimental Neurology, Vol. 203(2), pp 293-301 (2007); U.S. Pat. No. 7,186,683; J. Pharm. Exp. Ther. vol. 312, No. 1, pp 303-308 (2005); Diabetes, vol. 54, pp 146-151 (2005); US2007/0021339, which are incorporated herein by reference.
  • In view of the DGAT inhibitory activity, in particular the DGAT1 inhibitory activity, the present compounds of formula (I), their N-oxide forms, their pharmaceutically acceptable salts or their solvates, can be used as a medicine. In particular, the present invention relates to a compound of formula (I), a N-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof for use as a medicine, in particular for use as a medicine for the prevention or the treatment of a disease which can benefit from an elevated GLP-1 level. In particular, the present invention also relates to the use of a compound of formula (I) for the manufacture of a medicament for the prevention or the treatment of a disease which can benefit from an elevated GLP-1 level, such as the diseases and disorders mentioned above.
  • In view of the above-described utility for a DGAT inhibitor, in particular a DGAT1 inhibitor, there is provided a method of treating a warm-blooded mammal, including a human, suffering from or a method of preventing a warm-blooded mammal, including a human, to suffer from a disease which can benefit from an elevated level of GLP-1, in particular a method of treating a warm-blooded mammal, including a human, suffering from a disease which can benefit from an elevated level of GLP-1. Said methods comprise the administration of an effective amount of a DGAT inhibitor, in particular a DGAT1 inhibitor, to a warm-blooded mammal, including a human.
  • In view of the DGAT inhibitory activity of the compounds of formula (I), there is provided a method of treating a warm-blooded mammal, including a human, suffering from or a method of preventing a warm-blooded mammal, including a human, to suffer from a disease which can benefit from an elevated level of GLP-1, in particular a method of treating a warm-blooded mammal, including a human, suffering from a disease which can benefit from an elevated level of GLP-1. Said methods comprise the administration of an effective amount of a compound of formula (I), a N-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, to a warm-blooded mammal, including a human.
  • In view of the DGAT inhibitory activity, in particular the DGAT1 inhibitory activity, the present invention also relates to a compound of formula (I), a N-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof for use as a medicine, in particular for use as a medicine for the prevention or the treatment of a diseases which can benefit from inhibition of DGAT, in particular DGAT1. The invention also relates to the use of a compound of formula (I), a N-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, for the manufacture of a medicament for the prevention or the treatment of a disease or disorder which can benefit from inhibition of DGAT, in particular DGAT1. Diseases or disorders which can benefit from inhibition of DGAT, in particular DGAT1 include, but are not limited to metabolic disorders, such as obesity and obesity related disorders (including peripheral vascular disease, cardiac failure, myocardial ischaemia, cerebral ischaemia, cardiac myopathies), diabetes, in particular type II diabetes mellitus, and complications arising therefrom (such as retinopathy, neuropathy, nephropathy), syndrome X, insulin resistance, impaired glucose tolerance, conditions of impaired fasting glucose, hypoglycemia, hyperglycemia, hyperuricemia, hyperinsulinemia, pancreatitis, hypercholesterolemia, hyperlipidemia, dyslipidemia, mixed dyslipidemia, hypertriglyceridemia and nonalcoholic fatty liver disease, fatty liver, increased mesenteric fat, non-alcoholic steatohepatitis, liverfibrosis, metabolic acidosis, ketosis, dysmetabolic syndrome; dermatological conditions such as acne, psoriasis; cardiovascular diseases, such as atherosclerosis, arteriosclerosis, acute heart failure, congestive heart failure, coronary artery disease, cardiomyopathy, myocardial infarction, angina pectoris, hypertension, hypotension, stroke, ischemia, ischemic reperfusion injury, aneurysm, restenosis and vascular stenosis; neoplastic diseases, such as solid tumors, skin cancer, melanoma, lymphoma and endothelial cancers, e.g., breast cancer, lung cancer, colorectal cancer, stomach cancer, other cancers of the gastrointestinal tract (e.g., esophageal cancer and pancreatic cancer), prostate cancer, kidney cancer, liver cancer, bladder cancer, cervical cancer, uterine cancer, testicular cancer and ovarian cancer; and other diseases and conditions that are sensitive or responsive to modulation, in particular inhibition, of DGAT function, in particular DGAT1 function.
  • Particular diseases or disorders which can benefit from inhibition of DGAT, in particular DGAT1, are selected from obesity, hypercholesterolemia, hyperlipidemia, dyslipidemia, mixed dyslipidemia, hypertriglyceridemia, fatty liver, nonalcoholic fatty liver disease, liverfibrosis, non-alcoholic steatohepatitis and diabetes, in particular type II diabetes.
  • In view of the DGAT inhibitory activity of the compounds of formula (I), there is provided a method of treating a warm-blooded mammal, including a human, suffering from or a method of preventing a warm-blooded mammal, including a human, to suffer from a disease which can benefit from inhibition of DGAT, in particular a method of treating a warm-blooded mammal, including a human, suffering from a disease which can benefit from inhibition of DGAT. Said methods comprise the administration of an effective amount of a compound of formula (I), a N-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, to a warm-blooded mammal, including a human.
  • The present invention also provides compositions for preventing or treating a disease which can benefit from an elevated GLP-1 level or which can benefit from inhibition of DGAT, in particular DGAT1, in particular for treating a disease which can benefit from elevated GLP-1 levels or which can benefit from inhibition of DGAT, in particular DGAT1. Said compositions comprise a therapeutically effective amount of a compound of formula (I), a N-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, and a pharmaceutically acceptable carrier.
  • The compounds of the present invention may be formulated into various pharmaceutical forms for administration purposes. As appropriate compositions there may be cited all compositions usually employed for systemically administering drugs. To prepare the pharmaceutical compositions of this invention, an effective amount of the particular compound, optionally in salt form, as the active ingredient is combined in intimate admixture with a pharmaceutically acceptable carrier, which carrier may take a wide variety of forms depending on the form of preparation desired for administration. These pharmaceutical compositions are desirable in unitary dosage form suitable, particularly, for administration orally, rectally, percutaneously, or by parenteral injection. For example, in preparing the compositions in oral dosage form, any of the usual pharmaceutical media may be employed such as, for example, water, glycols, oils, alcohols and the like in the case of oral liquid preparations such as suspensions, syrups, elixirs, emulsions and solutions; or solid carriers such as starches, sugars, kaolin, diluents, lubricants, binders, disintegrating agents and the like in the case of powders, pills, capsules, and tablets. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit forms, in which case solid pharmaceutical carriers are obviously employed. For parenteral compositions, the carrier will usually comprise sterile water, at least in large part, though other ingredients, for example, to aid solubility, may be included. Injectable solutions, for example, may be prepared in which the carrier comprises saline solution, glucose solution or a mixture of saline and glucose solution. Injectable suspensions may also be prepared in which case appropriate liquid carriers, suspending agents and the like may be employed. Also included are solid form preparations, which are intended to be converted, shortly before use, to liquid form preparations. In the compositions suitable for percutaneous administration, the carrier optionally comprises a penetration enhancing agent and/or a suitable wetting agent, optionally combined with suitable additives of any nature in minor proportions, which additives do not introduce a significant deleterious effect on the skin. Said additives may facilitate the administration to the skin and/or may be helpful for preparing the desired compositions. These compositions may be administered in various ways, e.g., as a transdermal patch, as a spot-on, as an ointment.
  • The compounds of the present invention may also be administered via inhalation or insufflation by means of methods and formulations employed in the art for administration via this way. Thus, in general the compounds of the present invention may be administered to the lungs in the form of a solution, a suspension or a dry powder. Any system developed for the delivery of solutions, suspensions or dry powders via oral or nasal inhalation or insufflation are suitable for the administration of the present compounds.
  • The compounds of the present invention may also be topically administered in the form of drops, in particular eye drops. Said eye drops may be in the form of a solution or a suspension. Any system developed for the delivery of solutions or suspensions as eye drops are suitable for the administration of the present compounds.
  • It is especially advantageous to formulate the aforementioned pharmaceutical compositions in unit dosage form for ease of administration and uniformity of dosage. Unit dosage form as used herein refers to physically discrete units suitable as unitary dosages, each unit containing a predetermined quantity of active ingredient calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. Examples of such unit dosage forms are tablets (including scored or coated tablets), capsules, pills, powder packets, wafers, suppositories, injectable solutions or suspensions and the like, and segregated multiples thereof.
  • The exact dosage and frequency of administration depends on the particular compound of formula (I) used, the particular condition being treated, the severity of the condition being treated, the age, weight, sex, extent of disorder and general physical condition of the particular patient as well as other medication the individual may be taking, as is well known to those skilled in the art. Furthermore, it is evident that said effective daily amount may be lowered or increased depending on the response of the treated subject and/or depending on the evaluation of the physician prescribing the compounds of the instant invention.
  • Depending on the mode of administration, the pharmaceutical composition will preferably comprise from 0.05 to 99% by weight, more preferably from 0.1 to 70% by weight, even more preferably from 0.1 to 50% by weight of the compound of formula (I), and, from 1 to 99.95% by weight, more preferably from 30 to 99.9% by weight, even more preferably from 50 to 99.9% by weight of a pharmaceutically acceptable carrier, all percentages being based on the total weight of the composition.
  • In view of the above described effects of DGAT inhibitors and/or the effect on GLP-1 levels by DGAT inhibitors, the present invention also relates to
  • a) a combination of a DGAT inhibitor, in particular a DGAT1 inhibitor, more in particular a compound of formula (I), a N-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, and a dipeptidyl peptidase-4 inhibitor (DPP-4 inhibitor).
  • DPP-4 is a membrane-spanning cell surface aminopeptidase widely expressed in many tissues, such as liver, lung, kidney, intestinal brush-border membranes, lymphocytes, endothelial cells. DPP-4 cleaves peptides with a proline or alanine residue in the second aminoterminal position. Many gastro-intestinal hormones are substrates for DPP-4, among them GLP-1. A DPP-4 inhibitor thus inhibits cleavage of GLP-1 and hence provides for an increase in the level of GLP-1. Therefore, a combination as indicated above can be used to combine the activity of the DGAT inhibitor and the DPP4 inhibitor in order to elevate GLP-1 levels. By administering a DGAT inhibitor, in particular a DGAT1 inhibitor, more in particular a compound of formula (I), a N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, with a DPP4 inhibitor, different mechanisms may be targeted in order to achieve elevated levels of GLP-1. In this way, the use of such a combination may reduce the dosage of the DGAT inhibitor and the DPP4 inhibitor required for a desired elevation in GLP-1 level as compared to when the DGAT inhibitor or the DPP4 inhibitor is administered as a monotherapy. Therefore, these combinations may reduce or eliminate side effects of monotherapy while not interfering with the GLP-1 level increasing activity. Also, the combination of a DGAT inhibitor, in particular a DGAT1 inhibitor, more in particular a compound of formula (I), a N-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, and a DPP4 inhibitor can be used as a medicine. The present invention also relates to a product comprising (a) a DGAT inhibitor, in particular a DGAT1 inhibitor, more in particular a compound of formula (I), a N-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, and (b) a DPP4 inhibitor, as a combined preparation for simultaneous, separate or sequential use in the treatment of a disease which can benefit from an elevated level of GLP-1. The different drugs of such a combination or product may be combined in a single preparation together with pharmaceutically acceptable carriers or they may each be present in a separate preparation together with pharmaceutically acceptable carriers. Said DPP4 inhibitor which may be combined with a DGAT inhibitor according to the present invention, in particular a DGAT1 inhibitor, may be a known DPP4 inhibitor such as for example sitagliptin, vildagliptin, and saxagliptin.
  • b) a combination of a DGAT inhibitor, in particular a DGAT1 inhibitor, more in particular a compound of formula (I), a N-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, and a GLP-1 analogue. Said GLP-1 analogue can be considered as an agonist at the GLP-1 receptor.
  • Also, the combination of a DGAT inhibitor, in particular a DGAT1 inhibitor, more in particular a compound of formula (I), a N-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, and a GLP-1 analogue can be used as a medicine. The present invention also relates to a product containing (a) a DGAT inhibitor, in particular a DGAT1 inhibitor, more in particular a compound of formula (I), a N-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, and (b) a GLP-1 analogue, as a combined preparation for simultaneous, separate or sequential use in the treatment of a disease which can benefit from an elevated level of GLP-1. The different drugs of such a combination or product may be combined in a single preparation together with pharmaceutically acceptable carriers or they may each be present in a separate preparation together with pharmaceutically acceptable carriers.
  • Said GLP-1 analogue which may be combined with a DGAT inhibitor according to the present invention may be a known GLP-1 analogue such as for example exenatide, exenatide LAR or liraglutide.
  • c) a combination of a DGAT inhibitor, in particular a DGAT1 inhibitor, more in particular a compound of formula (I), a N-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, and an anti-diabeticum.
  • Also, the combination of a DGAT inhibitor, in particular a DGAT1 inhibitor, more in particular a compound of formula (I), a N-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, and an anti-diabeticum can be used as a medicine. The present invention also relates to a product containing (a) a DGAT inhibitor, in particular a DGAT1 inhibitor, more in particular a compound of formula (I), a N-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, and (b) an anti-diabeticum, as a combined preparation for simultaneous, separate or sequential use in the treatment of a disease which can benefit from an elevated level of GLP-1 or DGAT inhibition, such as for example diabetes, in particular type II diabetes. The different drugs of such a combination or product may be combined in a single preparation together with pharmaceutically acceptable carriers or they may each be present in a separate preparation together with pharmaceutically acceptable carriers. Said anti-diabeticum which may be combined with a DGAT inhibitor according to the present invention may be a known anti-diabeticum such as for example metformin, glibenclamide, rosiglitazon, pioglitazon, repaglinide, glimepiride, acarbose, glicazide, glipizide, nateglinide, tolbutamide, a protein tyrosine phosphatase 1 inhibitor, or a 11-beta-hydroxysteroid dehydrogenase inhibitor.
  • d) a combination of a DGAT inhibitor, in particular a DGAT1 inhibitor, more in particular a compound of formula (I), a N-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, and a phosphodiesterase (PDE) inhibitor, in particular a PDE10A or PDE11A inhibitor. Phosphodiesterase (PDE) inhibitors, in particular PDE10A or PDE11A inhibitors, are known to be insulin secretagogues, and to enhance the signalling of GLP-1 by inhibition of the hydrolysis of cAMP. Also, the combination of a DGAT inhibitor, in particular a DGAT1 inhibitor, more in particular a compound of formula (I), a N-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, and a phosphodiesterase (PDE) inhibitor, in particular a PDE10A or PDE11A inhibitor, can be used as a medicine. The present invention also relates to a product containing (a) a DGAT inhibitor, in particular a DGAT1 inhibitor, more in particular a compound of formula (I), a N-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, and (b) a phosphodiesterase (PDE) inhibitor, in particular a PDE10A or PDE11A inhibitor, as a combined preparation for simultaneous, separate or sequential use in the treatment of a disease which can benefit from an elevated level of GLP-1 or DGAT inhibition, such as for example diabetes, in particular type II diabetes, or obesity. The different drugs of such a combination or product may be combined in a single preparation together with pharmaceutically acceptable carriers or they may each be present in a separate preparation together with pharmaceutically acceptable carriers. Said phosphodiesterase (PDE) inhibitor, in particular a PDE10A or PDE11A inhibitor, which may be combined with a DGAT inhibitor according to the present invention may be a known PDE inhibitor such as for example papaverine, PQ-10, dipyridamole, ibudilast or tadalafil.
  • e) a combination of a DGAT inhibitor, in particular a DGAT1 inhibitor, more in particular a compound of formula (I), a N-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, and an appetite suppressant.
  • Also, the combination of a DGAT inhibitor, in particular a DGAT1 inhibitor, more in particular a compound of formula (I), a N-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, and an appetite suppressant can be used as a medicine. The present invention also relates to a product containing (a) a DGAT inhibitor, in particular a DGAT1 inhibitor, more in particular a compound of formula (I), a N-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, and (b) an appetite suppressant, as a combined preparation for simultaneous, separate or sequential use in the treatment of a disease which can benefit from an elevated level of GLP-1 or DGAT inhibition, such as for example diabetes, in particular type II diabetes, or obesity. The different drugs of such a combination or product may be combined in a single preparation together with pharmaceutically acceptable carriers or they may each be present in a separate preparation together with pharmaceutically acceptable carriers. Said appetite suppressants, which may be combined with a DGAT inhibitor according to the present invention may be a known appetite suppressant such as for example sibutramine and phentermine.
  • f) a combination of a DGAT inhibitor, in particular a DGAT1 inhibitor, more in particular a compound of formula (I), a N-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, and an anti-obesity drug with a CNS (central nervous system) mode of action such as for example a CB1 antagonist or inverse agonists.
  • Also, the combination of a DGAT inhibitor, in particular a DGAT1 inhibitor, more in particular a compound of formula (I), a N-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, and an anti-obesity drug with a CNS (central nervous system) mode of action can be used as a medicine. The present invention also relates to a product containing (a) a DGAT inhibitor, in particular a DGAT1 inhibitor, more in particular a compound of formula (I), a N-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, and (b) an anti-obesity drug with a CNS (central nervous system) mode of action, as a combined preparation for simultaneous, separate or sequential use in the treatment of a disease which can benefit from an elevated level of GLP-1 or DGAT inhibition, such as for example diabetes, in particular type II diabetes, or obesity. The different drugs of such a combination or product may be combined in a single preparation together with pharmaceutically acceptable carriers or they may each be present in a separate preparation together with pharmaceutically acceptable carriers. Said anti-obesity drugs with a CNS (central nervous system) mode of action, which may be combined with a DGAT inhibitor according to the present invention may be a known a anti-obesity drug such as for example Rimonabant, orlistat, SLV-319, or MK-0364.
  • g) a combination of a DGAT inhibitor, in particular a DGAT1 inhibitor, more in particular a compound of formula (I), a N-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, and an hypolipidemic drug such as for example 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA) reductase inhibitors, squalene synthase inhibitors, FXR (farnesoid X receptor) and LXR (liver X receptor) ligands, cholestyramine, fibrates, nicotinic acid and aspirin.
  • Also, the combination of a DGAT inhibitor, in particular a DGAT1 inhibitor, more in particular a compound of formula (I), a N-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, and an hypolipidemic drug can be used as a medicine. The present invention also relates to a product containing (a) a DGAT inhibitor, in particular a DGAT1 inhibitor, more in particular a compound of formula (I), a N-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, and (b) an hypolipidemic drug, as a combined preparation for simultaneous, separate or sequential use in the treatment of a disease which can benefit from an elevated level of GLP-1 or DGAT inhibition, such as for example diabetes, in particular type II diabetes, or obesity. The different drugs of such a combination or product may be combined in a single preparation together with pharmaceutically acceptable carriers or they may each be present in a separate preparation together with pharmaceutically acceptable carriers. Said hypolipidemic drug which may be combined with a DGAT inhibitor according to the present invention may be a known hypolipidemic drug such as for example lovastatin, pravastatin, simvastatin, pravastatin, cerivastatin, mevastatin, velostatin, fluvastatin, dalvastatin, atorvastatin, rosuvastatin and rivastatin.
  • h) a combination of a DGAT inhibitor, in particular a DGAT1 inhibitor, more in particular a compound of formula (I), a N-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, and an agonist of peroxisome proliferator-activator receptor such as for example fenofibrate.
  • Also, the combination of a DGAT inhibitor, in particular a DGAT1 inhibitor, more in particular a compound of formula (I), a N-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, and an agonist of peroxisome proliferator-activator receptor such as for example fenofibrate, can be used as a medicine. The present invention also relates to a product containing (a) a DGAT inhibitor, in particular a DGAT1 inhibitor, more in particular a compound of formula (I), a N-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, and (b) an agonist of peroxisome proliferator-activator receptor such as for example fenofibrate, as a combined preparation for simultaneous, separate or sequential use in the treatment of a disease which can benefit from an elevated level of GLP-1 or DGAT inhibition, such as for example diabetes, in particular type II diabetes, or obesity. The different drugs of such a combination or product may be combined in a single preparation together with pharmaceutically acceptable carriers or they may each be present in a separate preparation together with pharmaceutically acceptable carriers.
  • i) a combination of a DGAT inhibitor, in particular a DGAT1 inhibitor, more in particular a compound of formula (I), a N-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, and an antihypertensive agent.
  • Also, the combination of a DGAT inhibitor, in particular a DGAT1 inhibitor, more in particular a compound of formula (I), a N-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, and an antihypertensive agent, can be used as a medicine. The present invention also relates to a product containing (a) a DGAT inhibitor, in particular a DGAT1 inhibitor, more in particular a compound of formula (I), a N-oxide form thereof, a pharmaceutically acceptable salt thereof or a solvate thereof, and (b) an antihypertensive agent, as a combined preparation for simultaneous, separate or sequential use in the treatment of a disease which can benefit from an elevated level of GLP-1 or DGAT inhibition, such as for example diabetes, in particular type II diabetes, or obesity. The different drugs of such a combination or product may be combined in a single preparation together with pharmaceutically acceptable carriers or they may each be present in a separate preparation together with pharmaceutically acceptable carriers. Said anti-hypertensive agent which may be combined with a DGAT inhibitor according to the present invention may be a known anti-hypertensive agent, e g loop diuretics such as ethacrynic acid, furosemide and torsemide, angiotensin converting enzyme (ACE) inhibitors such as benazepril, captopril, enalapril, fosinopril, lisinopril, moexipril, perinodopril, quinapril, ramipril and trandolapril; inhibitors of the Na-K-ATPase membrane pump such as digoxin; neutralendopeptidase (NEP) inhibitors; ACE/NEP inhibitors such as omapatrilat, sampatrilat and fasidotril; angiotensin II antagonists such as candesartan, eprosartan, irbesartan, losartan, telmisartan and valsartan, in particular valsartan; renin inhibitors such as ditekiren, zankiren, terlakiren, aliskiren, RO 66-1132 and RO-66-1168; β-adrenergic receptor blockers such as acebutolol, atenolol, betaxolol, bisoprolol, metoprolol, nadolol, propranolol, sotalol and timolol; inotropic agents such as digoxin, dobutamine and milrinone; calcium channel blockers such as amlodipine, bepridil, diltiazem, felodipine, nicardipine, nimodipine, nifedipine, nisoldipine and verapamil; aldosterone receptor antagonists; and aldosterone synthase inhibitors.
  • The following examples are intended to illustrate the present invention.
  • Experimental Part
  • Hereinafter, the term ‘THF’ means tetrahydrofuran, ‘Et2O’ means diethyl ether, ‘CH3OH’ means methanol, ‘Pd(OH)2’ means palladium hydroxide, ‘POCl3’ means phosphoric trichloride, ‘EtOAc’ means ethyl acetate, ‘Na2CO3’ means carbonic acid disodium salt, ‘NaHCO3’ means carbonic acid monosodium salt, ‘CH2Cl2’ or ‘DCM’ means dichloromethane, ‘CH3CN’ means acetonitrile, ‘EtOH’ means ethanol, ‘DIPE’ means diisopropyl ether, ‘HBTU’ means 1-[bis(di-methylamino)methylene]-1H-benzotriazoliumhexafluorophosphate(1-)3-oxide, ‘DMF’ means N,N-dimethyl-formamide, ‘DMA’ means N,N-dimethylacetamide, ‘DIPEA’ means N-ethyl-N-(1-methylethyl)-2-propanamine, ‘HOBt’ means 1-hydroxy-1H-benzotriazole, ‘Na2SO3’ means sulphurous acid, disodium salt, ‘KOH’ means potassium hydroxide, ‘iPrOH’ means 2-propanol, ‘EDCI’ means N′-(ethylcarbonimidoyl)-N,N-dimethyl-1,3-propanediamine monohydrochloride, ‘HCTU” means 1-[bis(dimethyl-amino)methylene]-5-chloro-1H-benzotriazolium-hexafluorophosphate(1-) 3-oxide.
  • Isolute HM-N™ filter is a product of Argonaut, Foster City, Calif. 94404, USA, and is a short column comprising a modified form of diatomaceous earth that can remove water from a sample in combinatorial chemistry aplications.
  • Extrelut™ is a product of Merck KgaA, Darmstadt, Germany, and is a short column comprising diatomaceous earth.
  • A number of compounds were purified by reversed phase high-performance liquid chromatography using one of the methods below (indicated in the compound procedure with method A, method B and method C). When necessary, these methods can be slightly adjusted by a person skilled in the art to obtain a more optimal result for the separation.
  • HPLC Method A
  • The product was purified by reversed-phase high-performance liquid chromatography (Shandon Hyperprep® C18 BDS (Base Deactivated Silica) 8 μm, 250 g, I.D. 5 cm). Two mobile phases were used (phase A: a 0.25% NH4HCO3 solution in water; phase B: CH3CN). First, 85% A and 15% B with a flow rate of 40 ml/min was hold for 0.5 minutes. Then a gradient was applied to 10% A and 90% B in 41 minutes with a flow rate of 80 ml/min. Then a gradient was applied to 100% B in 20 minutes with a flow rate of 80 ml/min and hold for 4 minutes.
  • HPLC Method B
  • The product was purified by reversed-phase high-performance liquid chromatography (Shandon Hyperprep® C18 BDS (Base Deactivated Silica) 8 μm, 250 g, I.D. 5 cm). Two mobile phases were used (phase A: 90% of a 0.5% NH4OAc solution in water+10% CH3CN; phase B: CH3CN). First, 85% A and 15% B with a flow rate of 40 ml/min was hold for 0.5 minutes. Then a gradient was applied to 10% A and 90% B in 41 minutes with a flow rate of 80 ml/min. Then a gradient was applied to 100% B in 20 minutes with a flow rate of 80 ml/min and hold for 4 minutes.
  • HPLC Method C
  • The product was purified by reversed phase high-performance liquid chromatography (Shandon Hyperprep® C18 BDS (Base Deactivated Silica) 8 μm, 250 g, I.D. 5 cm). Three mobile phases were used (phase A: 90% of a 0.5% NH4OAc solution in water+10% CH3CN; phase B: CH3OH; phase C: CH3CN). First, 75% A and 25% B with a flow rate of 40 ml/min was hold for 0.5 minutes. Then a gradient was applied to 50% B and 50% C in 41 minutes with a flow rate of 80 ml/min. Then a gradient was applied to 100% C in 20 minutes with a flow rate of 80 ml/min and hold for 4 minutes.
  • A. Preparation of the Intermediates
    • EXAMPLE A1
  • a) Preparation of Intermediate 1
  • Figure US20100216809A1-20100826-C00439
  • 4-[4-(Phenylmethyl)-1-piperazinyl]benzoic acid, ethyl ester (58 g) was suspended in an aqueous HCl solution (430 ml, 2 N) and the reaction mixture was stirred for 17 hours at 100° C. Water was removed by evaporation, co-evaporated twice with dioxane, and the residue was suspended in Et2O and filtered, yielding 55.4 g (84%) of intermediate 1 as blue solid (.2HCl).
  • b) Preparation of Intermediate 2
  • Figure US20100216809A1-20100826-C00440
  • 1-[(4-Methylphenyl)methyl]-1H-pyrazole-4,5-diamine, sulfate (2:1) (1.48 g, 0.005887 mol), intermediate 1 (2.5 g, 0.00677 mol), HOBt (1.08 g, 0.007064 mol) and HBTU (2.68 g, 0.007064 mmol) were dissolved in DMF (22 ml). DIPEA (3 ml, 0.01766 mol) was added dropwise and the reaction mixture was stirred for 3 hours. To the reaction mixture was added an aqueous Na2CO3 solution (170 ml, half saturated) and EtOAc (35 ml). The formed precipitate was filtered off, washed with H2O and EtOAc, and dried, yielding 1.93 g (68%) of intermediate 2 as pink powder.
  • c) Preparation of Intermediate 3
  • Figure US20100216809A1-20100826-C00441
  • Intermediate 2 (1.9 g) was dissolved in dioxane (28 ml), and POCl3 (28 ml) was added to the solution. The reaction mixture was heated for 90 minutes at 40° C., 90 minutes at 60° C. and for 2 hours at 80° C. Afterwards POCl3 was distilled off and the residue was dissolved in dioxane (2 ml) and treated with an ice cold aqueous Na2CO3 solution (half saturated). The organic material was extracted with EtOAc (3×), dried (Na2SO4), filtered and the solvent was evaporated. The residue was purified by flash chromatography (Si 60, EtOAc/hexane gradient from 1:1 to 1:0) to yield 1.3 g (73%) of intermediate 3 as a yellow powder.
  • d) Preparation of Intermediate 4
  • Figure US20100216809A1-20100826-C00442
  • Intermediate 3 (0.5 g) dissolved in CH3OH (15 ml)/THF (2 ml) was hydrogenated for 17 hours in the presence of Pd(OH)2 (0.1 g). The reaction mixture was filtered over Celite, washed with THF/CH3OH (1/1) and evaporated to yield 0.396 g of intermediate 4 as a yellow powder.
    • EXAMPLE A2
  • a) Preparation of Intermediate 5
  • Figure US20100216809A1-20100826-C00443
  • A mixture of 4-(4-acetylphenyl)-1-piperazinecarboxylic acid, 1,1-dimethylethyl ester (12.16 g, 0.04 mol) and 1,1-dimethoxy-N,N-dimethylmethanamine (100 ml) was stirred and refluxed for 48 hours at 120° C. (oil bath). Subsequently, the mixture was cooled. The precipitate was filtered off, washed with DIPE and dried, yielding 8.7 g of intermediate 5.
  • b) Preparation of Intermediates 6 and 7
  • Figure US20100216809A1-20100826-C00444
  • A mixture of sodium (0.096 g, 0.004 mol) and EtOH (10 ml, p.a.) was stirred at room temperature till a solution was obtained. (2-Phenylethyl)-hydrazine sulfate (0.468 g, 0.002 mol) was added and the mixture was stirred for 20 minutes. Intermediate 5 (0.539 g, 0.0015 mol) was added and the mixture was stirred for 144 hours at 85° C. The solvent was evaporated. The residue was stirred in H2O (2 ml) and the product was extracted with CH2Cl2. The mixture was dried over an Isolute filter and the organic layer was evaporated. The residue was purified by HPLC Method A. Two different product fractions were collected and the solvent of each fraction was evaporated, yielding intermediate 6 and intermediate 7, residues were used as such in a next reaction.
  • c) Preparation of Intermediate 8
  • Figure US20100216809A1-20100826-C00445
  • A mixture of intermediate 6 (0.091 g, 0.00021 mol), HCl/2-propanol (1.5 ml) and CH3CN (3 ml) was stirred for 3 hours at room temperature. The solvent was evaporated (by a N2 stream at 40° C.). The crude residue was dried, yielding 0.085 g of intermediate 8 (0.2HCl).
    • EXAMPLE A3
  • a) Preparation of Intermediate 9
  • Figure US20100216809A1-20100826-C00446
  • A mixture of sodium (0.036 g, 0.0015 mol) in EtOH (5 ml) was stirred at room temperature until the mixture became a solution. Subsequently N-cyclohexylguanidine sulfate (2:1) (0.285 g, 0.00075 mol) was added to the solution and the mixture was stirred for 15 minutes at room temperature. Intermediate 5 (0.539 g, 0.0015 mol) was added and the mixture was stirred for 188 hours at 85° C. The solvent was evaporated and the residue was stirred in H2O (2 ml). The product was extracted with CH2Cl2. The mixture was filtered over an Isolute filter and the solvent was evaporated. The residue was purified by reversed phase HPLC. The pure fractions were collected and worked-up, yielding 0.33 g of intermediate 9, used as such in the next reaction.
  • b) Preparation of Intermediate 10
  • Figure US20100216809A1-20100826-C00447
  • A mixture of intermediate 9 (0.330 g, 0.00075 mol), HCl/2-propanol (3 ml) and CH3CN (6 ml) was stirred for 3 hours at room temperature. The solvent was evaporated under N2 at 40° C. and the residue was dried, yielding 0.307 of intermediate 10 (.2HCl).
    • EXAMPLE A4
  • a) Preparation of Intermediate 11
  • Figure US20100216809A1-20100826-C00448
  • A mixture of 4[4-(methoxycarbonyl)phenyl]-1-piperazinecarboxylic acid, 1,1-dimethylethyl ester (6.4 g, 0.0200 mol) in THF (200 ml) and CH3OH (50 ml) was stirred at room temperature. 1N aqueous NaOH solution (200 ml, 0.200 mol) was added. The mixture was stirred for 4 hours at 50° C. 1N HCl (200 ml) was added and the product was precipitated. The product was filtered off, washed with water and dried, yielding 4.8 g of intermediate 11.
  • b) Preparation of Intermediate 12
  • Figure US20100216809A1-20100826-C00449
  • A mixture of intermediate 11 (6.7 g, 0.0220 mol), N′-(ethylcarbonimidoyl)-N,N-dimethyl-1,3-propanediamine, monohydrochloride (4.79 g, 0.0250 mol), 1-hydroxy-1H-benzotriazole (3.38 g, 0.0250 mol) and DMF was stirred at room temperature for 30 minutes. NH3 was passed through the solution for 5 minutes (cooling with ice) and the mixture was stirred at room temperature for 18 hours. NH3 was passed again for 5 minutes through the solution and the mixture was stirred for 2 hours at room temperature. H2O (50 ml) was added and the product was precipitated. The product was filtered off, washed with water and dried, yielding 5.77 g (85%) of intermediate 12.
  • c) Preparation of Intermediate 13
  • Figure US20100216809A1-20100826-C00450
  • A mixture of intermediate 12 (1.5 g, 0.005 mol) and 1,1-dimethoxy-N,N-dimethylmethanamine (20 ml) was stirred for 5 hours at 120° C. The mixture was cooled. The product was precipitated, filtered off, washed (DIPE) and dried, yielding 1.170 g (65%) of intermediate 13.
  • d) Preparation of Intermediate 14
  • Figure US20100216809A1-20100826-C00451
  • A mixture of intermediate 13 (0.180 g, 0.0005 mol), butylhydrazine, ethanedioate (1:1) (0.107 g, 0.0006 mol) and HOAc (4 ml) was stirred for 2 hours at 50° C. The solvent was evaporated (N2 stream at 50° C.), yielding 0.192 g of intermediate 14 used as such in the next reaction step.
  • e) Preparation of Intermediate 15
  • Figure US20100216809A1-20100826-C00452
  • A mixture of intermediate 14 (0.192 g, 0.0005 mol), HCl/2-propanol (1.5 ml) and CH3CN (3 ml) was stirred for 3 hours at room temperature. The solvent was evaporated (N2 stream at 50° C.), yielding 0.179 g of intermediate 15 (0.2HCl) used as such in the next reaction (Example B2c).
    • EXAMPLE A5
  • a) Preparation of Intermediate 16
  • Figure US20100216809A1-20100826-C00453
  • A mixture of 4-[4-(1,5-dihydro-5-oxo-4H-1,2,4-triazol-4-yl)phenyl]-1-piperazine-carboxylic acid, ethyl ester (0.032 mol), 2-bromo-1-(4-bromophenyl)-1-butanone (0.04 mol) and Na2CO3 (0.08 mol) in DMF (150 ml) was stirred and heated at 40° C. overnight. The mixture was filtered off and the filtrate was evaporated. The oily residue was stirred up in CH2Cl2/H2O and separated. The organic layer was dried, filtered off and evaporated till a small volume. The oily residue was purified by column chromatography over silica gel (eluent: CH2Cl2/hexane/EtOAc 1/1/1). The pure fractions were collected and evaporated. The residue was purified again by column chromatography over silica gel (eluent: CH2Cl2/EtOAc/hexane 1/1/1). The pure fractions were collected and evaporated. The oily residue (12 g) was crystallized from Et2O, yielding 9 g (52%) of intermediate 16.
  • b) Preparation of Intermediate 17
  • Figure US20100216809A1-20100826-C00454
  • A mixture of Na2SO3 (1 g) in a 48% HBr solution (250 ml) was stirred for 10 minutes. Intermediate 16 (0.062 mol) was added. The mixture was stirred and refluxed for 5 hours. The mixture was stirred at room temperature overnight. The solvent was evaporated, yielding 21 g (72%) of intermediate 17 (.HBr).
    • EXAMPLE A6
  • a) Preparation of Intermediate 18
  • Figure US20100216809A1-20100826-C00455
  • A mixture of 4-[4-(1,5-dihydro-5-oxo-4H-1,2,4-triazol-4-yl)phenyl]-1-piperazinecarboxylic acid, ethyl ester (0.0063 mol), (1-chloroethyl)benzene (0.0063 mol) and KOH (0.0063 mol) in DMF (30 ml) was stirred and heated overnight at 70° C., then the reaction mixture was cooled and poured out into ice/H2O. The resulting precipitate was filtered off and washed with water. The solids were recrystallised from EtOAc/hexane and the pure product was collected, yielding 1 g (38%) of intermediate 18.
  • b) Preparation of Intermediate 19
  • Figure US20100216809A1-20100826-C00456
  • A mixture of intermediate 18 (6.08 g, 0.0150 mol) and NaHSO3 (0.78 g, 0.0075 mol) in HBr (5 ml; 48%) was stirred and refluxed for 48 hours. Then the solvent was evaporated. The residue was washed with an alkaline aqueous solution. The aqueous layer was extracted with CH2Cl2 and the separated organic layer was dried, filtered and the solvent was evaporated. The crude residue was purified by column chromatography (eluent: first EtOAc and then CH3OH (yielding intermediate 19)). The product fractions were collected and the solvent was evaporated. Yield: 1.5 g of intermediate 19 (29%; m.p.: 178-180° C.).
    • EXAMPLE A7
  • a) Preparation of Intermediate 20
  • Figure US20100216809A1-20100826-C00457
  • Reaction under N2 atmosphere. A solution of 4-(4-aminophenyl)-1-piperidine-carboxylic acid, 1,1-dimethylethyl ester (0.39 mol) in 1-methyl-2-pyrrolidinone (210 ml) was stirred and heated to 140° C. [(Dimethylamino)methylene]hydrazine-carboxylic acid, ethyl ester (0.465 mol) was added in four portions, each portion added after 20 minutes. The reaction mixture was stirred for 3 hours at 140° C. The mixture was allowed to cool to room temperature. H2O (800 ml) was added and the resulting precipitate was filtered off and dried (vacuum, 50° C., 24 hours, under a gentle stream of N2), yielding 134 g (100%) of intermediate 20.
  • b) Preparation of Intermediate 21
  • Figure US20100216809A1-20100826-C00458
  • A mixture of intermediate 20 (0.27 mol), 2-bromopropane (0.78 mol) and Cs2CO3 (0.39 mol) in DMA (580 ml) was stirred for 5 hours at 50° C., then overnight at room temperature. The mixture was poured out into water (1500 ml). CH2Cl2 (1 L) was added. The layers were separated. The organic layer was washed with water (5×1.0 L), dried (MgSO4), filtered and the solvent was evaporated. The residue was stirred in 2-propanol and the resulting precipitate was filtered off and dried (vacuum, 50° C.), yielding 72.8 g of intermediate 21.
  • c) Preparation of Intermediate 22
  • Figure US20100216809A1-20100826-C00459
  • A mixture of intermediate 21 (199 g, 0.51 mol) in CH2Cl2 (800 ml, c.p. (chemical pure)) was stirred at room temperature. HCl (1.18 mol, c.p.) was added and the reaction mixture was heated slowly to 40° C. The reaction mixture was stirred overnight at 40° C. HCl (50 ml, c.p.) was added and the mixture was stirred for 4 hours at 40° C., then allowed to cool to room temperature. The layers were separated. The water layer was alkalized (until pH=10). The resulting precipitate was filtered off, dissolved in CH2Cl2 and the organic solution was dried (MgSO4), filtered and the solvent was evaporated. The residue was stirred in EtOAc, filtered off and dried (vacuum, 50° C.), yielding 103 g (70%) of intermediate 22.
    • EXAMPLE A8
  • a) Preparation of Intermediate 23
  • Figure US20100216809A1-20100826-C00460
  • 1-(1-Methylethyl)-1H-pyrazole-4,5-diamine, sulfate (2:1) (46 g, 0.1928 mol), intermediate 1 (89 g, 0.241 mol), 6-chloro-l-hydroxy-1H-benzotriazole (3.3 g, 0.01928 mol) and HCTU (95.7 g, 0.2314 mol) were dissolved in DMF (530 ml). To the reaction mixture was added DIPEA (165 ml, 0.964 mol) within 5 minutes and the mixture was stirred for 17 hours at room temperature. To the reaction mixture was added an aqueous Na2CO3 (half saturated) solution and the organic material was extracted with EtOAc, dried (Na2SO4), filtered and the solvent was evaporated. The crude was suspended in Et20 and filtered, yielding 60.4 g (75%) of intermediate 23 as pink powder.
  • b) Preparation of Intermediate 24
  • Figure US20100216809A1-20100826-C00461
  • Intermediate 23 (30 g) was dissolved in dioxane (250 ml). POCl3 (250 ml) was added to the solution. The reaction mixture was heated for 1 hour at 40° C. and subsequently dioxane (100 ml) was added and heating was continued for 2 hours at 80° C. Afterwards POCl3 was distilled off and the residue was dissolved in dioxane (100 ml) and treated with an ice cold aqueous Na2CO3 (half saturated) solution. The organic material was extracted with EtOAc (3×), dried (Na2SO4), filtered and the solvent was evaporated. The residue was purified by flash chromatography (Si 60, EtOAc). The most clean fractions were suspended in Et2O and filtered, yielding 16.88 g (59%) of intermediate 24 as a brown powder.
  • c) Preparation of Intermediate 25
  • Figure US20100216809A1-20100826-C00462
  • Intermediate 24 (16.8 g) was dissolved in CH3OH (330 ml). The solution was hydrogenated for 6 hours in the presence of Pd(OH)2 (8.4 g). After filtration over Celite, the solvent was evaporated, yielding 13.28 g of intermediate 25 as a yellow powder.
    • EXAMPLE A9
  • a) Preparation of Intermediate 26
  • Figure US20100216809A1-20100826-C00463
  • (+−)-2-[1-(4-chlorobenzoyl)propyl]-2,4-dihydro-4-[4-(1-piperazinyl)phenyl]-3H-1,2,4-triazol-3-one dihydrochloride.monohydrate (0.0087 mol) in CH3OH (100 ml) and CH3OH/NH4OH (10 ml) was cooled till −20° C. and the mixture was warmed-up slowly to room temperature. The mixture was poured into H2O and the solid was filtered off. The precipitate was crystallized from 2-propanol. The product was dried in vacuo for 24 hours at 100° C. Yield: 2.9 g of intermediate 26 (78%).
    • EXAMPLE A10
  • a) Preparation of Intermediate 27
  • Figure US20100216809A1-20100826-C00464
  • A solution of ethyl 4-fluorobenzoic acid ester (17.51 g; 0.104 mol) and 1-benzyl-piperazine (36.83 g; 0.209 mol) in DMA (100 ml) was stirred and refluxed for 15 hours. The reaction mixture was allowed to reach room temperature and poured into ±750 ml stirring H2O. The solid part was filtered off, washed with plenty of water, dried for 15 hours at 50° C. in vacuo, recrystallized with 150 ml iPrOH, filtered off, washed with iPrOH and dried for 48 hours at 50° C. in vacuo, yielding 27.11 g of intermediate 27 (80%).
  • b) Preparation of Intermediate 28
  • Figure US20100216809A1-20100826-C00465
  • Intermediate 27 (14.001 g; 0.0432 mol) was added to sodium hydroxide (86 ml; 0.086 mol) while stirring. 1,4-Dioxane (175 ml) was added gently to the stirred reaction mixture. A turbid mixture was formed. The mixture was heated at 45° C. and the product was dissolved in 30 minutes. After heating for 20 hours, the reaction mixture was cooled off in icewater and HCl 1M (86 ml) was added. The product was filtered off, washed with water and dried in vacuo at 50° C. , yielding 12.16 g of intermediate 28 (95%).
  • c) Preparation of Intermediate 29
  • Figure US20100216809A1-20100826-C00466
  • POCl3 (5 ml; 53.642 mmol) was added to intermediate 28 (405.344 mg; 1.368 mmol) and 1-phenyl-1H-Pyrazole-4,5-diamine dihydrochloride (338 mg; 1.368 mmol). The fine suspension was stirred overnight at 100° C. The reaction mixture was poured unto ice and stirred for an hour. While cooling on an ice bath, some DCM was added and made alkaline with 50% NaOH. The resulting salt was filtered off and the DCM layer was separated. The aqueous layer was mixed with the salt and extracted twice with DCM. The combined DCM layers were dried (MgSO4), filtered and evaporated. The residue was purified by reversed phase high-performance liquid chromatography (Shandon Hyperprep® C18 BDS (Base Deactivated Silica) 8 μm, 250 g, I.D. 5 cm). A gradient with 2 mobile phases was applied. Phase A: 90% of a 0.5% NH4OAc solution in water+10% CH3CN; phase B: CH3CN). The desired fractions were collected and the eluent was evaporated. The residue was neutralized with NaHCO3, extracted with DCM and dried (MgSO4), filtered and the solvent was evaporated, yielding 254 mg of intermediate 29 (43%).
  • d) Preparation of Intermediate 30
  • Figure US20100216809A1-20100826-C00467
  • Intermediate 29 (1.279 g; 2.943 mmol) was hydrogenated with Pd/C 10% (0.5g) in methanol (150 ml) under N2 atmosphere. The reaction mixture was stirred at 25° C. under H2 atmosphere until 1 eq. hydrogen was absorbed. The catalyst was filtered off over dicalite and the residue was evaporated, yielding 959 mg of intermediate 30 (95%).
    • EXAMPLE A11
  • Preparation of Intermediate 31 and Intermediate 32
  • Figure US20100216809A1-20100826-C00468
  • 2,6-Dichloro-4-chloromethyl-phenylamine (11 g, 0.0445 mol) was added portionwise to a stirring solution of pyrrolidine (15.84 g, 0.223 mol) in CH3CN (250 ml). The reaction mixture was placed in a water bath (exothermic reaction). The solvent was evaporated and the residue was dissolved in CH2Cl2 (150 ml) and a 50% saturated NaHCO3 solution (100 ml). The mixture was stirred for 15 minutes. The organic layer was separated, dried (MgSO4), filtered and the solvent was evaporated and co-evaporated with toluene. The oily residue (11.46 g) was stirred in DIPE (30 ml) for 15 minutes and then the DIPE was evaporated again. The residue was combined with 2.65 g of another batch and the total amount of crude product was purified by column chromatography over silicagel (eluent: CH2Cl2/MeOH 95/5). The pure fractions were combined and the solvent was evaporated and co-evaporated with toluene. The residue was stirred in DIPE (25 ml). The DIPE was decanted from the solid, yielding a DIPE layer (*) and a solid. The remaining DIPE on the solid was evaporated and the solid was dried (50° C., in vacuo), yielding 2.75 g of intermediate 31 (28.18%). The impure fractions from the column were combined and the solvent was evaporated and co-evaporated with toluene. The residue (7.45 g) was dissolved in DIPE (20 ml) and 6N HCl in 2-propanol (5 ml) was added while the mixture was stirred vigorously. A yellowish oil was formed that became solid after continuous stirring. The solid was filtered off and washed with DIPE, yielding a filtrate (*) and a solid. The solid was dried (50° C., in vacuo). Yield: 5.19 g of intermediate 32 (41%; .HCl). The filtrate (*) and the DIPE layer (*) were combined and the solvent was evaporated. The residue (2.59 g) was dissolved in CH2Cl2 and NaHCO3 in H2O. The layers were separated and the organic layer was dried (MgSO4), filtered and the solvent was partially evaporated. The concentrated solution was re-purified over silicagel (eluent: CH2Cl2/MeOH 95/5). The pure fractions were collected and the solvent was evaporated and co-evaporated with toluene. The residue was dried (50° C., 18 hours, in vacuo). Yield: 1.85 g of intermediate 31 (17%).
    • EXAMPLE A12
  • Preparation of Intermediate 33
  • Figure US20100216809A1-20100826-C00469
  • HCl 1M in Et2O (10.32 ml; 0.0206 mol) was added to a stirring solution of intermediate 31 (4.6 g; 0.0188 mol) in CH3CN p.a. dried on molecular sieves (75 ml) and CH2Cl2 p.a (10 ml). Stirring was continued for 1 hour. A precipitate was formed. The reaction mixture was cooled on an ice-bath, and phosgene 20% in toluene (14 ml) was added. The reaction mixture was stirred further for 3 hours. Extra phosgene 20% in toluene (7 ml) was added, and the reaction mixture was stirred further at room temperature for 18 hours. The product was filtered off, washed with CH3CN (3×) and dried at 50° C. [vacuum, 1 hour], yielding 5.45 g of intermediate 33 (94%).
    • EXAMPLE A13
  • a) Preparation of Intermediate 34
  • Figure US20100216809A1-20100826-C00470
  • Hydrazine monohydrate (1.75g; 35 mmol) was added to 25 ml acetic acid (exothermic). This mixture was added dropwise to intermediate 13 and 50 ml of acetic acid at room temperature. The mixture was stirred for 40 hours. The solvent was evaporated. The residue was stirred in H2O, treated with Na2CO3 and extracted with CH2Cl2. The organic layer was dried, filtered and evaporated, yielding 5.6 g of intermediate 34.
  • b) Preparation of Intermediate 35
  • Figure US20100216809A1-20100826-C00471
  • A mixture of intermediate 34 (0.987 g; 3 mmol) and 15 ml of DMF was stirred at room temperature. NaH 60% (0.131 g; 3.3 mmol) was added and the mixture was stirred for 15 minutes at room temperature. 1-(Bromomethyl)-4-methoxybenzene (0.475 ml; 3.3 mmol) and 5 ml of DMF was added dropwise over 15 minutes. The mixture was stirred at room temperature for 18 hours. 0.026 g of NaH 60% and 0.095 ml of 1-(bromo-methyl)-4-methoxybenzene were added and the mixture was stirred for 3 hours. The solvent was evaporated and the residue was stirred in water and extracted with CH2Cl2. The organic layer was dried, filtered and evaporated. The residue was purified and the regioisomers were separated with HPLC method A. The desired fraction was collected and the solvent was evaporated, yielding 0.699 of intermediate 35.
  • c) Preparation of Intermediate 36
  • Figure US20100216809A1-20100826-C00472
  • A mixture of intermediate 35 (0.649 g; 1.4 mmol), 5 ml of HCl/iPrOH and 10 ml of CH3CN was stirred at room temperature for 3 hours. A solid precipitated and the solvent was evaporated. The residue was dried, yielding 0.748 g of intermediate 36.
    • EXAMPLE A14
  • a) Preparation of Intermediate 38
  • Figure US20100216809A1-20100826-C00473
  • A mixture of intermediate 11 (0.918 g; 3 mmol), EDCI (0.843 g; 4.4 mmol), HOBt (0.594 g; 4.4 mmol) and 10 ml of DMF was stirred at room temperature for 15 minutes. Benzenepropanoic acid hydrazide (1.045 g; 6.4 mmol) was added. The mixture was stirred at room temperature for 18 hours. The solvent was evaporated. The residue was stirred in water and extracted with CH2Cl2. The organic layer was dried, filtered and evaporated. The mixture was purified with HPLC method C. The pure fraction were collected and the solvent was evaporated. The residue was dried, yielding 0.941 g of intermediate 38.
  • b) Preparation of Intermediate 39
  • Figure US20100216809A1-20100826-C00474
  • A mixture of intermediate 38 (0.863 g; 1.9 mmol) and 15 ml of THF was stirred at room temperature. 7-Oxa-4-thia-3,5-diazaoctane-2,4-diaminium, 3,3-diethyl-6-oxo-, inner salt 4,4-dioxide (0.715 g; 3 mmol) (Burgess' reagent) was added. The mixture was stirred at 60° C. for 3 hours. The solvent was evaporated. The residue was stirred in 2 ml of water and extracted with CH2Cl2. The mixture was filtered over Isolute filter and the organic layer was evaporated. The residue was filtered over silicagel using a mixture of CH2Cl2 and CH3OH (97/3 by volume) as eluent. The pure fraction were collected and the solvent was evaporated. The residue was dried, yielding 0.690 g of intermediate 39.
  • c) Preparation of Intermediate 40
  • Figure US20100216809A1-20100826-C00475
  • A mixture of intermediate 39 (0.690 g; 1.59 mmol) and 15 ml of CH2Cl2 was stirred at room temperature. 1.5 ml of CF3COOH was added. The mixture was stirred for 3 hours. The solvent was evaporated at 50° C. by a nitrogen stream. The residue was stirred in CH2Cl2 and washed with water and NaHCO3. The mixture was dried over Isolute filter and the organic layer was evaporated. The residue was dried, yielding 0.439 g of intermediate 40.
    • EXAMPLE A15
  • a) Preparation of Intermediate 41
  • Figure US20100216809A1-20100826-C00476
  • A mixture of N-hydroxybenzenebutanimidamide (0.713 g; 4 mmol), NaH 60% (0.200g; 5 mmol) and 20 ml of THF was stirred at room temperature. 1,1-dimethylethyl 4-[4-(methoxycarbonyl)phenyl]-1-piperazinecarboxylic acid ester (0.640 g; 2 mmol) was added portionwise over 15 minutes. The mixture was stirred and refluxed for 18 hours. The solvent was evaporated. The residue was stirred in water and extracted with CH2Cl2. The organic layer was dried, filtered and evaporated. The residue was filtered over silicagel using a mixture of CH2Cl2 and CH3OH (99/1 by volume) as eluent. The desired fractions were collected and the solvent was evaporated, yielding 0.206 of intermediate 41.
  • b) Preparation of Intermediate 42
  • Figure US20100216809A1-20100826-C00477
  • A mixture of intermediate 41 (0.206 g; 0.46 mmol), 4 ml of HCl/iPrOH and 8 ml of CH3CN was stirred at room temperature for 5 hours. The product was precipitated, filtered off and dried, yielding 0.104 g of intermediate 42.
    • EXAMPLE A16
  • a) Preparation of Intermediate 43
  • Figure US20100216809A1-20100826-C00478
  • A mixture of intermediate 11 (0.918 g; 3 mmol), EDCI (0.843g; 4.4 mmol), HOBt (0.594 g; 4.4 mmol) and 10 ml of DMF was stirred at room temperature for 15 minutes. Phenylacetic acid hydrazide (1 g; 6.65 mmol) was added. The mixture was stirred at room temperature for 18 hours. The solvent was evaporated. The residue was stirred in water and extracted with CH2Cl2. The organic layer was dried, filtered and evaporated. The residue was purified by reversed-phase high-performance liquid chromatography (Shandon Hyperprep® C18 BDS (Base Deactivated Silica) 8 μm, 250 g, I.D. 5 cm). A gradient with the following mobile phases was applied. Phase A: a 0.25% NH4HCO3 solution in water; phase B (optional): CH3OH; phase C: CH3CN). The desired fractions were collected and the solvent was evaporated. The residue was dried, yielding 0.802 g of intermediate 43.
  • b) Preparation of Intermediate 44
  • Figure US20100216809A1-20100826-C00479
  • A mixture of intermediate 43 (0.263 g; 0.6 mmol) and 10 ml of THF was stirred at room temperature. 7-Oxa-4-thia-3,5-diazaoctane-2,4-diaminium, 3,3-diethyl-6-oxo-, inner salt 4,4-dioxide (0.214 g; 0.9 mmol) (Burgess'reagent) was added at once. The mixture was stirred at 60° C. for 3 hours. The solvent was evaporated. The residue was stirred in 2 ml of water and extracted with CH2Cl2. The mixture was dried over Isolute filter and the organic layer was evaporated. The residue was filtered over silicagel using a mixture of CH2Cl2 and CH3OH (96/4 by volume) as eluent. The pure fraction were collected and the solvent was evaporated. The residue was dried, yielding 0.214 g of intermediate 44.
  • c) Preparation of Intermediate 45
  • Figure US20100216809A1-20100826-C00480
  • A mixture of intermediate 44 (0.172 g; 0.41 mmol) and 8 ml of CH2Cl2 was stirred at room temperature for 5 minutes. 0.8 ml of CF3COOH was added. The mixture was stirred at room temperature for 18 hours. The solvent was evaporated at 50° C. by a nitrogen stream. The residue was stirred in water, treated with NaHCO3 and extracted with CH2Cl2. The organic layer was evaporated and dried, yielding 0.127 g of intermediate 45.
    • EXAMPLE A11
  • a) Preparation of Intermediate 46 and Intermediate 47
  • Figure US20100216809A1-20100826-C00481
  • A mixture of 1-[4-(1-piperazinyl)phenyl]ethanone (25 g; 0.122 mol), Na2CO3 (14.269 g; 0.135 mol) and 150 ml of THF was stirred at room temperature. Bromomethyl-benzene (16.102 ml; 0.135 mol) and 50 ml THF was added dropwise over 30 minutes at room temperature. The mixture was stirred at room temperature for 18 hours. The solvent was evaporated. The residue was stirred in water and extracted with CH2Cl2. The organic layer was dried, filtered and evaporated. The residue was stirred in DIPE. The product was filtered off and dried, yielding 31.5 g of intermediate 46. 10 g of intermediate 46 was dissolved in 50 ml acetonitrile . Salt was formed by adding HBr 48% . The salt was precipitated, filtered off and dried, yielding 5.5 g of intermediate 47.
  • b) Preparation of Intermediate 48
  • Figure US20100216809A1-20100826-C00482
  • A mixture of intermediate 47 (3.94 g; 0.00864 mol) and 75 ml of HBr/CH3COOH was stirred at room temperature. Br2 (0.487 ml; 0.0095 mol) was added and the mixture was stirred at room temperature for 18 hours. The mixture was poured in ice water. The product was filtered off, washed with DIPE and dried, yielding 3.69 g of intermediate 48 (80%).
  • c) Preparation of Intermediate 49
  • Figure US20100216809A1-20100826-C00483
  • A mixture of intermediate 48 (1.069 g; 0.002 mol), 2-thiazolamine (0.2 g; 0.002 mol) and 25 ml of ethanol was stirred at 80° C. for 18 hours . The mixture was cooled. The product was filtered off, washed with ethanol and DIPE and dried, yielding 0.794 g of intermediate 49.
  • d) Preparation of Intermediate 50
  • Figure US20100216809A1-20100826-C00484
  • Intermediate 49 (0.661 g; 0.00123 mol) was stirred in water, treated with Na2CO3 and extracted with CH2Cl2. The organic layer was dried, filtered and evaporated. The residue and 30 ml of dichloroethane was stirred at room temperature. 1-Chloroethyl carbonochloridic acid ester (0.161 ml; 0.00148 mol) was added and the mixture was stirred at 85° C. for 2 hours. The solvent was evaporated. The residue was dissolved in methanol and stirred at 85° C. in a closed vessel for 7 days. The solvent was evaporated, yielding 0.357 g of intermediate 50.
    • EXAMPLE A18
  • a) Preparation of Intermediate 51
  • Figure US20100216809A1-20100826-C00485
  • A mixture 4-(diethylamino)-N-hydroxybutanimidamide (0.693 g; 4 mmol), NaH 60% (0.160 g; 4 mmol) and 20 ml of THF was stirred at room temperature. 1,1-Dimethyl-ethyl 4-[4-(methoxycarbonyl)phenyl]-1-piperazinecarboxylic acid ester (0.640 g; 2 mmol) was added portionwise over 15 minutes. The mixture was stirred and refluxed for 144 hours. The solvent was evaporated. The residue was stirred in water and extracted with CH2Cl2. The organic layer was dried, filtered and evaporated. The residue was purified with HPLC method C. The pure fraction were collected and the solvent was evaporated. The residue was dried, yielding 0.161 g of intermediate 51.
  • b) Preparation of Intermediate 52
  • Figure US20100216809A1-20100826-C00486
  • A mixture of intermediate 51 (0.161 g; 0.36 mmol), 2.5 ml of HCl/iPrOH and 5 ml of CH3CN was stirred at room temperature for 3 hours. The solvent was evaporated, yielding 0.163 of intermediate 52.
    • EXAMPLE A19
  • a) Preparation of Intermediate 53
  • Figure US20100216809A1-20100826-C00487
  • A mixture of intermediate 48 (2.17 g; 0.004 mol), 5-phenyl-2-thiazolamine (2.115 g; 0.012 mol) and 50 ml of ethanol was stirred at 75° C. for 18 hours. The product was precipitated, filtered off, washed with DIPE and dried, yielding 1.8 g of intermediate 53.
  • b) Preparation of intermediate 54
  • Figure US20100216809A1-20100826-C00488
  • 1-Chloroethyl carbonochloridic acid ester (1.734 ml; 0.0159 mol) was added to a stirred mixture of intermediate 53 (1.79 g; 0.00397 mol), 1.522 ml of DIPEA and 30 ml of 1,2-dichloroethane. The reaction mixture was stirred and refluxed for 2 hours. The solvent was evaporated and three times co-evaporated with xylene, yielding intermediate 54, a residue used as such in the next reaction.
  • c) Preparation of Intermediate 55
  • Figure US20100216809A1-20100826-C00489
  • A mixture of intermediate 54 (1.821 g; 0.0039 mol) and 25 ml of methanol was refluxed for 18 hours. 2 ml of HBr 48% was added. The reaction mixture was stirred, refluxed for 83 hours and poured into 100 ml H2O containing 2 g NaHCO3. After stirring for 15 minutes, the product was filtered off, washed with H2O three times and dried at 50° C. (vacuum), yielding 0.5 g of intermediate 55 (36%).
    • EXAMPLE A20
  • a) Preparation of Intermediate 56
  • Figure US20100216809A1-20100826-C00490
  • C,C′-bis(1,1-dimethylethyl) dicarbonic acid ester (60.1 g; 0.276 mol) was added in small portions to a stirred solution of 1-[4-(1-piperazinyl)phenyl]ethanone (50.0 g; 0.245 mol) in dry CH2Cl2 (400 ml) at room temperature. The obtained solution was stirred for 0.5 hour. The solvent was removed in vacuum. The residue was purified by chromatography (eluent: chloroform), yielding 40.7 g (55%) of intermediate 56.
  • b) Preparation of Intermediate 57
  • Figure US20100216809A1-20100826-C00491
  • Intermediate 56 (78.4 g; 0.258 mol) was dissolved in 1,1-dimethoxy-N,N-dimethyl-methanamine (300 ml; 2.24 mol) and obtained solution was refluxed for 20 hours. Then diisopropyl ether (150 ml) was added to the hot solution and obtained mixture was allowed to cool. The formed crystals were filtered off and washed with diisopropyl ether, yielding intermediate 57.
  • The filtrate was concentrated in vacuum to remove diisopropyl ether followed by reflux of the residue for 10 hours. Then diisopropyl ether (150 ml) was added, the mixture was allowed to cool and the formed crystals were filtered off to give an additional amount of intermediate 57. The total yield of intermediate 57 is 67.5 g (73%).
  • c) Preparation of Intermediate 58
  • Figure US20100216809A1-20100826-C00492
  • Hydrazine monohydrate (7.5 ml; 115.0 mmol) was added to a solution of intermediate 57 (13.8 g; 38.4 mmol) in ethanol (100 ml) and resulting solution was refluxed for 5 hours. Then water (100 ml) was added to the hot solution, after that ethanol (about 50 ml) was removed by distillation. The mixture was allowed to cool to room temperature and formed crystals were filtered off, washed with water and dried on air, yielding 11.5 g (91%) of intermediate 58.
  • d) Preparation of Intermediate 59
  • Figure US20100216809A1-20100826-C00493
  • Intermediate 58 (15.52 g; 0.0473 mol) was dissolved in dry DMF (100 ml), then NaH 60% (4.16 g; 0.1040 mol) was added and the reaction mixture was stirred at room temperature for 0.5 hours. Subsequently, 2-bromoethylbenzene (14.25 ml; 0.1040 mol) was added and the reaction mixture was stirred for 20 hours more at room temperature. The mixture was poured out into water (300 ml) and diluted with hexane (100 ml). The organic layer was washed with water three times and the organic layer was separated. The product was filtered off and re-crystallized from the mixture DCM-hexane, yielding 15.0 g (73%) of intermediate 59.
  • e) Preparation of Intermediate 60
  • Figure US20100216809A1-20100826-C00494
  • Intermediate 59 (23.55 g; 0.0545 mol) was dissolved in dry acetonitrile (500 ml), then HCl 6N (250 ml; 1.50 mol) was added and the reaction mixture was held overnight. After that the reaction mixture was evaporated to remove acetonitrile (about 400 ml), diluted with water (300 ml) and extracted with benzene. The aqueous layer was separated and basified with 1N KOH to pH=9-10. This led to the formation of oily product that gradually became crystalline. This product was filtered and washed with water. Then the precipitate was dissolved in DCM (200 ml) and insoluble admixtures were filtered off. The filtrate was concentrated in vacuum, yielding 17.0 g (94%) of intermediate 60.
    • EXAMPLE A21
  • a) Preparation of Intermediate 61
  • Figure US20100216809A1-20100826-C00495
  • Norite (0.8 g) was added to a solution of methyl 4-amino-3,5-dichlorobenzoic acid ester (8.00 g; 36.3 mmol) and trichloromethyl carbonochloridic acid ester (8.0 ml; 66.2 mmol) in dry toluene (72 ml). The resulting mixture was heated at stirring in stainless steel bomb of a Parr apparatus at 110° C. for 20 hours. Then the reaction mixture was cooled and filtered through a pad of celite. The filtrate was bubbled with argon for 2 hours to remove phosgene and hydrogen chloride. Then the filtrate was concentrated in vacuum. The crude product was treated with cold hexane (15 ml), the precipitate was filtered off and the filtrate was evaporated to yield 2.82 g (31.5%) of intermediate 61. The precipitate was treated with hexane (40 ml) at stirring at 40° C. The small amount of dark sediment was removed by filtration and the filtrate was concentrated to yield 5.68 g (64%) of intermediate 61. The total yield of intermediate 61 is 8.50 g (95%).
  • B. Preparation of the Compounds
    • EXAMPLE B1
  • Preparation of Compound 1
  • Figure US20100216809A1-20100826-C00496
  • A mixture of intermediate 4 (0.060 g, 0.000161 mol) and 1,3-dichloro-2-isocyanatobenzene (0.033 g, 0.000177 mol) in dry THF (1 ml) was shaken overnight at room temperature. The solvent was evaporated and the residue was washed with Et2O (2×), yielding 0.081 g (90%) of compound 1.
    • EXAMPLE B2
  • a) Preparation of Compound 2
  • Figure US20100216809A1-20100826-C00497
  • A mixture of intermediate 8 (0.085 g, 0.00021 mol), Et3N (0.091 g, 0.0009 mol) and CH2Cl2 (5 ml) was stirred for 15 minutes at room temperature. 1,3-Dichloro-2-isocyanatobenzene (0.056 g, 0.0003 mol) was added and the reaction mixture was stirred overnight at room temperature. The mixture was washed with H2O (2 ml) and was dried over an Isolute filter. The organic layer was evaporated. The residue was purified by HPLC Method B. The pure fractions were collected and the solvent was evaporated. The residue was stirred in DIPE. The solvent was evaporated (stream of N2 at 50° C.) and the solid was dried, yielding 0.046 g of compound 2.
  • b) Preparation of Compound 3
  • Figure US20100216809A1-20100826-C00498
  • A mixture of intermediate 10 (0.307 g, 0.00075 mol), Et3N (0.243 g, 0.0024 mol) and CH2Cl2 (q.s.) was stirred for 30 minutes at room temperature. Subsequently, 1,3-dichloro-2-isocyanatobenzene (0.147 g, 0.00078 mol) was added and the reaction mixture was stirred overnight at room temperature. The mixture was washed with H2O (2 ml), dried over an Isolute filter and the solvent was evaporated. The residue was stirred in CH3CN. The product was filtered off, washed with DIPE and dried, yielding 0.21 g of compound 3.
  • c) Preparation of Compound 4
  • Figure US20100216809A1-20100826-C00499
  • A mixture of intermediate 15 (0.179 g, 0.0005 mol), Et3N (0.182 g, 0.0018 mol) and CH2Cl2 (10 ml) was stirred for 30 minutes at room temperature. 1,3-Dichloro-2-isocyanatobenzene (0.112 g, 0.0006 mol) was added and the reaction mixture was stirred for 3 hours at room temperature. The mixture was washed with H2O (2 ml) and was dried over an Isolute filter. The organic layer was evaporated and the residue was purified by high-performance liquid chromatography. The pure fractions were collected and the solvent was evaporated. The residue was solidified by stirring in DIPE (2 ml). The solvent was evaporated and the solid residue was dried, yielding 0.071 g of compound 4.
    • EXAMPLE B3
  • Preparation of Compound 5
  • Figure US20100216809A1-20100826-C00500
  • Intermediate 17 was converted into its hydrochloric acid salt by literature-known methods (0.25 g, 0.00049 mol; .HCl), and was then mixed with 1,3-dichloro-2-isocyanatobenzene (0.102 g, 0.00054 mol) and DIPEA (0.097 g, 0.00075 mol) in CH2Cl2 (25 ml) and stirred for 2 hours at room temperature. The solvent was evaporated and the residue was crystallized from DIPE. The precipitate was filtered off and dried. The crude product was stirred in H2O and the aqueous layer was extracted with CH2Cl2. The separated organic layer was dried (Extrelut) and the solvent was evaporated, yielding 0.07 g of compound 5.
    • EXAMPLE B4
  • a) Preparation of Compound 6
  • Figure US20100216809A1-20100826-C00501
  • A mixture of intermediate 19 (0.00060 mol) and 1,3-dichloro-2-isocyanatobenzene (0.00066 mol) in CH2Cl2 (20 ml) was stirred at room temperature for 4 hours. The solvent was evaporated. The residue was triturated under DIPE. The precipitate was filtered off and dried, yielding 0.264 g of compound 6.
  • b) Preparation of Compound 7
  • Figure US20100216809A1-20100826-C00502
  • 1,3-Dichloro-2-isocyanatobenzene (0.000698 mol) was added to a slightly cloudy solution of intermediate 22 (0.000698 mol) in CH2Cl2 (10 ml, p.a.), stirred at room temperature. The reaction mixture was stirred overnight at room temperature. The mixture was purified by flash column chromatography over a Biotage 60 cartridge (eluent: CH2Cl2/(7N NH3/CH3OH) from 100/0 to 95/5 v/v). The product fractions were collected and the solvent was evaporated, yielding 0.171 g of compound 7.
    • EXAMPLE B5
  • Preparation of Compound 8
  • Figure US20100216809A1-20100826-C00503
  • A mixture of intermediate 25 (0.060 g, 0.000193 mol), 2,6-dichlorobenzeneacetic acid (0.048 g, 0.000232 mol), EDCI (0.044 g, 0.000232 mol), HOBt .H20 (0.036 g, 0.000232 mol) and DIPEA (0.000965 mol) in dry CH2Cl2 (1 ml) was shaken overnight at 50° C. CH2Cl2 was added to the mixture and the mixture was extracted with NaHCO3 (half saturated) and H2O. The separated organic layer was filtered over silica and dried (MgSO4). The solvent was evaporated. The residue was purified by preparative HPLC (column 100×21 mm, Nucleosil (Macherey-Nagel) Si50, 10 μm; gradient: CH2Cl2/CH3OH: 0.0 min: 100/0; 1.2 min: 100/0; 5.0 min: 0/100; 9.0 min: 0/100; flow rate: 35 ml/min). The desired fractions were collected and worked-up, yielding 0.070 g (73%) of compound 8.
    • EXAMPLE B6
  • Preparation of Compound 24
  • Figure US20100216809A1-20100826-C00504
  • A mixture of intermediate 26 (0.250 g, 0.00058 mol), 1,3-dichloro-2-isocyanatobenzene (0.121 g, 0.00064 mol) and CH2Cl2 (25 ml) was stirred for 2 hours at room temperature. The solvent was evaporated and DIPE was added to the residue. The solid was filtered off and dried. The crude compound was purified by reversed-phase HPLC (HPLC method C). The desired fractions were collected and worked-up, yielding 0.204 g of compound 24.
    • EXAMPLE B7
  • Preparation of Compound 29
  • Figure US20100216809A1-20100826-C00505
  • A mixture of intermediate 36 (0.295 g; 0.7 mmol), triethylamine (0.56 ml; 4 mmol) and CH2Cl2 (10 ml) was stirred at room temperature for 15 minutes. 1,3-Dichloro-2-isocyanatobenzene (0.188 g; 1 mmol) was added. The mixture was stirred at room temperature for 18 hours. The mixture was washed with 2 ml water and dried over Isolute filter. The organic layer was evaporated. The residue was filtered over silica gel using a mixture of CH2Cl2 and CH3OH (97/3 by volume) as eluent. The pure fractions were collected and the solvent was evaporated. The residue was dried, yielding 0.277 g of compound 29.
    • EXAMPLE B8
  • Preparation of Compound 54
  • Figure US20100216809A1-20100826-C00506
  • To a suspension of intermediate 32 (527.048 mg; 1.872 mmol) in 10 ml of acetonitrile and 4 ml of DCM, C(═O)Cl2 20% in toluene (1.701 ml; 3.403 mmol) was added. The suspension was stirred overnight at room temperature. The reaction was filtered and washed with fresh dry CH3CN. The isocyanate precipitate was added to a suspension of intermediate 30 (586 mg; 1.701 mmol) and DIPEA (0.845 ml; 5.104 mmol in DCM (20 ml). Meanwhile,the filtrate was concentrated at 30° C. to remove DCM and 1.7 ml of fresh C(═O)Cl2 20% in toluene was added and stirred for 3 hours at room temperature. A second batch of intermediate 32 (431 mg) was added to the mixture and stirred overnight. The suspension was filtered, the residue was washed with a little dry CH3CN and added to the reaction mixture of intermediate 30. The reaction was evaporated. The residue was purified by reversed phase high-performance liquid chromatography (Shandon Hyperprep® C18 BDS (Base Deactivated Silica) 8 μm, 250 g, I.D. 5 cm). A gradient with the following mobile phases was applied. Phase A: 90% of a 0.5% NH4OAc solution in water+10% CH3CN; phase B (optional): CH3OH; phase C: CH3CN). The desired fractions were collected, partially evaporated at 30° C. and neutralized to pH 8-9 with a saturated NaHCO3 solution. The formed precipitate was filtered off and dried, yielding 820 mg of compound 54 (78%).
  • Table 1a lists compounds of formula (I) according to the present invention prepared by analogy to one of the above Example Nr.
  • TABLE 1a
    Figure US20100216809A1-20100826-C00507
    Co. No. Ex. No. A X R1 Rq
    1 B1 N
    Figure US20100216809A1-20100826-C00508
    Figure US20100216809A1-20100826-C00509
         		H- - - 
    2 B2.a N
    Figure US20100216809A1-20100826-C00510
    Figure US20100216809A1-20100826-C00511
         		H- - - 
    3 B2.b N
    Figure US20100216809A1-20100826-C00512
    Figure US20100216809A1-20100826-C00513
         		H- - - 
    4 B2.c N
    Figure US20100216809A1-20100826-C00514
    Figure US20100216809A1-20100826-C00515
         		H- - - 
    5 B3 N
    Figure US20100216809A1-20100826-C00516
    Figure US20100216809A1-20100826-C00517
         		H- - - 
    6 B4.a N
    Figure US20100216809A1-20100826-C00518
    Figure US20100216809A1-20100826-C00519
         		H- - - 
    7 B4.b CH
    Figure US20100216809A1-20100826-C00520
    Figure US20100216809A1-20100826-C00521
         		H- - - 
    8 B5 N
    Figure US20100216809A1-20100826-C00522
    Figure US20100216809A1-20100826-C00523
         		H- - - 
    9 B1 N
    Figure US20100216809A1-20100826-C00524
    Figure US20100216809A1-20100826-C00525
         		H- - - 
    10 B2.a N
    Figure US20100216809A1-20100826-C00526
    Figure US20100216809A1-20100826-C00527
         		H- - - 
    11 B2.a N
    Figure US20100216809A1-20100826-C00528
    Figure US20100216809A1-20100826-C00529
         		H- - - 
    12 B2.a N
    Figure US20100216809A1-20100826-C00530
    Figure US20100216809A1-20100826-C00531
         		H- - - 
    13 B2.a N
    Figure US20100216809A1-20100826-C00532
    Figure US20100216809A1-20100826-C00533
         		H- - - 
    14 B2.a N
    Figure US20100216809A1-20100826-C00534
    Figure US20100216809A1-20100826-C00535
         		H- - - 
    15 B2.a N
    Figure US20100216809A1-20100826-C00536
    Figure US20100216809A1-20100826-C00537
         		H- - - 
    16 B2.a N
    Figure US20100216809A1-20100826-C00538
    Figure US20100216809A1-20100826-C00539
         		H- - - 
    17 B2.a N
    Figure US20100216809A1-20100826-C00540
    Figure US20100216809A1-20100826-C00541
         		H- - - 
    18 B2.a N
    Figure US20100216809A1-20100826-C00542
    Figure US20100216809A1-20100826-C00543
         		H- - - 
    19 B2.b N
    Figure US20100216809A1-20100826-C00544
    Figure US20100216809A1-20100826-C00545
         		H- - - 
    20 B2.b N
    Figure US20100216809A1-20100826-C00546
    Figure US20100216809A1-20100826-C00547
         		H- - - 
    21 B2.b N
    Figure US20100216809A1-20100826-C00548
    Figure US20100216809A1-20100826-C00549
         		H- - - 
    22 B2.c N
    Figure US20100216809A1-20100826-C00550
    Figure US20100216809A1-20100826-C00551
         		H- - - 
    23 B2.c N
    Figure US20100216809A1-20100826-C00552
    Figure US20100216809A1-20100826-C00553
         		H- - - 
    24 B6 N
    Figure US20100216809A1-20100826-C00554
    Figure US20100216809A1-20100826-C00555
         		H- - - 
    25 B4.a N
    Figure US20100216809A1-20100826-C00556
    Figure US20100216809A1-20100826-C00557
         		H- - - 
    26 B4.a N
    Figure US20100216809A1-20100826-C00558
    Figure US20100216809A1-20100826-C00559
         		H- - - 
    27 B5 N
    Figure US20100216809A1-20100826-C00560
    Figure US20100216809A1-20100826-C00561
         		H- - - 
    28 B7 N
    Figure US20100216809A1-20100826-C00562
    Figure US20100216809A1-20100826-C00563
         		H- - - 
    29 B7 N
    Figure US20100216809A1-20100826-C00564
    Figure US20100216809A1-20100826-C00565
         		H- - - 
    30 B7 N
    Figure US20100216809A1-20100826-C00566
    Figure US20100216809A1-20100826-C00567
         		H- - - 
    31 B7 N
    Figure US20100216809A1-20100826-C00568
    Figure US20100216809A1-20100826-C00569
         		H- - - 
    32 B7 N
    Figure US20100216809A1-20100826-C00570
    Figure US20100216809A1-20100826-C00571
         		H- - - 
    33 B7 N
    Figure US20100216809A1-20100826-C00572
    Figure US20100216809A1-20100826-C00573
         		H- - - 
    34 B7 N
    Figure US20100216809A1-20100826-C00574
    Figure US20100216809A1-20100826-C00575
         		H- - - 
    35 B7 N
    Figure US20100216809A1-20100826-C00576
    Figure US20100216809A1-20100826-C00577
         		H- - - 
    36 B7 N
    Figure US20100216809A1-20100826-C00578
    Figure US20100216809A1-20100826-C00579
         		H- - - 
    37 B7 N
    Figure US20100216809A1-20100826-C00580
    Figure US20100216809A1-20100826-C00581
         		H- - - 
    38 B7 N
    Figure US20100216809A1-20100826-C00582
    Figure US20100216809A1-20100826-C00583
         		H- - - 
    39 B7 N
    Figure US20100216809A1-20100826-C00584
    Figure US20100216809A1-20100826-C00585
         		H- - - 
    40 B7 N
    Figure US20100216809A1-20100826-C00586
    Figure US20100216809A1-20100826-C00587
         		H- - - 
    41 B2.a N
    Figure US20100216809A1-20100826-C00588
    Figure US20100216809A1-20100826-C00589
         		H- - - 
    42 B7 N
    Figure US20100216809A1-20100826-C00590
    Figure US20100216809A1-20100826-C00591
         		H- - - 
    43 B7 N
    Figure US20100216809A1-20100826-C00592
    Figure US20100216809A1-20100826-C00593
         		H- - - 
    44 B4.b N
    Figure US20100216809A1-20100826-C00594
    Figure US20100216809A1-20100826-C00595
         		H- - - 
    45 B2.c N
    Figure US20100216809A1-20100826-C00596
    Figure US20100216809A1-20100826-C00597
         		H- - - 
    46 B4.b N
    Figure US20100216809A1-20100826-C00598
    Figure US20100216809A1-20100826-C00599
         		H- - - 
    47 B2.c N
    Figure US20100216809A1-20100826-C00600
    Figure US20100216809A1-20100826-C00601
         		H- - - 
    48 B4.b N
    Figure US20100216809A1-20100826-C00602
    Figure US20100216809A1-20100826-C00603
         		H- - - 
    49 B7 N
    Figure US20100216809A1-20100826-C00604
    Figure US20100216809A1-20100826-C00605
         		H- - - 
    50 B4.b N
    Figure US20100216809A1-20100826-C00606
    Figure US20100216809A1-20100826-C00607
         		H- - - 
    51 B7 N
    Figure US20100216809A1-20100826-C00608
    Figure US20100216809A1-20100826-C00609
         		H- - - 
    52 B5 N
    Figure US20100216809A1-20100826-C00610
    Figure US20100216809A1-20100826-C00611
         		H- - - 
    53 B8 N
    Figure US20100216809A1-20100826-C00612
    Figure US20100216809A1-20100826-C00613
         		H- - - 
    54 B8 N
    Figure US20100216809A1-20100826-C00614
    Figure US20100216809A1-20100826-C00615
         		H- - - 
    55 B8 N
    Figure US20100216809A1-20100826-C00616
    Figure US20100216809A1-20100826-C00617
         		H- - - 
    56 B8 N
    Figure US20100216809A1-20100826-C00618
    Figure US20100216809A1-20100826-C00619
         		H- - - 
    57 B2.a N
    Figure US20100216809A1-20100826-C00620
    Figure US20100216809A1-20100826-C00621
         		H- - - 
    58 B8 N
    Figure US20100216809A1-20100826-C00622
    Figure US20100216809A1-20100826-C00623
         		H- - - 
    59 B2.a N
    Figure US20100216809A1-20100826-C00624
    Figure US20100216809A1-20100826-C00625
         		H- - - 
    60 B8 N
    Figure US20100216809A1-20100826-C00626
    Figure US20100216809A1-20100826-C00627
         		H- - - 
    61 B2.a N
    Figure US20100216809A1-20100826-C00628
    Figure US20100216809A1-20100826-C00629
         		H- - - 
    62 B2.a N
    Figure US20100216809A1-20100826-C00630
    Figure US20100216809A1-20100826-C00631
         		HO- - - 
    63 B7 N
    Figure US20100216809A1-20100826-C00632
    Figure US20100216809A1-20100826-C00633
    Figure US20100216809A1-20100826-C00634
    64 B8 N
    Figure US20100216809A1-20100826-C00635
    Figure US20100216809A1-20100826-C00636
    Figure US20100216809A1-20100826-C00637
    65 B7 N
    Figure US20100216809A1-20100826-C00638
    Figure US20100216809A1-20100826-C00639
    Figure US20100216809A1-20100826-C00640
  • TABLE 1b
    Figure US20100216809A1-20100826-C00641
    Co. No. X R1 R2 Salt
    66
    Figure US20100216809A1-20100826-C00642
    Figure US20100216809A1-20100826-C00643
    Figure US20100216809A1-20100826-C00644
    67
    Figure US20100216809A1-20100826-C00645
    Figure US20100216809A1-20100826-C00646
    Figure US20100216809A1-20100826-C00647
    68
    Figure US20100216809A1-20100826-C00648
    Figure US20100216809A1-20100826-C00649
    Figure US20100216809A1-20100826-C00650
    69
    Figure US20100216809A1-20100826-C00651
    Figure US20100216809A1-20100826-C00652
    Figure US20100216809A1-20100826-C00653
    70
    Figure US20100216809A1-20100826-C00654
    Figure US20100216809A1-20100826-C00655
    Figure US20100216809A1-20100826-C00656
    71*
    Figure US20100216809A1-20100826-C00657
    Figure US20100216809A1-20100826-C00658
    Figure US20100216809A1-20100826-C00659
    72
    Figure US20100216809A1-20100826-C00660
    Figure US20100216809A1-20100826-C00661
    Figure US20100216809A1-20100826-C00662
    73*
    Figure US20100216809A1-20100826-C00663
    Figure US20100216809A1-20100826-C00664
    Figure US20100216809A1-20100826-C00665
    74*
    Figure US20100216809A1-20100826-C00666
    Figure US20100216809A1-20100826-C00667
    Figure US20100216809A1-20100826-C00668
    75
    Figure US20100216809A1-20100826-C00669
    Figure US20100216809A1-20100826-C00670
    Figure US20100216809A1-20100826-C00671
    76*
    Figure US20100216809A1-20100826-C00672
    Figure US20100216809A1-20100826-C00673
    Figure US20100216809A1-20100826-C00674
    77
    Figure US20100216809A1-20100826-C00675
    Figure US20100216809A1-20100826-C00676
    Figure US20100216809A1-20100826-C00677
    78
    Figure US20100216809A1-20100826-C00678
    Figure US20100216809A1-20100826-C00679
    Figure US20100216809A1-20100826-C00680
    79
    Figure US20100216809A1-20100826-C00681
    Figure US20100216809A1-20100826-C00682
    Figure US20100216809A1-20100826-C00683
    80*
    Figure US20100216809A1-20100826-C00684
    Figure US20100216809A1-20100826-C00685
    Figure US20100216809A1-20100826-C00686
    81
    Figure US20100216809A1-20100826-C00687
    Figure US20100216809A1-20100826-C00688
    Figure US20100216809A1-20100826-C00689
    82
    Figure US20100216809A1-20100826-C00690
    Figure US20100216809A1-20100826-C00691
    Figure US20100216809A1-20100826-C00692
    83
    Figure US20100216809A1-20100826-C00693
    Figure US20100216809A1-20100826-C00694
    Figure US20100216809A1-20100826-C00695
    84
    Figure US20100216809A1-20100826-C00696
    Figure US20100216809A1-20100826-C00697
    Figure US20100216809A1-20100826-C00698
    85
    Figure US20100216809A1-20100826-C00699
    Figure US20100216809A1-20100826-C00700
    Figure US20100216809A1-20100826-C00701
    86
    Figure US20100216809A1-20100826-C00702
    Figure US20100216809A1-20100826-C00703
    Figure US20100216809A1-20100826-C00704
    87*
    Figure US20100216809A1-20100826-C00705
    Figure US20100216809A1-20100826-C00706
    Figure US20100216809A1-20100826-C00707
    88
    Figure US20100216809A1-20100826-C00708
    Figure US20100216809A1-20100826-C00709
    Figure US20100216809A1-20100826-C00710
    89
    Figure US20100216809A1-20100826-C00711
    Figure US20100216809A1-20100826-C00712
    Figure US20100216809A1-20100826-C00713
    90
    Figure US20100216809A1-20100826-C00714
    Figure US20100216809A1-20100826-C00715
    Figure US20100216809A1-20100826-C00716
    91
    Figure US20100216809A1-20100826-C00717
    Figure US20100216809A1-20100826-C00718
    Figure US20100216809A1-20100826-C00719
    92
    Figure US20100216809A1-20100826-C00720
    Figure US20100216809A1-20100826-C00721
    Figure US20100216809A1-20100826-C00722
    93*
    Figure US20100216809A1-20100826-C00723
    Figure US20100216809A1-20100826-C00724
    Figure US20100216809A1-20100826-C00725
    94
    Figure US20100216809A1-20100826-C00726
    Figure US20100216809A1-20100826-C00727
    Figure US20100216809A1-20100826-C00728
    95
    Figure US20100216809A1-20100826-C00729
    Figure US20100216809A1-20100826-C00730
    Figure US20100216809A1-20100826-C00731
    96
    Figure US20100216809A1-20100826-C00732
    Figure US20100216809A1-20100826-C00733
    Figure US20100216809A1-20100826-C00734
    97
    Figure US20100216809A1-20100826-C00735
    Figure US20100216809A1-20100826-C00736
    Figure US20100216809A1-20100826-C00737
    98*
    Figure US20100216809A1-20100826-C00738
    Figure US20100216809A1-20100826-C00739
    Figure US20100216809A1-20100826-C00740
    99
    Figure US20100216809A1-20100826-C00741
    Figure US20100216809A1-20100826-C00742
    Figure US20100216809A1-20100826-C00743
    100
    Figure US20100216809A1-20100826-C00744
    Figure US20100216809A1-20100826-C00745
    Figure US20100216809A1-20100826-C00746
    101
    Figure US20100216809A1-20100826-C00747
    Figure US20100216809A1-20100826-C00748
    Figure US20100216809A1-20100826-C00749
    102
    Figure US20100216809A1-20100826-C00750
    Figure US20100216809A1-20100826-C00751
    Figure US20100216809A1-20100826-C00752
    103
    Figure US20100216809A1-20100826-C00753
    Figure US20100216809A1-20100826-C00754
    Figure US20100216809A1-20100826-C00755
    104
    Figure US20100216809A1-20100826-C00756
    Figure US20100216809A1-20100826-C00757
    Figure US20100216809A1-20100826-C00758
    105
    Figure US20100216809A1-20100826-C00759
    Figure US20100216809A1-20100826-C00760
    Figure US20100216809A1-20100826-C00761
    106
    Figure US20100216809A1-20100826-C00762
    Figure US20100216809A1-20100826-C00763
    Figure US20100216809A1-20100826-C00764
    107*
    Figure US20100216809A1-20100826-C00765
    Figure US20100216809A1-20100826-C00766
    Figure US20100216809A1-20100826-C00767
    108
    Figure US20100216809A1-20100826-C00768
    Figure US20100216809A1-20100826-C00769
    Figure US20100216809A1-20100826-C00770
    109*
    Figure US20100216809A1-20100826-C00771
    Figure US20100216809A1-20100826-C00772
    Figure US20100216809A1-20100826-C00773
    110
    Figure US20100216809A1-20100826-C00774
    Figure US20100216809A1-20100826-C00775
    Figure US20100216809A1-20100826-C00776
    111*
    Figure US20100216809A1-20100826-C00777
    Figure US20100216809A1-20100826-C00778
    Figure US20100216809A1-20100826-C00779
    112
    Figure US20100216809A1-20100826-C00780
    Figure US20100216809A1-20100826-C00781
    Figure US20100216809A1-20100826-C00782
    113*
    Figure US20100216809A1-20100826-C00783
    Figure US20100216809A1-20100826-C00784
    Figure US20100216809A1-20100826-C00785
    114
    Figure US20100216809A1-20100826-C00786
    Figure US20100216809A1-20100826-C00787
    Figure US20100216809A1-20100826-C00788
    115
    Figure US20100216809A1-20100826-C00789
    Figure US20100216809A1-20100826-C00790
    Figure US20100216809A1-20100826-C00791
         		trifluoroacetate salt
    116
    Figure US20100216809A1-20100826-C00792
    Figure US20100216809A1-20100826-C00793
    Figure US20100216809A1-20100826-C00794
    117*
    Figure US20100216809A1-20100826-C00795
    Figure US20100216809A1-20100826-C00796
    Figure US20100216809A1-20100826-C00797
    *library compounds from third party
  • C. Analytical Part
  • LCMS
  • For LCMS-characterization of the compounds of the present invention, the following methods were used.
  • General Procedure A
  • The HPLC measurement was performed using an Alliance HT 2790 (Waters) system comprising a quaternary pump with degasser, an autosampler, a column oven (set at 40° C., unless otherwise indicated), a diode-array detector (DAD) and a column as specified in the respective methods below. Flow from the column was split to a MS detector. The MS detector was configured with an electrospray ionization source. Mass spectra were acquired by scanning from 100 to 1000 in 1 second using a dwell time of 0.1 second. The capillary needle voltage was 3 kV and the source temperature was maintained at 140° C. Nitrogen was used as the nebulizer gas. Data acquisition was performed with a Waters-Micromass MassLynx-Openlynx data system.
  • General Procedure B
  • The LC measurement was performed using an Acquity UPLC (Waters) system comprising a binary pump, a sample organizer, a column heater (set at 55° C.), a diode-array detector (DAD) and a column as specified in the respective methods below. Flow from the column was split to a MS detector. The MS detector was configured with an electrospray ionization source. Mass spectra were acquired by scanning from 100 to 1000 in 0.18 seconds using a dwell time of 0.02 seconds. The capillary needle voltage was 3.5 kV and the source temperature was maintained at 140° C. Nitrogen was used as the nebulizer gas. Data acquisition was performed with a Waters-Micromass MassLynx-Openlynx data system.
  • General Procedure C
  • The LCMS analyses for the compounds were done at the Surveyor MSQ™ (Thermo Finnigan, USA) comprising a photo diode array detector (PDA; 190-800 nm) and a column as specified in the respective methods below. Flow from the column was split to a MS spectrometer. The MS detector was configured with APCI (atmospheric pressure chemical ionization, +or −ions). Mass spectra were acquired by scanning from 45 to 1000 (of atomic mass unit) in 0.3 seconds. Typical APCI conditions use a corona discharge current of 10 μA and a cone voltage of 30 V. The APCI probe temperature was 640° C. Nitrogen was used as the nebulizer gas. Data acquisition was performed with an Xcalibur™ data system.
  • LCMS Procedure 1
  • In addition to general procedure A: Reversed phase HPLC was carried out on an Xterra MS C18 column (3.5 μm, 4.6×100 mm) with a flow rate of 1.6 ml/min. Three mobile phases (mobile phase A: 95% 25 mM ammoniumacetate+5% acetonitrile; mobile phase B: acetonitrile; mobile phase C: methanol) were employed to run a gradient condition from 100% A to 1% A, 49% B and 50 C in 6.5 minutes, to 1% A and 99% B in 1 minute and hold these conditions for 1 minute and reequilibrate with 100% A for 1.5 minutes. An injection volume of 10 μl was used. Cone voltage was 10 V for positive ionization mode and 20 V for negative ionization mode.
  • LCMS Procedure 2
  • In addition to general procedure A: Column heater was set at 60° C. Reversed phase HPLC was carried out on an Xterra MS C18 column (3.5 μm, 4.6×100 mm) with a flow rate of 1.6 ml/min. Three mobile phases (mobile phase A: 95% 25 mM ammoniumacetate+5% acetonitrile; mobile phase B: acetonitrile; mobile phase C: methanol) were employed to run a gradient condition from 100% A to 50% B and 50% C in 6.5 minutes, to 100% B in 0.5 minute and hold these conditions for 1 minute and reequilibrate with 100% A for 1.5 minutes. An injection volume of 10 μl was used. Cone voltage was 10 V for positive ionization mode and 20 V for negative ionization mode.
  • LCMS Procedure 3
  • In addition to general procedure A: Reversed phase HPLC was carried out on a Chromolith (4.6×25 mm) with a flow rate of 3 ml/min. Three mobile phases (mobile phase A: 95% 25 mM ammoniumacetate+5% acetonitrile; mobile phase B: acetonitrile; mobile phase C: methanol) were employed to run a gradient condition from 96% A, 2% B and 2% C, to 49% B and 49% C in 0.9 minutes, to 100% B in 0.3 minutes and hold for 0.2 minutes. An injection volume of 2 μl was used. Cone voltage was 10 V for positive ionization mode and 20 V for negative ionization mode.
  • LCMS Procedure 4
  • In addition to general procedure B: Reversed phase UPLC (Ultra Performance Liquid Chromatography) was carried out on a bridged ethylsiloxane/silica (BEH) C18 column (1.7 μm, 2.1×50 mm) with a flow rate of 0.8 ml/min. Two mobile phases (mobile phase A: 0.1% formic acid in H2O/methanol 95/5; mobile phase B: methanol) were used to run a gradient condition from 95% A and 5% B to 5% A and 95% B in 1.3 minutes and hold for 0.2 minutes. An injection volume of 0.5 μl was used. Cone voltage was 10 V for positive ionization mode and 20 V for negative ionization mode.
  • LCMS Procedure 5
  • In addition to general procedure C: Reversed phase HPLC was carried out on a Waters XTerra MS C18 column (3.5 μm, 2.1×30 mm) with a flow rate of 1.0 ml/min. Two mobile phases (mobile phase A: 0.1% aqueous solution of formic acid; mobile phase B: acetonitrile) were used. First, 100% A was hold for 0.1 minutes. Then a gradient was applied to 5% A and 95% B in 3 minutes and hold for 0.8 minutes. The injection volume was 1 The column was at room temperature.
  • Melting Points
  • For a number of compounds, melting points were determined with a DSC823e (Mettler-Toledo). Melting points were measured with a temperature gradient of 30° C/minute. Maximum temperature was 400° C. Values are peak values and are obtained with experimental uncertainties that are commonly associated with this analytical method.
  • For a number of compounds, melting points were determined by using a Gallenkamp apparatus from Sanyo Gallenkamp. The melting points determined in this way are indicated with ‘*’.
  • TABLE 2a
    LCMS and melting point analytical data (Rt: Retention time in minutes;
    [M + H]+ means the protonated mass of the compound, LCMS procedure
    refers to the method used for LCMS).
    Comp. Nr. Rt [M + H]+ LCMS Procedure Melting point (° C.)
    1 1.28 560 4 n.d.
    9 1.15 498 4 n.d.
    8 1.26 497 4 n.d.
    27 1.36 559 4 n.d.
    2 6.23 520 1 163.4
    6 5.81 537 1 207.9
    10 6.10 506 1 191.4
    24 5.96 615 1 n.d.
    4 5.36 473 2 135.5
    5 6.23 657 1 n.d.
    25 0.89 489 3 165.7
    3 5.96 525 2 203.2
    22 5.33 507 2 209.4
    19 5.89 513 2 179.3
    23 5.46 521 2 181.0
    26 5.15 475 1 194.1
    20 5.57 533 2 220.3
    7 4.98 474 2 215.0
    11 5.99 586 2 249.8
    12 5.96 498 2 n.d.
    14 6.60 504 1 222.3
    13 6.22 520 1 167.3
    15 5.44 472 2 183.2
    21 6.04 511 2 247.7
    16 6.61 484 1 193.8
    17 5.43 598 2 n.d.
    18 5.27 522 2 n.d.
    28 5.67 521 1 174.8
    29 5.24 537 2 185.4
    30 5.97 535 1 181.9
    31 5.70 522 2 189.4
    32 5.26 473 2 175.2
    33 6.59 536 1 146.3
    34 6.18 508 1 180.1
    35 5.44 508 2 201.0
    36 5.52 474 2 181.9
    38 5.75 474 1 214.0
    39 6.28 474 1 209.3
    40 4.94 459 2 186.7
    41 6.04 534 2 137.3
    42 4.34 418 1 n.d.
    43 n.d. n.d. — n.d.
    44 1.94 550 5 177-178*
    45 5.17 537 2 173.9
    46 1.85 552 5 100-105*
    47 4.89 459 2 202.5
    48 1.89 536 5 200-201*
    49 4.87 432 1 235.0
    50 1.85 522 5 180-181*
    51 4.39 531 2 n.d.
    52 6.83 547 1 290.5
    53 5.26 507 2 n.d.
    54 5.78 615 1 231.7
    55 5.32 643 2 208.4
    56 5.09 629 2 160.2
    57 1.83 550 5 147-148*
    58 4.77 581 2 n.d.
    59 1.91 564 5 189-191*
    60 n.d. n.d. — 172.8
    61 1.85 536 5 165-167*
    62 1.95 550 5 207-209*
    63 2.01 578 5 194-195*
    64 n.d. n.d. — 235.3
    65 2.07 592 5 148-149*
    66 1.19 498 4 n.d.
    67 1.19 464 4 n.d.
    68 1.31 560 4 n.d.
    69 1.30 498 4 n.d.
    70 1.32 526 4 n.d.
    71 1.51 474 4 n.d.
    72 1.20 480 4 n.d.
    73 1.48 500 4 n.d.
    74 1.37 438 4 n.d.
    75 1.40 560 4 n.d.
    76 1.49 466 4 n.d.
    77 1.32 542 4 n.d.
    78 0.88 473 4 n.d.
    79 1.06 535 4 n.d.
    80 1.41 482 4 n.d.
    81 1.19 444 4 n.d.
    82 1.11 460 4 n.d.
    83 1.30 522 4 n.d.
    84 1.17 460 4 n.d.
    85 1.20 444 4 n.d.
    86 1.21 476 4 n.d.
    87 1.25 415 4 n.d.
    88 1.26 480 4 n.d.
    89 1.14 444 4 n.d.
    90 1.14 460 4 n.d.
    91 1.13 515 4 n.d.
    92 1.11 474 4 n.d.
    93 1.32 429 4 n.d.
    94 1.26 522 4 n.d.
    95 1.27 492 4 n.d.
    96 1.18 456 4 n.d.
    97 1.16 549 4 n.d.
    98 1.25 442 4 n.d.
    99 1.25 536 4 n.d.
    101 1.14 430 4 n.d.
    102 1.28 506 4 n.d.
    103 1.26 577 4 n.d.
    104 1.16 429 4 n.d.
    105 1.32 506 4 n.d.
    106 0.99 473 4 n.d.
    107 1.34 441 4 n.d.
    108 1.30 491 4 n.d.
    109 1.45 492 4 n.d.
    110 1.34 505 4 n.d.
    111 1.29 441 4 n.d.
    112 1.24 464 4 n.d.
    113 1.44 481 4 n.d.
    115 1.07 474 4 n.d.
    116 1.35 526 4 n.d.
    117 1.38 467 4 n.d.
    n.d. = not determined
  • TABLE 2b
    LCMS analytical data - Rt means retention time (in minutes),
    [M − H]− means the deprotonated mass of the compound
    (negative mode), LCMS procedure refers to the method used for LCMS.
    Comp. LCMS Melting
    Nr. Rt [M − H]− procedure point (° C.)
    37 6.46 492 1 232.4
  • D. Pharmacological Example
  • A) Measurement of Inhibition of DGAT1 Activity by the Present Compounds
  • The inhibiting activity of the present compounds on DGAT1 activity was screened in a single well procedure assay using DGAT1 comprising membrane preparations and DGAT1 substrate comprising micelles and determining formed radio-active triacylglycerol coming in close proximity of a flashplate surface by radio luminescence.
  • Said assay is described in full detail in WO2006/067071, the content of which is incorporated herein by reference.
  • By DGAT1 activity is meant the transfer of coenzyme A activated fatty acids to the 3-position of 1,2-diacylglycerols, thus forming a triglyceride molecule, by enzyme DGAT1.
  • Step 1 if the Assay: Expression of DGAT1
  • human DGAT1 (NM012079.2) was cloned into the pFastBac vector, containing translation start, a FLAG-tag at the N-terminus as described in literature and a viral Kozak sequence (AAX) preceding the ATG to improve expression in insect cells. Expression was done as described in literature (Cases, S., Smith, S. J., Zheng, Y., Myers H. M., Lear, S. R., Sande, E., Novak, S., Collins, C., Welch, C. B., Lusis, A. J., Erickson, S. K. and Farese, R. V. (1998) Proc. Natl. Acad. Sci. USA 95, 13018-13023.) using SF9 cells.
  • Step 2 of the Assay: Preparation of DGAT1 Membranes
  • 72 h transfected SF9 cells were collected by centrifugation (13000 rpm-15 min-4° C.) and lysed in 2×500 ml lysisbuffer (0.1M Sucrose, 50 mM KCl, 40 mM KH2PO4, 30 mM EDTA pH 7.2. Cells were homogenized by cell disruptor. After centrifugation 1380 rpm-15min-4° C. (SN discarded), pellet was resuspended in 500 ml lysisbuffer and total cell membranes collected by ultracentrifugation at 34000rpm(100 000 g) for 60 min (4° C.). The collected membranes were resuspended in lysis buffer, divided in aliquots and stored with 10% glycerol at -80° C. until use.
  • Step 3 of the Assay: Preparation of DGAT Substrate Comprising Micelles Materials
  • a) 1,2-dioleoyl-sn-glycerol, 10 mg/ml (1,2-diacylglycerol (DAG))
      • Dissolve in acetonitrile; evaporate the acetonitrile solution under nitrogen and reconstitute in chloroform at a final concentration of 10 mg/ml.
  • b) L-α-phosphatidylcholine, 1 mg/ml (phosphatidylcholine (PC))
      • Dissolve in chloroform at a final concentration of 1 mg/ml and store at 4° C.
  • c) L-α-phosphatidyl-L-serine, 1 mg/ml (phophatidylserine (PS))
      • Dissolve in chloroform at a final concentration of 1 mg/ml and store at 4° C.
  • Method
  • Add 1 ml dioleoyl-sn-glycerol (10 mg/ml) to 10 ml of L-α-phosphatidylcholine (1 mg/ml) and 10 ml of L-α-phosphatidyl-L-serine (1 mg/ml) in a thick glass recipient. Evaporate under nitrogen and put on ice for 15 minutes. Reconstitute in 10 ml Tris/HCl (10 mM, pH 7.4) by sonication on ice. The sonification process consists of sonification cycles of 10 seconds in the sonification bath followed by 10 seconds cool down on ice and repeating this sonification cycle till a homogeneous solution is obtained (takes about 15 minutes). The thus obtained micelles are stored at -20° C. till later use and contain DAG at a final concentration of 1.61 mM.
  • Step 4 of the Assay: DGAT FlashPlate™ Assay
  • Materials
  • a) Assaybuffer
      • 50 mM Tris-HCl (pH 7.4), 150 mM MgCl2, 1 mM EDTA, 0.2% BSA.
  • b) N-ethylmaleimide, 5M
      • Dissolve 5 g into a final volume of 8 ml DMSO 100% and store at −20° C. in aliquots till later use.
  • c) Substrate mix (for 1 384 well plate=3840 μl)
      • 612 μl micelles stock (5104 final)
      • 16.6 μl oleoylCoA 9.7mM
      • 23 μl [3H]-oleoylCoA (49 Ci/mmol, 500 μCi./ml)
      • 3188.4 μl Tris pH 7.4, 10 mM
  • d) Enzyme mix (for 1 384 well plate=3520 μl) (5 μg/ml)
      • Add 11.73 μl of DGAT membrane stock (1500 μg/ml stock) to 3508 μl assay buffer.
  • e) Stop mix (for 1 384 well plate=7.68 ml) (250 mM)
      • Add 384 μl of N-ethylmaleimide (5M) to 3.456 ml DMSO 100%, and further dilute 3.84 ml of said solution with 3.84 ml DMSO 10%.
  • Method
  • DGAT activity in membrane preparations was assayed in 50 mM Tris-HCl (pH 7.4), 150 mM MgCl2, 1 mM EDTA and 0.2% BSA, containing 50 μM DAG, 32 μg/ml PC/PS and 8.4 μM [3H]-oleoylCoA (at a specific activity of 30 nCi/well) in a final volume of 50 μl in 384-well format using the red shifted Basic Image FlashPlate™ (Perkin Elmer Cat.No. SMP400).
  • In detail, 10 μl enzyme mix and 10 μl substrate mix were added to 30 μl of assay buffer, optionally in the presence of 1 μl DMSO (blank and controls) or 1 μl of the compound to be tested. This reaction mixture was incubated for 120 minutes at 37° C. and the enzymatic reaction stopped by adding 20 μl of the stop mix. The plates were sealed and the vesicles allowed to settle overnight at room temperature. Plates were centrifuged for 5 minutes at 1500 rpm and measured in Leadseeker. Experiments with different concentrations of the test compound were performed and curves were calculated and drawn based on % CTRLmin (% of normalized control).
  • % CTRLmin was calculated according to equation 1,

  • % CTRLmin=(sample−LC)/(HC−LC)   Equation 1:
  • where HC (high control) refers to the median of radioluminescence value measured in the wells with enzyme and substrate but without test compound, LC (low control) refers to median background radioluminescence value measured in the wells with substrate without enzyme and without test compound, and sample refers to the radio luminescence value measured in the wells with substrate, enzyme and test compound at a particular concentration.
  • The calculated % CTRLmin values form a sigmoidal dose response descending curve and from this curve pIC50 values were calculated (−logIC50 where IC50 represents the concentration at which the test compound gives 50% inhibition of DGAT1 activity). Table 3 shows the pIC5O values for the compounds of formula (I).
  • In order to determine selectivity of the present compounds for DGAT1 compared to DGAT2, the inhibiting activity of the compounds on DGAT2 was also determined in the above assay, slightly modified to obtain optimal assay conditions for DGAT2. The tested compounds did not show inhibiting activity for DGAT2 (Human DGAT2 (NM032564) was cloned and expressed as described in J. Biolog. Chem. 276(42), pp 38870-38876 (2001)).
  • TABLE 3
    pIC50 values (IC50 values expressed in M)
    pIC50 pIC50
    Co. (mean if tested Co. (mean if tested
    No. more than once) No. more than once)
    7 5.61 15 5.31
    26 5.74 18 5.05
    25 6.13 10 6.50
    6 6.52 13 5.46
    20 5.88 2 6.96
    3 6.30 23 5.93
    19 5.99 22 6.00
    21 5.24 4 6.39
    17 5.17 9 8.19
    11 5.71 8 7.52
    16 5.19 1 8.05
    14 5.46 27 6.92
    12 5.55 24 6.35
    5 6.18 36 6.82
    45 6.03 61 6.82
    29 7.51 62 6.47
    42 6.13 31 7.39
    47 5.77 58 7.33
    30 7.49 56 7.76
    41 6.22 53 7.91
    32 7.08 60 7.01
    40 6.39 55 7.82
    115 5.05 64 5.92
    70 6.74 43 6.12
    103 5.38 93 5.46
    79 5.74 74 6.02
    99 5.42 117 5.04
    108 5.31 107 5.32
    95 5.45 80 5.69
    105 5.36 113 5.09
    94 5.45 76 5.87
    116 5.04 73 6.04
    83 5.51 109 5.27
    97 5.44 71 6.10
    96 5.45 98 5.43
    102 5.39 111 5.12
    110 5.14 87 5.48
    77 5.86 54 7.88
    68 6.89 114 5.07
    75 5.94 67 7.07
    49 5.73 112 5.10
    33 6.98 66 7.10
    44 6.03 90 5.47
    48 5.76 85 5.50
    46 5.93 92 5.47
    50 5.71 89 5.47
    39 6.40 78 5.79
    37 6.76 84 5.50
    28 7.60 82 5.54
    38 6.56 81 5.58
    51 5.52 86 5.48
    35 6.84 91 5.47
    34 6.85 106 5.33
    63 6.12 88 5.48
    57 7.63 72 6.08
    65 5.81 101 5.39
    59 7.13 69 6.78
    100 5.40 52 n.d.
    104 5.37
  • B) In vivo Study for Effect of Test Compound on GLP-1 Plasma Levels
  • Elevation of GLP-1 plasma levels by a DGAT inhibitor can be studied as follows:
  • Dogs are deprived from food for a period of 22 hours. At time 0, animals are given a liquid meal, containing 18% fat (w/w), by gavage with a stomach tube. The test compound is given orally together with the meal. Afterwards, a postprandial plasma profile is determined for GLP-1. Therefore, blood is collected at predetermined time intervals in ice-cooled Vacutainers EDTA-plasma tubes and GLP-1 levels are measured in the samples taken at 0 hour (just before the meal) and at 0.5, 1, 2, 4, 6, 8 and 24 hours after dosing. Six dogs (3 males and 3 females) are included per dosage group and the plasma GLP-1 profile is compared with their own GLP-1 profile previously determined in the same conditions but without administration of the test compound.
  • GLP-1 determinations in plasma are performed with a Glucagon-like peptide-1 (active) ELISA kit 96-well plate of LINCO Research.
  • E. Composition Examples
  • “Active ingredient” (a.i.) as used throughout these examples relates to a compound of formula (I), including any stereochemically isomeric form thereof, a N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof; in particular to any one of the exemplified compounds.
  • Typical examples of recipes for the formulation of the invention are as follows:
  • 1. Tablets
  •
    Active ingredient 5 to 50 mg
    Di-calcium phosphate 20 mg
    Lactose 30 mg
    Talcum 10 mg
    Magnesium stearate 5 mg
    Potato starch ad 200 mg
  • 2. Suspension
  • An aqueous suspension is prepared for oral administration so that each milliliter contains 1 to 5 mg of active ingredient , 50 mg of sodium carboxymethyl cellulose, 1 mg of sodium benzoate, 500 mg of sorbitol and water ad 1 ml.
  • 3. Injectable
  • A parenteral composition is prepared by stirring 1.5% (weight/volume) of active ingredient in 0.9% NaCl solution.
  • 4. Ointment
  •
    Active ingredient 5 to 1000 mg
    Stearyl alcohol 3 g
    Lanoline 5 g
    White petroleum 15 g
    Water ad 100 g

Claims (21)

1. A compound of formula
Figure US20100216809A1-20100826-C00798
including any stereochemically isomeric form thereof, wherein
A represents CH or N;
the dotted line represents an optional bond in case A represents a carbon atom;
X represents —NRx—C(═O)—; —Z—C(═O)—; or —Z—NRx—C(═O)—;
Z represents a bivalent radical selected from C1-6alkanediyl;
Rx represents hydrogen or C1-4alkyl;
R1 represents a 5-membered monocyclic heterocycle containing at least 2 heteroatoms; a 6-membered aromatic monocyclic heterocycle; or a 5-membered heterocycle containing at least 2 heteroatoms fused with phenyl, cyclohexyl or a 5- or 6-membered heterocycle; wherein each of said heterocycles may optionally be substituted with at least one substituent, each substituent independently being selected from the group consisting of hydroxyl; oxo; carboxyl; halo; C1-6alkyl optionally substituted with carboxyl, C1-4alkyloxycarbonyl or aryl-C(═O)—; hydroxyC1-6alkyl optionally substituted with aryl or aryl-C(═O)—; polyhaloC1-6alkyl; C1-6alkyloxy optionally substituted with C1-4alkyloxy;
C1-6alkylthio; polyhaloC1-6alkyloxy; C1-6alkyloxy-carbonyl wherein C1-6alkyl may optionally be substituted with aryl; cyano; aminocarbonyl; mono-or di(C1-4alkyl)-aminocarbonyl; C1-6alkylcarbonyl; amino; mono-or di(C1-6alkyl)amino;
R5R4N—C1-6alkyl; C3-6cycloalkyl-NRx—; aryl-NRx—; Het-NRx—; C3-6cycloalkyl-C1-4alkyl-NRx—; arylC1-4alkyl-NRx—; HetC1-4alkyl-NRx—;—S(═O)p—C1-4alkyl;
C3-6cycloalkyl; C3-6cycloalkylC1-4alkyl; C3-6cycloalkyl-C(═O)—; aryl; aryloxy; arylC1-4alkyl; aryl-C(═O)—; aryl-C(═O)—C1-4alkyl; Het; HetC1-4alkyl; Het-C(═O)—; Het-C(═O)—C1-4alkyl; and Het-O—;
R2 represents R3;
R3 represents C3-6cycloalkyl, phenyl, naphtalenyl, 2,3-dihydro-1,4-benzodioxinyl, 1,3-benzodioxolyl, 2,3-dihydrobenzofuranyl or a 6-membered aromatic heterocycle containing 1 or 2 N atoms, wherein said C3-6cycloalkyl, phenyl, naphtalenyl,
2,3-dihydro-1,4-benzodioxinyl, 1,3-benzodioxolyl, 2,3-dihydrobenzofuranyl or 6-membered aromatic heterocycle may optionally be substituted with at least one substituent, each substituent independently selected from the group consisting of hydroxyl; carboxyl; halo; C1-6alkyl optionally substituted with hydroxy; polyhaloC1-6alkyl; C1-6alkyloxy optionally substituted with C1-4alkyloxy; C1-6alkylthio; polyhalo-C1-6alkyloxy; C1-6alkyloxycarbonyl wherein C1-6alkyl may optionally be substituted with aryl; cyano; C1-6alkylcarbonyl; nitro; amino; mono-or di(C1-4alkyl)amino; C1-4alkylcarbonylamino;
—S(═O)p—C1-4alkyl; R5R4N—C(═O)—; R5R4N—C1-6alkyl; C3-6cycloalkyl-C1-4alkyl; C3-6cycloalkyl-C(═O)—; aryl; aryloxy; arylC1-4alkyl; aryl-C(═O)—C1-4alkyl;
aryl-C(═O)—; Het; HetC1-4alkyl; Het-C(═O)—C1-4alkyl; Het-C(═O)—; and Het-O—;
R4 represents hydrogen; C1-4alkyl optionally substituted with hydroxyl or C1-4alkyloxy;
R7R6N—C1-4alkyl; C1-4alkyloxy; Het; aryl; or R7R6N—C(═O)—C1-4alkyl;
R5 represents hydrogen or C1-4alkyl;
R6 represents hydrogen; C1-4alkyl; or C1-4alkylcarbonyl;
R7 represents hydrogen or C1-4alkyl; or
R6 and R7 may be taken together with the nitrogen to which they are attached to form a saturated monocyclic 5, 6 or 7-membered heterocycle which may further contain one or more heteroatoms selected from the group consisting of O, S, S(═O)p and N; and which heterocycle may optionally be substituted with C1-4alkyl;
R8 represents hydrogen, halo; C1-4alkyl; or C1-4alkyl substituted with hydroxyl;
aryl represents phenyl or phenyl substituted with at least one substituent, each substituent independently being selected from the group consisting of hydroxyl; carboxyl;
halo; C1-6alkyl optionally substituted with
C1-4alkyloxy, amino or mono-or di(C1-4alkyl)amino; polyhaloC1-6alkyl;
C1-6alkyloxy optionally substituted with C1-4alkyloxy; C1-6alkylthio;
polyhaloC1-6alkyloxy; C1-6alkyloxycarbonyl; cyano; aminocarbonyl; mono-or
di(C1-4alkyl)aminocarbonyl; C1-6alkylcarbonyl; nitro; amino; mono-or
di(C1-4alkyl)amino; and —S(═O)p—C1-4alkyl;
Het represents a monocyclic non-aromatic or aromatic heterocycle containing at least one heteroatom selected from the group consisting of O, S, S(═O)p and N;
or a bicyclic or tricyclic non-aromatic or aromatic heterocycle containing at least one heteroatom selected from the group consisting of O, S, S(═O)p and N; said monocyclic heterocycle or said bi-or tricyclic heterocycle optionally being substituted with at least one substituent, each substituent independently being selected from hydroxyl; oxo; carboxyl; halo; C1-6alkyl optionally substituted with C1-4alkyloxy, amino or mono-or di(C1-4alkyl)amino; polyhaloC1-6alkyl; C1-6alkyloxy optionally substituted with C1-4alkyloxy; C1-6alkylthio; polyhaloC1-6alkyloxy; C1-6alkyl-oxycarbonyl; cyano; aminocarbonyl; mono-or di(C1-4alkyl)aminocarbonyl; C1-6alkylcarbonyl; nitro; amino; mono-or di(C1-4alkyl)amino; and —S(═O)p—C1-4alkyl
p represents 1 or 2;
a N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof;
provided that the following compounds
Figure US20100216809A1-20100826-C00799
 X R1 R2
Figure US20100216809A1-20100826-C00800
Figure US20100216809A1-20100826-C00801
Figure US20100216809A1-20100826-C00802
Figure US20100216809A1-20100826-C00803
Figure US20100216809A1-20100826-C00804
Figure US20100216809A1-20100826-C00805
Figure US20100216809A1-20100826-C00806
Figure US20100216809A1-20100826-C00807
Figure US20100216809A1-20100826-C00808
Figure US20100216809A1-20100826-C00809
Figure US20100216809A1-20100826-C00810
Figure US20100216809A1-20100826-C00811
Figure US20100216809A1-20100826-C00812
Figure US20100216809A1-20100826-C00813
Figure US20100216809A1-20100826-C00814
Figure US20100216809A1-20100826-C00815
Figure US20100216809A1-20100826-C00816
Figure US20100216809A1-20100826-C00817
Figure US20100216809A1-20100826-C00818
Figure US20100216809A1-20100826-C00819
Figure US20100216809A1-20100826-C00820
Figure US20100216809A1-20100826-C00821
Figure US20100216809A1-20100826-C00822
Figure US20100216809A1-20100826-C00823
Figure US20100216809A1-20100826-C00824
Figure US20100216809A1-20100826-C00825
Figure US20100216809A1-20100826-C00826
Figure US20100216809A1-20100826-C00827
Figure US20100216809A1-20100826-C00828
Figure US20100216809A1-20100826-C00829
Figure US20100216809A1-20100826-C00830
Figure US20100216809A1-20100826-C00831
Figure US20100216809A1-20100826-C00832
Figure US20100216809A1-20100826-C00833
Figure US20100216809A1-20100826-C00834
Figure US20100216809A1-20100826-C00835
Figure US20100216809A1-20100826-C00836
Figure US20100216809A1-20100826-C00837
Figure US20100216809A1-20100826-C00838
are excluded; and
provided that
Figure US20100216809A1-20100826-C00839
a stereochemically isomeric form thereof, a N-oxide thereof, a pharmaceutically acceptable salt thereof, or a solvate thereof;
are excluded.
2. The compound as claimed in claim 1 having the following formula
Figure US20100216809A1-20100826-C00840
including any stereochemically isomeric form thereof, wherein
A represents CH or N;
the dotted line represents an optional bond in case A represents a carbon atom;
X represents —NRx—C(═O)—; —Z—C(═O)—; or —Z—NRx—C(═O)—;
Z represents a bivalent radical selected from C1-6alkanediyl;
R1 represents a 5-membered monocyclic heterocycle containing at least 2 heteroatoms; a 6-membered aromatic monocyclic heterocycle; or a 5-membered heterocycle containing at least 2 heteroatoms fused with phenyl, cyclohexyl or a 5- or 6-membered heterocycle; wherein each of said heterocycles may optionally be substituted with at least one substituent, each substituent independently being selected from the group consisting of hydroxyl; oxo; carboxyl; halo; C1-6alkyl optionally substituted with aryl-C(═O)-; hydroxyC1-6alkyl optionally substituted with aryl or aryl-C(═O)—;
polyhaloC1-6alkyl; C1-6alkyloxy optionally substituted with C1-4alkyloxy; C1-6alkylthio; polyhaloC1-6alkyloxy;
C1-6alkyloxy-carbonyl wherein C1-6alkyl may optionally be substituted with aryl;
cyano; aminocarbonyl; mono-or di(C1-4alkyl)aminocarbonyl; C1-6alkylcarbonyl;
nitro; amino; mono-or di(C1-6alkyl)amino; C3-6cycloalkyl-NRx—; aryl-NRx—;
Het-NRx—; C3-6cycloalkylC1-4alkyl-NRx—; arylC1-4alkyl-NRx—; HetC1-4alkyl-NRx—;
—S(═O)p—C1-4alkyl; C3-6cycloalkyl; C3-6cycloalkylC1-4alkyl; C3-6cycloalkyl-C(=O)—;
aryl; aryloxy; arylC1-4alkyl; aryl-C(═O)—; Het; HetC1-4alkyl; Het-C(═O)—; and Het-O—;
R2 represents R3;
R3 represents C3-6cycloalkyl, phenyl, naphtalenyl, 2,3-dihydro-1,4-benzodioxinyl, 1,3-benzodioxolyl, wherein said C3-6cycloalkyl, phenyl, naphtalenyl, 2,3-dihydro-1,4-benzodioxinyl, 1,3-benzodioxolyl may optionally be substituted with at least one substituent, each substituent independently selected from the group consisting of hydroxyl;
carboxyl; halo; C1-6alkyl optionally substituted with hydroxy; polyhaloC1-6alkyl; C1-6 alkyloxy optionally substituted with C1-4alkyloxy; C1-6alkylthio; polyhalo-C1-6alkyloxy;
C1-6alkyloxycarbonyl wherein C1-6alkyl may optionally be substituted with aryl;
cyano; C1-6alkylcarbonyl; nitro; amino; mono-or di(C1-4alkyl)amino;
—S(═O)p—C1-4alkyl; R5R4N—C(═O)—; R5R4N—C1-6alkyl; C3-6cycloalkyl;
C3-6cycloalkylC1-4alkyl; C3-6cycloalkyl-C(═O)—; aryl; aryloxy; arylC1-4alkyl;
aryl-C(═O)—; Het; HetC1-4alkyl; Het-C(═O)—; and Het-O—;
R4 represents hydrogen; C1-4alkyl optionally substituted with hydroxyl or C1-4alkyloxy;
R7R6N—Ci-4alkyl; C1-4alkyloxy; Het; aryl; or R7R6N—C(═O)—C1-4alkyl;
R5 represents hydrogen or C1-4alkyl;
R6 represents hydrogen; C1-4alkyl; or C1-4alkylcarbonyl;
R7 represents hydrogen or C1-4alkyl; or
R6 and R7 may be taken together with the nitrogen to which they are attached to form a saturated monocyclic 5, 6 or 7-membered heterocycle which may further contain one or more heteroatoms selected from the group consisting of O, S, S(═O)p and N; and which heterocycle may optionally be substituted with C1-4alkyl;
aryl represents phenyl or phenyl substituted with at least one substituent, each substituent independently being selected from hydroxyl; carboxyl; halo; C1-6alkyl optionally substituted with
C1-4alkyloxy, amino or mono-or di(C1-4alkyl)amino; polyhaloC1-6alkyl;
C1-6alkyloxy optionally substituted with C1-4alkyloxy; C1-6alkylthio;
polyhaloC1-6alkyloxy; C1-6alkyloxycarbonyl; cyano; aminocarbonyl; mono-or
di(C1-4alkyl)aminocarbonyl; C1-6alkylcarbonyl; nitro; amino; mono-or
di(C1-4alkyl)amino; and —S(═O)p—C1-4alkyl;
Het represents a monocyclic non-aromatic or aromatic heterocycle containing at least one heteroatom selected from the group consisting of O, S, S(═O)p and N;
or a bicyclic or tricyclic non-aromatic or aromatic heterocycle containing at least one heteroatom selected from the group consisting of O, S, S(═O)p and N; said monocyclic heterocycle or said bi-or tricyclic heterocycle optionally being substituted with at least one substituent, each substituent independently being selected from the group consisting of hydroxyl; oxo; carboxyl; halo; C1-6alkyl optionally substituted with C1-4alkyloxy, amino or mono-or di(C1-4alkyl)amino; polyhaloC1-6alkyl; C1-6alkyloxy optionally substituted with C1-4alkyloxy; C1-6alkylthio; polyhaloC1-6alkyloxy; C1-6alkyl-oxycarbonyl; cyano; aminocarbonyl; mono-or di(C1-4alkyl)aminocarbonyl;
C1-6alkylcarbonyl; nitro; amino; mono-or di(C1-4alkyl)amino; and —S(═O)p—C1-4alkyl;
p represents 1 or 2;
a N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof.
3. The compound as claimed in claim 1 wherein A represents N.
4. The compound as claimed in claim 1 wherein R1 represents an optionally substituted 5-membered monocyclic heterocycle containing at least 2 heteroatoms.
5. The compound as claimed in claim 1 wherein R1 represents an optionally substituted 6-membered aromatic monocyclic heterocycle.
6. The compound as claimed in claim 1 wherein R1 represents an optionally substituted 5-membered heterocycle containing at least 2 heteroatoms fused with a 5-membered heterocycle.
7. The compound as claimed in claim 1 wherein the compound has the following formula
Figure US20100216809A1-20100826-C00841
wherein R3a and R3b each independently represent hydrogen; hydroxyl; carboxyl;
halo; C1-6alkyl optionally substituted with hydroxyl; polyhaloC1-6alkyl; C1-6alkyloxy optionally substituted with C1-4alkyloxy; C1-6alkylthio; polyhaloC1-6alkyloxy;
C1-6alkyloxycarbonyl; cyano; aminocarbonyl; mono-or di(C1-4alkyl)aminocarbonyl;
C1-6alkylcarbonyl; nitro; amino; mono-or di(C1-4alkyl)amino; C1-4alkylcarbonylamino;
or —S(═O)p—C1-4alkyl; and wherein R3c represents hydrogen; hydroxyl; carboxyl; halo;
C1-6alkyl; polyhaloC1-6alkyl; C1-6alkyloxy optionally substituted with C1-4alkyloxy;
C1-6alkylthio; polyhalo-C1-6alkyloxy; C1-6alkyloxycarbonyl wherein C1-6alkyl may optionally be substituted with aryl; cyano; C1-6alkylcarbonyl; nitro; amino; mono-or di(C1-4alkyl)amino; —S(═O)p—C1-4alkyl; R5R4N—C(═O)—; R5R4N'C1-6alkyl;
C3-6cycloalkyl; aryl; aryloxy; arylC1-4alkyl; aryl-C(═O)—; Het; HetC1-4alkyl;
Het-C(═O)—; or Het-O—.
8. The compound as claimed in claim 1 wherein the compound has the following formula
Figure US20100216809A1-20100826-C00842
wherein R3a and R3b each independently represent hydrogen; hydroxyl; carboxyl;
halo; C1-6alkyl; polyhaloC1-6alkyl; C1-6alkyloxy optionally substituted with C1-4alkyloxy;
C1-6alkylthio; polyhaloC1-6alkyloxy; C1-6alkyloxycarbonyl; cyano; aminocarbonyl;
mono-or di(C1-4alkyl)aminocarbonyl; C1-6alkylcarbonyl; nitro; amino; mono-or di(C1-4alkyl)amino; or —S(═O)p—C1-4alkyl; and wherein R3c represents hydrogen;
hydroxyl; carboxyl; halo; C1-6alkyl optionally substituted with hydroxyl; polyhaloC1-6alkyl;
C1-6alkyloxy optionally substituted with C1-4alkyloxy; C1-6alkylthio; polyhalo-C1-6alkyloxy; C1-6alkyloxycarbonyl wherein C1-6alkyl may optionally be substituted with aryl; cyano; C1-6alkylcarbonyl; nitro; amino; mono-or di(C1-4alkyl)amino;
C1-4alkylcarbonylamino; —S(═O)p—C1-4alkyl; R5R4N—C(═O)—; R5R4N—C1-6alkyl;
C3-6cycloalkyl; aryl; aryloxy; arylC1-4alkyl; aryl-C(═O)—; Het; HetC1-4alkyl;
Het-C(═O)—; or Het-O—.
9. The compound as claimed in claim 7 wherein R3a and R3b each independently represent halo or C1-6alkyl.
10. The compound as claimed in claim 7 wherein both R3a and R3b represent halo.
11. The compound as claimed in claim 7 wherein R3c represents HetC1-4alkyl.
12. The compound as claimed in claim 1 wherein R8 represents hydrogen.
13. The compound as claimed in claim 1 wherein the dotted line does not represents a bond in case A represents a carbon atom; Rx represents hydrogen; R1 represents a 5-membered monocyclic heterocycle containing at least 2 heteroatoms; a 6-membered aromatic monocyclic heterocycle; or a 5-membered heterocycle containing at least 2 heteroatoms fused with a 5-membered heterocycle;
wherein each of said heterocycles may optionally be substituted with one or two substituents, each substituent independently being selected from the group consisting of oxo; C1-6alkyl optionally substituted with C1-4alkyl-oxycarbonyl; hydroxyC1-6alkyl optionally substituted with aryl; mono-or di(C1-6alkyl)-amino; R5R4N-C1-6alkyl; Het-NRx—; arylC1-4alkyl-NRx—; C3-6cycloalkyl; C3-6cyclo-alkyl C1-4alkyl; aryl; arylC1-4alkyl; aryl-C(═O)—C1-4alkyl; and Het; R3 represents C3-6cyclo-alkyl, phenyl, naphtalenyl, 1,3-benzodioxolyl, or a 6-membered aromatic heterocycle containing 1 or 2 N atoms, wherein said C3-6cycloalkyl, phenyl, naphtalenyl, 1,3-benzodioxolyl or 6-membered aromatic heterocycle may optionally be substituted with one or two substituents, each substituent independently selected from the group consisting of hydroxyl; carboxyl; halo; C1-6alkyl optionally substituted with hydroxy;
polyhaloC1-6alkyl;
C1-6alkyloxy; C1-6alkylthio; C1-6alkyloxycarbonyl; mono-or di(C1-4alkyl)amino;
C1-4alkylcarbonylamino; Het; and HetC1-4alkyl; R4 represents hydrogen or C1-4alkyl;
R5 represents hydrogen or C1-4alkyl; R5 represents hydrogen; aryl represents phenyl or phenyl substituted with at least one substituent, said substituent being selected from the group consisting of halo; C1-6alkyl; and C1-6alkyloxy; Het represents a monocyclic non-aromatic or aromatic heterocycle containing at least one heteroatom selected from the group consisting of O, S, S(═O)p and N; said monocyclic heterocycle optionally being substituted with C1-6alkyloxycarbonyl.
14. The compound as claimed in claim 1 wherein the compound is selected from
Figure US20100216809A1-20100826-C00843
 A X R1 Rq N
Figure US20100216809A1-20100826-C00844
Figure US20100216809A1-20100826-C00845
Figure US20100216809A1-20100826-C00846
 N
Figure US20100216809A1-20100826-C00847
Figure US20100216809A1-20100826-C00848
Figure US20100216809A1-20100826-C00849
 N
Figure US20100216809A1-20100826-C00850
Figure US20100216809A1-20100826-C00851
Figure US20100216809A1-20100826-C00852
 N
Figure US20100216809A1-20100826-C00853
Figure US20100216809A1-20100826-C00854
Figure US20100216809A1-20100826-C00855
 N
Figure US20100216809A1-20100826-C00856
Figure US20100216809A1-20100826-C00857
Figure US20100216809A1-20100826-C00858
 N
Figure US20100216809A1-20100826-C00859
Figure US20100216809A1-20100826-C00860
Figure US20100216809A1-20100826-C00861
a N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof.
15. (canceled)
16. A compound for the treatment of obesity, hypercholesterolemia, hyperlipidemia, dyslipidemia, mixed dyslipidemia, hypertriglyceridemia, fatty liver, nonalcoholic fatty liver disease, liverfibrosis, non-alcoholic steatohepatitis and diabetes, wherein the compound has the following formula
Figure US20100216809A1-20100826-C00862
including any stereochemically isomeric form thereof, wherein
A represents CH or N;
the dotted line represents an optional bond in case A represents a carbon atom;
X represents —NRx—C(═O)—; —Z—C(═O)—; —Z—NRx—C(═O)—; —S(═O)p-; —C(═S)—;
—NRx—C(═S)—; —Z—C(═S)—; —Z—NRx—C(═S)—; —O—C(═O)—; or —C(═O)—C(═O)—;
Z represents a bivalent radical selected from C1-6alkanediyl, C2-6alkenediylor
C2-6alkynediyl; wherein each of said C1-6alkanediyl, C2-6alkenediyl or
C2-6alkynediyl may optionally be substituted with hydroxyl or amino; and wherein two hydrogen atoms attached to the same carbon atom in C1-6alkanediyl may optionally be replaced by C1-6alkanediyl;
Rx represents hydrogen or C1-4alkyl;
R1 represents a 5-membered monocyclic heterocycle containing at least 2 heteroatoms; a 6-membered aromatic monocyclic heterocycle; or a 5-membered heterocycle containing at least 2 heteroatoms fused with phenyl, cyclohexyl or a 5- or 6-membered heterocycle; wherein each of said heterocycles may optionally be substituted with at least one substituent, each substituent independently being selected from the group consisting of hydroxyl; oxo; carboxyl; halo; C1-6alkyl optionally substituted with carboxyl, C1-4alkyloxycarbonyl or aryl-C(═O)—; hydroxyC1-6alkyl optionally substituted with aryl or aryl-C(═O)—; polyhaloC1-6alkyl; C1-6alkyloxy optionally substituted with C1-4alkyloxy;
C1-6alkylthio; polyhaloC1-6alkyloxy; C1-6alkyloxy-carbonyl wherein C1-6alkyl may optionally be substituted with aryl; cyano; aminocarbonyl; mono-or di(C1-4alkyl)-aminocarbonyl; C1-6alkylcarbonyl; amino; mono-or di(C1-6alkyl)amino;
R5R4N—C1-6alkyl; C3-6cycloalkyl-NRx—; aryl-NRx—; Het-NRx—; C3-6cycloalkyl-C1-4alkyl-NRx—; arylC1-4alkyl-NRx—; HetC1-4alkyl-NRx—;—S(═O)p—C1-4alkyl;
C3-6cycloalkyl; C3-6cycloalkylC1-4alkyl; C3-6cycloalkyl-C(═O)—; aryl; aryloxy; arylC1-4alkyl; aryl-C(═O)—; aryl-C(═O)—C1-4alkyl; Het; HetC1-4alkyl; Het-C(═O)—; Het-C(═O)—C1-4alkyl; and Het-O—;
R2 represents R3;
R3 represents C3-6cycloalkyl, phenyl, naphtalenyl, 2,3-dihydro-1,4-benzodioxinyl, 1,3-benzodioxolyl, 2,3-dihydrobenzofuranyl or a 6-membered aromatic heterocycle containing 1 or 2 N atoms, wherein said C3-6cycloalkyl, phenyl, naphtalenyl,
2,3-dihydro-1,4-benzodioxinyl, 1,3-benzodioxolyl, 2,3-dihydrobenzofuranyl or 6-membered aromatic heterocycle may optionally be substituted with at least one substituent, each substituent independently selected from the group consisting of hydroxyl;
carboxyl; halo; C1-6alkyl optionally substituted with hydroxy; polyhaloC1-6alkyl; C1-6alkyloxy optionally substituted with C1-4alkyloxy; C1-6alkylthio; polyhalo-C1-6alkyloxy; C1-6alkyloxycarbonyl wherein C1-6alkyl may optionally be substituted with aryl; cyano; C1-6alkylcarbonyl; nitro; amino; mono-or di(C1-4alkyl)amino; C1-4alkylcarbonylamino;
—S(═O)p—C1-4alkyl; R5R4N—C(═O)—; R5R4N—C1-6alkyl; C3-6cycloalkyl-C1-4alkyl; C3-6cycloalkyl-C(═O)—; aryl; aryloxy; arylC1-4alkyl; aryl-C(═O)—C1-4alkyl;
aryl-C(═O)—; Het; HetC1-4alkyl; Het-C(═O)—C1-4alkyl; Het-C(═O)—; and Het-O—;
R4 represents hydrogen; C1-4alkyl optionally substituted with hydroxyl or C1-4alkyloxy;
R7R6N—C1-4alkyl; C1-4alkyloxy; Het; aryl; or R7R6N—C(═O)—C1-4alkyl;
R5 represents hydrogen or C1-4alkyl;
R6 represents hydrogen; C1-4alkyl; or C1-4alkylcarbonyl;
R7 represents hydrogen or C1-4alkyl; or R6 and R7 may be taken together with the nitrogen to which they are attached to form a saturated monocyclic 5, 6 or 7-membered heterocycle which may further contain one or more heteroatoms selected from the group consisting of O, S, S(═O)p and N; and which heterocycle may optionally be substituted with C1-4alkyl;
R8 represents hydrogen, halo, C1-4alkyl, or C1-4alkyl substituted with hydroxyl;
aryl represents phenyl or phenyl substituted with at least one substituent, each substituent independently being selected from the group consisting of hydroxyl; carboxyl;
halo; C1-6alkyl optionally substituted with
C1-4alkyloxy, amino or mono-or di(C1-4alkyl)amino; polyhaloC1-6alkyl;
C1-6alkyloxy optionally substituted with C1-4alkyloxy; C1-6alkylthio;
polyhaloC1-6alkyloxy; C1-6alkyloxycarbonyl; cyano; aminocarbonyl; mono-or di(C1-4alkyl)aminocarbonyl; C1-6alkylcarbonyl; nitro; amino; mono-or di(C1-4alkyl)amino; and —S(═O)p—C1-4alkyl;
Het represents a monocyclic non-aromatic or aromatic heterocycle containing at least one heteroatom selected from the group consisting of O, S, S(═O)p and N;
or a bicyclic or tricyclic non-aromatic or aromatic heterocycle containing at least one heteroatom selected from the group consisting of O, S, S(═O)p and N; said monocyclic heterocycle or said bi-or tricyclic heterocycle optionally being substituted with at least one substituent, each substituent independently being selected from the group consisting of hydroxyl; oxo; carboxyl; halo; C1-6alkyl optionally substituted with C1-4alkyloxy, amino or mono-or di(C1-4alkyl)amino; polyhaloC1-6alkyl; C1-6alkyloxy optionally substituted with C1-4alkyloxy; C1-6alkylthio; polyhaloC1-6alkyloxy; C1-6alkyl-oxycarbonyl; cyano; aminocarbonyl; mono-or di(C1-4alkyl)aminocarbonyl;
C1-6alkylcarbonyl; nitro; amino; mono-or di(C1-4alkyl)amino; and —S(═O)p—C1-4alkyl
p represents 1 or 2;
a N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof.
17. A pharmaceutical composition comprising a pharmaceutically acceptable carrier, and as active ingredient a therapeutically effective amount of a compound as claimed in claim 1.
18-19. (canceled)
20. A process of preparing a compound as defined in claim 1 comprising
a) reacting an intermediate of formula (II) with an intermediate of formula (III) in the presence of a suitable solvent and optionally in the presence of a suitable base,
Figure US20100216809A1-20100826-C00863
with the variables as defined in claim 1 and with X1 representing a direct bond or Z;
b) reacting an intermediate of formula (II′) with Cl3COC(═O)—Cl or C(═O)Cl2, optionally in the presence of HCl in diethylether, and in the presence of a suitable solvent, followed by reaction with an intermediate of formula (III) in the presence of a suitable solvent, optionally in the presence of a suitable base,
Figure US20100216809A1-20100826-C00864
with the variables as defined in claim 1;
c) reacting an intermediate of formula (IV) with an intermediate of formula (III) in the presence of a suitable dehydrating (coupling) agent, a suitable solvent and optionally a suitable base, or reacting an intermediate of formula (IV) with an intermediate of formula (III) in the presence of a suitable activating agent, a suitable base and a suitable solvent,
Figure US20100216809A1-20100826-C00865
with the variables as defined in claim 1; or
h) reacting an intermediate of formula (XVI) wherein W4 represents a suitable leaving group, with NHR4R5 in the presence of a suitable solvent,
Figure US20100216809A1-20100826-C00866
with the variables as defined in claim 1 and with R2 representing R3, said R3 being substituted with R5R4N—C1-6alkyl, said R2 being represented by —R3′—C1-6alkyl-NR4R5;
and further, optionally converting the compounds of formula (I), into a therapeutically active non-toxic acid addition salt by treatment with an acid, or into a therapeutically active non-toxic base addition salt by treatment with a base, or conversely, converting the acid addition salt form into the free base by treatment with alkali, or converting the base addition salt into the free acid by treatment with acid; or, optionally preparing stereochemically isomeric forms, quaternary amines, solvates or N-oxide forms thereof.
21. A method of treating a warm blooded mammal suffering from a disorder selected from the group consisting of obesity, hypercholesterolemia, hyperlipidemia, dyslipidemia, mixed dyslipidemia, hypertriglyceridemia, fatty liver, nonalcoholic fatty liver disease, liverfibrosis, non-alcoholic steatohepatitis and diabetes comprising administering to the mammal an effective amount of a compound of claim 1.
22. The method of claim 23, wherein the disorder is type II diabetes mellitus.
US12/663,009 2007-06-08 2008-06-05 Piperidine/piperazine derivatives Active 2029-02-16 US8835437B2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP07109865.1 2007-06-08
EP07109865 2007-06-08
EP07109865 2007-06-08
PCT/EP2008/056983 WO2008148840A1 (en) 2007-06-08 2008-06-05 Piperidine/piperazine derivatives

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/056983 A-371-Of-International WO2008148840A1 (en) 2007-06-08 2008-06-05 Piperidine/piperazine derivatives

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US14/456,054 Division US9120821B2 (en) 2007-06-08 2014-08-11 Piperidine/piperazine derivatives

Publications (2)

Publication Number Publication Date
US20100216809A1 true US20100216809A1 (en) 2010-08-26
US8835437B2 US8835437B2 (en) 2014-09-16

Family

ID=38668783

Family Applications (4)

Application Number Title Priority Date Filing Date
US12/663,009 Active 2029-02-16 US8835437B2 (en) 2007-06-08 2008-06-05 Piperidine/piperazine derivatives
US14/456,054 Active US9120821B2 (en) 2007-06-08 2014-08-11 Piperidine/piperazine derivatives
US14/803,275 Active US9499567B2 (en) 2007-06-08 2015-07-20 Piperidine/piperazine derivatives
US15/292,196 Expired - Fee Related US9688696B2 (en) 2007-06-08 2016-10-13 Piperidine/piperazine derivatives

Family Applications After (3)

Application Number Title Priority Date Filing Date
US14/456,054 Active US9120821B2 (en) 2007-06-08 2014-08-11 Piperidine/piperazine derivatives
US14/803,275 Active US9499567B2 (en) 2007-06-08 2015-07-20 Piperidine/piperazine derivatives
US15/292,196 Expired - Fee Related US9688696B2 (en) 2007-06-08 2016-10-13 Piperidine/piperazine derivatives

Country Status (10)

Country Link
US (4) US8835437B2 (en)
EP (1) EP2152271B1 (en)
JP (1) JP5443342B2 (en)
AR (1) AR067327A1 (en)
AU (1) AU2008258549B2 (en)
CA (1) CA2687912C (en)
CL (1) CL2008001669A1 (en)
ES (1) ES2558152T3 (en)
TW (1) TWI424997B (en)
WO (1) WO2008148840A1 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
JP2008523133A (en) 2004-12-14 2008-07-03 アストラゼネカ アクチボラグ Oxadiazole derivatives as DGAT inhibitors
US7749997B2 (en) 2005-12-22 2010-07-06 Astrazeneca Ab Pyrimido [4,5-B] -Oxazines for use as DGAT inhibitors
EP2301923B1 (en) 2006-03-31 2016-06-08 Novartis AG Pyridine derivatives as dgat inhibitors
ATE492541T1 (en) 2006-05-30 2011-01-15 Astrazeneca Ab SUBSTITUTED 5-PHENYLAMINO-1,3,4-OXADIAZOLE-2-YLCARBONYLAMINO-4-PHENOXYCYCLOHEXANECARBONY ACIDS AS INHIBITORS OF ACETYLCOENZYME-A-DIACYLGLYCEROLACYLTRANSFERASE
AU2008258487B2 (en) 2007-06-08 2012-11-15 Janssen Pharmaceutica N.V. Piperidine/piperazine derivatives
ES2483898T3 (en) 2007-06-08 2014-08-08 Janssen Pharmaceutica, N.V. Piperidine / Piperazine Derivatives
US8835437B2 (en) 2007-06-08 2014-09-16 Janssen Pharmaceutica N.V. Piperidine/piperazine derivatives
JO2972B1 (en) 2007-06-08 2016-03-15 جانسين فارماسوتيكا ان. في Piperidine/Piperazine derivatives
AR066169A1 (en) 2007-09-28 2009-07-29 Novartis Ag DERIVATIVES OF BENZO-IMIDAZOLES, USEFUL FOR DISORDERS ASSOCIATED WITH THE ACTIVITY OF DGAT
JP5579170B2 (en) 2008-06-05 2014-08-27 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Pharmaceutical combination comprising a DGAT inhibitor and a PPAR agonist
KR101083421B1 (en) 2009-06-23 2011-11-14 한국과학기술연구원 Novel pyrazoloimidazole-based compounds or pharmaceutically acceptable salts thereof, preparation method thereof and pharmaceutical composition for the prevention and treatment of abnormal cell growth diseases containing the same as an active ingredient
WO2011002067A1 (en) * 2009-07-02 2011-01-06 武田薬品工業株式会社 Heterocyclic compound and use thereof
KR101154539B1 (en) 2010-04-13 2012-06-13 한국과학기술연구원 Novel aminopyrazole arylamide derivatives or pharmaceutically acceptable salts thereof, preparation method thereof and pharmaceutical composition for the prevention or treatment of abnormal cell growth diseases containing the same as an active ingredient
US8822464B2 (en) 2011-11-28 2014-09-02 Boehringer Ingelheim International Gmbh N-aryl-piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors
US8741892B2 (en) 2011-12-05 2014-06-03 Boehringer Ingelheim International Gmbh Compounds
US8642774B2 (en) 2011-12-08 2014-02-04 Boehringer Ingelheim International Gmbh Compounds
US8796467B2 (en) 2011-12-13 2014-08-05 Boehringer Ingelheim International Gmbh Compounds
US8846948B2 (en) * 2011-12-13 2014-09-30 Boehringer Ingelheim International Gmbh Compounds
US8716277B2 (en) 2011-12-14 2014-05-06 Boehringer Ingelheim International Gmbh Substituted imidazole compounds useful as positive allosteric modulators of mGlu5 receptor activity
US8937176B2 (en) 2011-12-14 2015-01-20 Boehringer Ingelheim International Gmbh Compounds
US8883789B2 (en) 2011-12-14 2014-11-11 Boehringer Ingelheim International Gmbh Piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors
US8889677B2 (en) 2012-01-17 2014-11-18 Boehringer Ingellheim International GmbH Substituted triazoles useful as mGlu5 receptor modulators
WO2014054053A1 (en) 2012-10-03 2014-04-10 Advinus Therapeutics Limited Spirocyclic compounds, compositions and medicinal applications thereof

Citations (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4698352A (en) * 1982-10-29 1987-10-06 Toyama Chemical Co., Ltd. 4-oxo-1,4-dihydronicotinic acid derivatives, salts thereof, and antibacterial agents containing the same
US5429770A (en) * 1993-05-21 1995-07-04 Basf Aktiengesellschaft Low-molecular-weight and polymeric liquid-crystalline benzotriazoles, and the use thereof
US5574055A (en) * 1993-12-13 1996-11-12 Hoffmann-La Roche Inc. Oxazolidinone derivatives
US5789412A (en) * 1994-07-20 1998-08-04 Pierre Fabre Medicament Piperazides derived from arylpiperazine, processes for their preparation, their use as medicaments and pharmaceutical compositions comprising them
US6492368B1 (en) * 1997-10-01 2002-12-10 Merck Patent Gmbh Benzamidine derivatives as factor XA inhibitors
US20030055055A1 (en) * 1999-06-22 2003-03-20 Lene Teuber Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds
US20030060472A1 (en) * 2000-06-21 2003-03-27 Learmonth David Alexander Novel substituted nitrocatechols, their use in the treatment of some central and peripheral nervous system disorders and pharmaceutical compositions containing them
US20040038858A1 (en) * 2000-12-16 2004-02-26 Dieter Dorsch Carboxamide derivatives and their use in the treatment of thromboembolic diseases and tumours
US20040162282A1 (en) * 2002-06-12 2004-08-19 Chemocentryx, Inc. Substituted piperazines
US20040220191A1 (en) * 2003-02-14 2004-11-04 Aventis Pharma Deutschland Gmbh Substituted N-aryl heterocycles, process for their preparation and their use as medicaments
US20050059650A1 (en) * 2003-07-14 2005-03-17 Jones Robert M. Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
US6884868B1 (en) * 1999-04-27 2005-04-26 Fujisawa Pharmaceutical Co., Ltd. Cyclic hexapeptides having antibiotic activity
US20050209241A1 (en) * 2003-08-11 2005-09-22 Jolidon Synese J Benzoyl-piperazine derivatives
US20060030612A1 (en) * 2004-08-03 2006-02-09 Wyeth Indazoles useful in treating cardiovascular diseases
US20070021339A1 (en) * 2005-06-30 2007-01-25 Resurreccion Alloza Miravete GLP-1 pharmaceutical compositions
US7186683B2 (en) * 2000-09-18 2007-03-06 Sanos Bioscience A/S Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders
US20070207999A1 (en) * 2006-02-22 2007-09-06 Heinz Stadtmueller New Compounds
US20070249620A1 (en) * 2004-07-02 2007-10-25 Hitoshi Kurata Urea Derivative

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1383906A (en) 1971-02-22 1974-02-12 Bdh Pharmaceuticals Ltd Pyridazinones
JPS5692887A (en) 1979-12-05 1981-07-27 Sumitomo Chem Co Ltd N-substituted imidazole derivative
GB8729083D0 (en) 1987-12-12 1988-01-27 Pfizer Ltd Triazole antifungal agents
JP2969359B2 (en) 1989-01-13 1999-11-02 武田薬品工業株式会社 Cyclic amine compounds
US5637592A (en) * 1994-07-12 1997-06-10 Janssen Pharmaceutica N.V. Acyl derivatives of azolones
US5639754A (en) * 1994-07-12 1997-06-17 Janssen Pharmaceutica N.V. Urea and thiourea derivatives of azolones
WO1996010822A1 (en) 1994-09-30 1996-04-11 Hitachi, Ltd. Magnetic recording/reproducing device having high-speed reproduction mode
SK282252B6 (en) 1995-01-11 2001-12-03 Samjin Pharmaceutical Co., Ltd. New piperazine derivatives and pharmaceutical composition containing the same
WO1997005877A1 (en) 1995-08-10 1997-02-20 Merck & Co., Inc. 2-substituted aryl pyrroles, compositions containing such compounds and methods of use
CA2228050A1 (en) 1995-08-10 1997-02-20 Harold G. Selnick 2,5-substituted aryl pyrroles, compositions containing such compounds and methods of use
GB9702213D0 (en) 1996-02-24 1997-03-26 Zeneca Ltd Chemical compounds
HN1997000027A (en) 1996-12-06 1997-06-05 Pfizer Prod Inc DERIVATIVES OF 6-PHENYL PIRIDIL - 2 AMINE
JPH11139969A (en) 1997-08-07 1999-05-25 Tanabe Seiyaku Co Ltd Pharmaceutical composition
BR9912299A (en) 1998-07-20 2001-11-20 Merck Patent Gmbh Biphenyl derivatives
GB9826412D0 (en) 1998-12-03 1999-01-27 Glaxo Group Ltd Chemical compounds
OA11943A (en) 1999-05-21 2006-04-12 Pfizer Prod Inc New pharmacetical combinations for nos inhibitors
KR20020062342A (en) * 1999-12-16 2002-07-25 쉐링 코포레이션 Substituted imidazole neuropeptide Y Y5 receptor antagonists
US20010047004A1 (en) 2000-02-10 2001-11-29 Hester Jackson B. Oxazolidinone thioamides with piperazine amide substituents
GB0013378D0 (en) 2000-06-01 2000-07-26 Glaxo Group Ltd Use of therapeutic benzamide derivatives
AU2001264376A1 (en) 2000-06-15 2001-12-24 Chaconne Nsi Co., Ltd. Urea derivative useful as an anti-cancer agent and process for preparing same
GB2363792A (en) 2000-06-21 2002-01-09 Portela & Ca Sa Nitrocatechols
JO2654B1 (en) 2000-09-04 2012-06-17 شركة جانسين فارماسوتيكا ان. في Polyarylcarboxamides useful as lipid lowering agents
AUPR201600A0 (en) 2000-12-11 2001-01-11 Fujisawa Pharmaceutical Co., Ltd. Quinazolinone derivative
EP1353913A2 (en) 2001-01-16 2003-10-22 AstraZeneca AB Therapeutic heterocyclic compounds
JO2390B1 (en) 2001-04-06 2007-06-17 شركة جانسين فارماسوتيكا ان. في Lipid lowering biphenulcarboxamides
PE20021081A1 (en) * 2001-04-12 2002-12-18 Pharmacopeia Drug Discovery ARIL AND BIARIL PIPERIDINES WITH MCH MODULATING ACTIVITY
DE10204116A1 (en) 2002-02-01 2003-08-07 Bayer Cropscience Ag DELTA · 1 · -pyrrolines
WO2003076400A1 (en) 2002-03-13 2003-09-18 Janssen Pharmaceutica N.V. New inhibitors of histone deacetylase
MXPA04007775A (en) 2002-03-13 2004-10-15 Janssen Pharmaceutica Nv Sulfonyl-derivatives as novel inhibitors of histone deacetylase.
BR0308837A (en) * 2002-04-01 2005-02-01 Cadila Healthcare Ltd Compound, composition, method and medicament for the treatment of bacterial infections, psoriasis or arthritis in mammals, method and medicament for the treatment of chemotherapy toxicity in a patient, pharmaceutical composition, process for preparing a compound and process for conversion of the compounds of formula (i) into additional compounds of formula (i)
TWI319387B (en) 2002-04-05 2010-01-11 Astrazeneca Ab Benzamide derivatives
CA2513416A1 (en) 2002-08-22 2004-03-04 Orchid Chemicals & Pharmaceuticals Ltd. Novel antibacterial agents
NZ539952A (en) 2002-11-22 2008-05-30 Japan Tobacco Inc Fused bicyclic nitrogen-containing heterocyclic compounds for treating diabetes, obesity and syndrome X
ATE551324T1 (en) 2003-02-03 2012-04-15 Janssen Pharmaceutica Nv QUINOLINE AMIDE DERIVATIVES AS MODULATORS OF VANILLOID VR1 RECEPTORS
DE10306250A1 (en) 2003-02-14 2004-09-09 Aventis Pharma Deutschland Gmbh Substituted N-aryl heterocycles, processes for their preparation and their use as pharmaceuticals
AR044152A1 (en) 2003-05-09 2005-08-24 Bayer Corp RENTAL DERIVATIVES, METHOD OF PREPARATION AND USE FOR THE TREATMENT OF OBESITY
US20070099884A1 (en) 2003-06-06 2007-05-03 Erondu Ngozi E Combination therapy for the treatment of diabetes
JP2005206492A (en) 2004-01-21 2005-08-04 Sankyo Co Ltd Sulfonamide compound
JP2007519605A (en) * 2004-01-30 2007-07-19 日本たばこ産業株式会社 Appetite suppressant
JP4787529B2 (en) 2004-04-09 2011-10-05 大塚製薬株式会社 Pharmaceutical composition
CN100360525C (en) * 2004-09-16 2008-01-09 中国科学院上海药物研究所 A new class of oxazolidinone derivatives, their preparation method and use
CA2580856A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
GB0421908D0 (en) 2004-10-01 2004-11-03 Angeletti P Ist Richerche Bio New uses
ES2357015T3 (en) 2004-10-15 2011-04-15 Bayer Healthcare Llc PREPARATION AND USE OF BIFENIL-4-ILCARBONYLAMINO ACID DERIVATIVES FOR THE TREATMENT OF OBESITY.
WO2006047277A2 (en) 2004-10-22 2006-05-04 Janssen Pharmaceutica, N.V. Inhibitors of c-fms kinase
JP2008523133A (en) 2004-12-14 2008-07-03 アストラゼネカ アクチボラグ Oxadiazole derivatives as DGAT inhibitors
KR20070088656A (en) 2004-12-22 2007-08-29 얀센 파마슈티카 엔.브이. Diacylglycerol acyltransferase assay
GT200600046A (en) * 2005-02-09 2006-09-25 COMBINATION THERAPY
GB0505084D0 (en) 2005-03-11 2005-04-20 Glaxo Group Ltd Compounds
WO2006105127A2 (en) 2005-03-31 2006-10-05 Takeda San Diego, Inc. Hydroxysteroid dehydrogenase inhibitors
CA2601983A1 (en) 2005-04-06 2006-10-12 Astrazeneca Ab Substituted heterocycles and their use as chk1, pdk1 and pak inhibitors
AU2006236155A1 (en) 2005-04-19 2006-10-26 Bayer Pharmaceuticals Corporation Aryl alkyl acid derivatives for and use thereof
CN100335588C (en) * 2005-04-28 2007-09-05 陈俊光 Active water-proof powder with organic silicone and production thereof
MX2007015759A (en) 2005-06-11 2008-02-21 Astrazeneca Ab Oxadiazole derivatives as dgat inhibitors.
JP2007131584A (en) 2005-11-11 2007-05-31 Sankyo Co Ltd New benzoxazole derivative
AU2006326815A1 (en) 2005-12-20 2007-06-28 Merck Frosst Canada Ltd. Heteroaromatic compounds as inhibitors of stearoyl-coenzyme A delta-9 desaturase
US7749997B2 (en) 2005-12-22 2010-07-06 Astrazeneca Ab Pyrimido [4,5-B] -Oxazines for use as DGAT inhibitors
EP1810974A1 (en) 2006-01-18 2007-07-25 Ludwig-Maximilians-Universität München Preparation and use of magnesium amides
US7728031B2 (en) 2006-02-24 2010-06-01 Abbott Laboratories Octahydro-pyrrolo[3,4-b]pyrrole derivatives
JPWO2007102392A1 (en) 2006-03-03 2009-07-23 塩野義製薬株式会社 MMP-13 selective inhibitor
JP2009542604A (en) 2006-07-06 2009-12-03 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 4-Heterocycloalkylpyrimidines, their preparation and use as pharmaceuticals
EP1918285A1 (en) 2006-11-03 2008-05-07 Merck Sante Diazepane-acetamide derivatives as selective 11beta-HSD1 inhibitors
GB0706793D0 (en) 2007-04-05 2007-05-16 Evotec Ag Compounds
CN101835757B (en) 2007-05-22 2014-03-05 玛德瑞哥制药公司 Diacylglycerol acyltransferase inhibitors
US8835437B2 (en) 2007-06-08 2014-09-16 Janssen Pharmaceutica N.V. Piperidine/piperazine derivatives
JO2972B1 (en) 2007-06-08 2016-03-15 جانسين فارماسوتيكا ان. في Piperidine/Piperazine derivatives
ES2483898T3 (en) 2007-06-08 2014-08-08 Janssen Pharmaceutica, N.V. Piperidine / Piperazine Derivatives
AU2008258487B2 (en) 2007-06-08 2012-11-15 Janssen Pharmaceutica N.V. Piperidine/piperazine derivatives
JP5579170B2 (en) 2008-06-05 2014-08-27 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Pharmaceutical combination comprising a DGAT inhibitor and a PPAR agonist

Patent Citations (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4698352A (en) * 1982-10-29 1987-10-06 Toyama Chemical Co., Ltd. 4-oxo-1,4-dihydronicotinic acid derivatives, salts thereof, and antibacterial agents containing the same
US5429770A (en) * 1993-05-21 1995-07-04 Basf Aktiengesellschaft Low-molecular-weight and polymeric liquid-crystalline benzotriazoles, and the use thereof
US5574055A (en) * 1993-12-13 1996-11-12 Hoffmann-La Roche Inc. Oxazolidinone derivatives
US5789412A (en) * 1994-07-20 1998-08-04 Pierre Fabre Medicament Piperazides derived from arylpiperazine, processes for their preparation, their use as medicaments and pharmaceutical compositions comprising them
US6492368B1 (en) * 1997-10-01 2002-12-10 Merck Patent Gmbh Benzamidine derivatives as factor XA inhibitors
US6884868B1 (en) * 1999-04-27 2005-04-26 Fujisawa Pharmaceutical Co., Ltd. Cyclic hexapeptides having antibiotic activity
US20030055055A1 (en) * 1999-06-22 2003-03-20 Lene Teuber Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds
US20030060472A1 (en) * 2000-06-21 2003-03-27 Learmonth David Alexander Novel substituted nitrocatechols, their use in the treatment of some central and peripheral nervous system disorders and pharmaceutical compositions containing them
US7186683B2 (en) * 2000-09-18 2007-03-06 Sanos Bioscience A/S Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders
US20040038858A1 (en) * 2000-12-16 2004-02-26 Dieter Dorsch Carboxamide derivatives and their use in the treatment of thromboembolic diseases and tumours
US20040162282A1 (en) * 2002-06-12 2004-08-19 Chemocentryx, Inc. Substituted piperazines
US20040220191A1 (en) * 2003-02-14 2004-11-04 Aventis Pharma Deutschland Gmbh Substituted N-aryl heterocycles, process for their preparation and their use as medicaments
US20050059650A1 (en) * 2003-07-14 2005-03-17 Jones Robert M. Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
US20050209241A1 (en) * 2003-08-11 2005-09-22 Jolidon Synese J Benzoyl-piperazine derivatives
US20070249620A1 (en) * 2004-07-02 2007-10-25 Hitoshi Kurata Urea Derivative
US20060030612A1 (en) * 2004-08-03 2006-02-09 Wyeth Indazoles useful in treating cardiovascular diseases
US20070021339A1 (en) * 2005-06-30 2007-01-25 Resurreccion Alloza Miravete GLP-1 pharmaceutical compositions
US20070207999A1 (en) * 2006-02-22 2007-09-06 Heinz Stadtmueller New Compounds

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Cao et al. J.Biol.Chem. vol.286, p.41838-41851 (2011). *
Vippagunta et al. Advanced Drug Delivery Reviews, vol.48, pp.3-26 (2001). *

Also Published As

Publication number Publication date
AU2008258549B2 (en) 2013-11-14
JP5443342B2 (en) 2014-03-19
TWI424997B (en) 2014-02-01
US20150322088A1 (en) 2015-11-12
US8835437B2 (en) 2014-09-16
US9688696B2 (en) 2017-06-27
WO2008148840A1 (en) 2008-12-11
AU2008258549A1 (en) 2008-12-11
EP2152271A1 (en) 2010-02-17
US9499567B2 (en) 2016-11-22
CL2008001669A1 (en) 2009-07-17
CA2687912A1 (en) 2008-12-11
ES2558152T3 (en) 2016-02-02
US20170029440A1 (en) 2017-02-02
US9120821B2 (en) 2015-09-01
TW200909430A (en) 2009-03-01
JP2010529084A (en) 2010-08-26
US20140350012A1 (en) 2014-11-27
AR067327A1 (en) 2009-10-07
CA2687912C (en) 2015-11-03
EP2152271B1 (en) 2015-10-21

Similar Documents

Publication Publication Date Title
US9688696B2 (en) Piperidine/piperazine derivatives
US9227935B2 (en) Piperidine/piperazine derivatives
US8981094B2 (en) Piperidine/piperazine derivatives
US8633197B2 (en) Piperidine/piperazine derivatives

Legal Events

Date Code Title Description
AS Assignment

Owner name: JANSSEN PHARMACEUTICA N.V., BELGIUM

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BOECKX, GUSTAAF MARIA;REEL/FRAME:023624/0892

Effective date: 20070607

Owner name: JANSSEN PHARMACEUTICA N.V., BELGIUM

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:VAN LOMMEN, GUY ROSALIA EUGEEN;REEL/FRAME:023624/0915

Effective date: 20070607

Owner name: POLYPHOR LTD., SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:OBRECHT, DANIEL;REEL/FRAME:023624/0990

Effective date: 20070607

Owner name: JANSSEN PHARMACEUTICA N.V., BELGIUM

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BUYCK, CHRISTOPHE FRANCIS ROBERT NESTOR;REEL/FRAME:023624/0948

Effective date: 20070607

Owner name: JANSSEN PHARMACEUTICA N.V., BELGIUM

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:MEERPOEL, LIEVEN;REEL/FRAME:023624/0872

Effective date: 20070607

Owner name: POLYPHOR LTD., SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ERMERT, PHILIPP;REEL/FRAME:023625/0007

Effective date: 20070607

Owner name: POLYPHOR LTD., SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:LUTHER, ANATOL;REEL/FRAME:023625/0030

Effective date: 20070607

Owner name: JANSSEN PHARMACEUTICA N.V., BELGIUM

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:POLYPHOR LTD;REEL/FRAME:023625/0035

Effective date: 20070607

Owner name: JANSSEN PHARMACEUTICA N.V., BELGIUM

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BONGARTZ, JEAN-PIERRE ANDRE MARC;REEL/FRAME:023624/0856

Effective date: 20070607

STCF Information on status: patent grant

Free format text: PATENTED CASE

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1551)

Year of fee payment: 4

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1552); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 8